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Abstract 
 
Cytotoxic chemotherapy remains the mainstay of treatment for patients with cancer, 
however, immunotherapy is starting to emerge as an additional modality of treatment.  
Evidence suggests that chemotherapy can synergise with immunotherapy to improve 
responses.   
Although CD8 T cells have been regarded as the main anti-tumour effector cell, the 
role of CD4 T cells in orchestrating CD8 and other anti-tumour responses is increasingly 
recognised.  However, the CD4 T cell population contains effector and suppressive 
subsets with diverse and opposing functions.  
This thesis describes the establishment of a murine mesothelioma model with which to 
study the effects of different CD4 subsets on anti-tumour immune responses, and 
investigate their capacity to provide cognate help to tumour antigen specific CD8 T 
cells.  Haemagluttin (HA) specific CD4 T cells from transgenic mice were polarised in 
vitro into Th1, Th2, Th17 and Treg subsets and adoptively transferred alongside HA 
specific CD8 T cells into mice bearing HA expressing tumours derived from a 
mesothelioma cell line.  The effects of the different CD4 subtypes on tumour growth 
ĂŶĚƚŚĞŝƌĐĂƉĂĐŝƚǇƚŽƉƌŽǀŝĚĞ ?ŚĞůƉ ?ƚŽ CD8 T cells was investigated in a prophylactic 
treatment model and in the context of treatment with gemcitabine chemotherapy. 
Results showed that survival and behaviour of in vitro differentiated CD4 subtypes 
after adoptive transfer was highly variable and that only Th1s displayed anti-tumour 
activity when injected prophylactically, prior to tumour inoculation.  Cytotoxic 
chemotherapy did not provide a favourable environment for adoptive transfer of in 
vitro differentiated CD4 cells. No antitumour activity was seen against established 
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tumours, which may have been due to overriding tumour induced immunosuppressive 
mechanisms.  Successful treatment of established tumours that had been treated with 
chemotherapy required both the provision of HA specific CD8 cells and the prior 
removal of an established, endogenous regulatory CD4 T cell population. 
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1.1 Overview of T cell anti-tumour immune responses  
 
Although anti-cancer immunity involves both the innate and adaptive immune system, 
CD8+ cytotoxic T lymphocytes (CTL) are one of the most important anti-tumour 
effector cells (Kennedy and Celis 2008).  The T cell immune response can be broken 
down into the following steps, all of which need to be fulfilled for effective anti-
tumour CTL to be generated (Lake and Robinson 2005):  i) Tumour antigen(s) must be 
present, and ii) these must be presented in a context which is seen as dangerous by 
the immune system;  iii) antigens must be acquired and presented by antigen 
presenting cells (APC) in the draining lymph node; iv) specific T cells must then 
recognise and respond to tumour antigen by proliferating, exiting the lymph node, 
recirculating and entering the tumour as cytotoxic T lymphocyes (CTL); and  v) once 
within the tumour they need to overcome the local immunosuppressive environment 
before they can kill tumour cells.  In addition memory cells may need to be generated 
to produce a sustained response.    
It is clear that a growing tumour has managed to escape this process.  Failure of the 
anti-tumour immune response can occur at one or more of these steps.  Targeting 
rate-limiting steps with therapies designed to boost the immune response can improve 
anti-tumour immunity (Yuan, Gnjatic et al. 2008).  In addition to specifically targeted 
immune therapies, it is also now clear that many traditional cancer therapies can 
improve key aspects of anti-cancer immunity by inducing tumour cell death in a way 
that is immuno-stimulatory or by modulating tumour induced immunosuppression 
(Nowak, Lake et al. 2006). 
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Tumour antigens  ? ǁŚĂƚƚŚĞŚŽƐƚŵŝŐŚƚ ?ƐĞĞ ?ĂƐďĞŝŶŐĚŝĨĨĞƌĞŶƚƚŽƐĞůĨ ? 
Tumours typically express two types of antigen: neo-antigens and self antigens.  Neo-
antigens (tumour specific antigens) are derived from mutated self proteins or 
oncogenic viruses, and are not expressed in normal tissue.  Malignant cells express 
numerous neo-antigens as a result of genomic instability (Tomlinson, Sasieni et al. 
2002; Weir, Woo et al. 2007; Srivastava and Srivastava 2009).  Most of these mutations 
do not have functional significance for the tumour cell but may still provide potential 
antigenic targets for immune cells.  However, oncogenic mutations in genes which 
drive tumour cell replication make more attractive targets for immunotherapy as 
immune escape through loss of gene expression should be incompatible with 
continued tumour growth.    
In addition, tumours can also express normal self proteins, but in abnormal quantities 
or locations (tumour associated antigens - TAAs)(Schietinger, Philip et al. 2008).   TAAs 
include cancer-testis antigens, for example MAGE and ESO; differentiation antigens, 
such as tyrosinase, which are also expressed in the tissue of origin; oncofetal antigens 
such as aFP and CEA; or over-expressed proteins such as Her2 or wild type p53 
(Antonia, Mirza et al. 2006; Cloosen, Arnold et al. 2007; Bioley, Dousset et al. 2009; van 
der Bruggen 2009).   
During T cell development, T cell precursors with a strongly self-reactive T cell receptor 
(TCR) are deleted in the thymus, resulting in a T cell repertoire with a high affinity for 
foreign antigens and a weak affinity for self antigens.  In addition, self reactive T cells 
can be tolerised peripherally following encounter with antigen in the absence of an 
activating stimulus and through the actions of regulatory cells.  Since tumour neo-
ĂŶƚŝŐĞŶƐĂƌĞ ?ĨŽƌĞŝŐŶ ? ?ŝŶƐŽŵƵĐŚĂƐƚŚĞǇĂƌĞŶŽƚĞǆƉƌĞƐƐĞĚŝŶƚŚĞƚŚǇŵƵƐ ?dĐĞůů
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precursors with high affinity for these antigens escape thymic deletion.  In a similar 
fashion, tumour antigens of the cancer-testis group are largely hidden from developing 
immune cells.  In contrast, most other tumour associated antigens are expressed in 
other tissues, including the thymus (Cloosen, Arnold et al. 2007), resulting in a 
lymphocyte population that is either deleted or has low affinity for these antigens. 
Multiple tumour antigens generate a hierarchy of T cell responses, with dominant 
antigens producing stronger responses than sub-dominant or cryptic antigens 
(Wortzel, Urban et al. 1983; Nelson, Bundell et al. 2000; Bundell, Jackaman et al. 
2006).  Tumour specific neo-antigens are dominant over antigens shared with normal 
tissues (Lennerz, Fatho et al. 2005).  CTL responses can be generated to weaker 
antigens, but require higher antigen concentrations and prolonged duration of 
exposure (Nelson, Bundell et al. 2000).   Furthermore, patients with differing HLA 
haplotypes may generate variable immune responses to the same tumour antigens or 
tumour vaccines due to differing affinity of the antigen for HLA molecules (Bioley, 
Guillaume et al. 2009; Bioley, Guillaume et al. 2009). 
Although there is a stronger T cell repertoire for tumour neo-antigens, the expression 
of mutated gene products is usually specific to individual tumours, limiting the general 
applicability of immunotherapy directed at these antigens.  Exceptions include genes 
such as ras, which mutate in a small number of predictable sites and may, therefore, 
generate epitopes that are shared between patients (Linard, Bezieau et al. 2002).  
Pleasance et al sequenced the genome of small cell lung cancer (Pleasance, Stephens 
et al. 2009) and melanoma (Pleasance, Cheetham et al. 2009) and identified signature 
mutational patterns of tobacco smoke and ultraviolet radiation respectively.  In the 
three lung cancer cell lines studied, mutations in CHD7, a chromatin remodeller and 
 17 
 
potential oncogene, were found, suggesting that this technique could potentially 
identify other neo-antigens shared between patients.  
In contrast, tumour associated self antigens are more likely to be shared between 
patients and cancer vaccine strategies to date have mainly focussed on TAAs due to 
their broader applicability.  However, the T cell repertoire for tumour associated 
antigens is often weak (Cloosen, Arnold et al. 2007) and TAA targeted immunotherapy 
can cross react with normal tissues, inducing autoimmunity (Gilboa 2001; Dudley, 
Wunderlich et al. 2002). 
ŶŝŶƚĂĐƚƚƵŵŽƌĂƐ ?ŝƚƐŽǁŶǀĂĐĐŝŶĞ ? 
Generating a strong, tumour specific response with treatments which are applicable to 
large patient groups is a challenge for vaccine-based immunotherapy and, to date, it 
has not been feasible to identify neo-antigens at an individual level.  To overcome this, 
immunotherapies have used autologous tumour vaccines, or autologous mRNA gene 
transfer, to circumvent the need to identify antigens.  Individual gene expression 
profiling and HLA typing is an alternative approach, but is time consuming, costly, and 
difficult to apply in routine clinical practice.  Whilst the above strategies require 
adequate, accessible tumour tissue, using the in-situ tumour as an antigenic source is 
an approach that does not require tissue manipulation.  Inducing tumour cell death 
through cytotoxic chemotherapy, radiotherapy or locally administered therapies may 
alter the amount or the way that tumour antigens engage with the immune system, 
through exposure of hidden antigens, increased exposure of antigens present at low 
concentration, or modification of low-affinity antigens. In this way, we can use tumour 
antigens to prime a more effective immune response without ever knowing their 
identities: in effect the tumour acts as its own vaccine (van der Most, Currie et al. 
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2006; Jackaman, Lew et al. 2008). Studies using chemotherapy to load tumor antigens 
have confirmed the feasibility of this notion (Nowak, Lake et al. 2003).  
 
Danger  ? how tumour cell death can induce an immune response 
The immune system has evolved to ask two main questions of any invading organism  W 
is it different and is it dangerous. Almost all vaccines harness those two features 
(antigen plus adjuvant); a key aim of tumour immunotherapy is to kill tumor cells in 
ways that make the death look dangerous to the host.  
Presentation of tumour antigens on MHC class I molecules by antigen presenting cells 
such as dendritic cells is necessary to prime CD8+ cytotoxic T lymphocytes (CTL).  
Alone, however, this is insufficient to generate functional effector T cells, and may in 
fact induce tolerance.   Antigens must also be encountered in the context of danger 
signals, such as those from microorganisms (pathogen associated molecular patterns - 
PAMPs) or from dying or damaged cells (damage associated molecular patterns - 
DAMPs) (Matzinger 2002; Lake and Robinson 2005).  The mode of cell death is 
important in determining whether the event is immunogenic or tolerising.  For 
instance, tumour cells treated with alkylating agents induce upregulation of MHC and 
costimulatory molecules on dendritic cells (DCs), and increase IL-12 secretion when 
compared to tumour cells killed by freeze-thawing or nucleoside analogues, 
ŝŵƉůŝĐĂƚŝŶŐEĚĂŵĂŐĞĂƐŽŶĞƉŽƚĞŶƚŝĂů ?ĚĂŶŐĞƌƐŝŐŶĂů ?(Rad, Pollara et al. 2003). 
Most chemotherapeutic agents kill tumour cells by inducing apoptosis.  Apoptosis is a 
tightly regulated cellular mechanism which follows the activation of caspases by cell 
surface death receptors or the release of pro-apoptotic molecules from mitochondria.  
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Orderly breakdown of cellular and chromosomal structures occurs without disruption 
of the cell membrane and cellular material is packaged into apoptotic bodies (Edinger 
and Thompson 2004; Okada and Mak 2004).   Apoptotic cell death during normal cell 
turnover does not induce immune responses, as potential antigens are removed by 
phagocytosis and are not presented in an immunogenic context.  However it is now 
clear that tumour cell apoptosis is not necessarily an immunologically bland or 
tolerising event, and under certain circumstances can be immunostimulatory (Restifo 
2000; Feng, Zeng et al. 2002).  This is dependent on soluble products released from the 
dying cell and on cell surface signalling molecules.  Phosphatidylserine (PS) is one such 
molecule. Normally restricted to the inner leaflet of the plasma membrane, during 
ĂƉŽƉƚŽƐŝƐŝƚĐƌŽƐƐĞƐƚŽƚŚĞŽƵƚĞƌůĞĂĨůĞƚĂŶĚƉƌŽǀŝĚĞƐĂŶ ?ĞĂƚŵĞ ?ƐŝŐŶĂůƚŽƉŚĂŐocytic 
cells.  PS promotes the uptake of dying cells by macrophages and induces expression of 
inhibitory cytokines and suppression of IL-12 production (Kim, Elkon et al. 2004).  It has 
an inhibitory effect on DCs, leading to maturation failure and reduced ability to 
stimulate CTL and IFNg-producing helper T cells (Chen, Doffek et al. 2004), effectively 
downregulating the immune response.  Calreticulin is an endoplasmic reticular protein 
that translocates to the tumour cell surface within hours of exposure to anthracyclines, 
ĂůƐŽĂĐƚŝŶŐĂƐĂŶ ?ĞĂƚŵĞ ?ƐŝŐŶĂůƚŽǁĞůůďĞĨŽƌĞW^ĞǆƉƌĞƐƐŝŽŶĂŶĚŽƚŚĞƌĂƉŽƉƚŽƚŝĐ
changes are manifest.  In contrast to PS mediated DC uptake, cells displaying 
calreticulin following anthracycline exposure are immunogenic, as evidenced by their 
ability to act as tumour vaccines and to stimulate IFNg production (Chaput, De Botton 
et al. 2007; Obeid, Tesniere et al. 2007; Panaretakis, Joza et al. 2008; Tesniere, 
Schlemmer et al. 2009).   
Other substances associated with cell damage may be released during apoptosis, and 
can provide the danger signals required for immunogenic cell death (Skoberne, 
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Beignon et al. 2004).  As infection provides a key evolutionary pressure for 
development of immunity, it is not unexpected that innate pathways closely associated 
with immune response to infection are involved in this activation.  During infection, 
pattern recognition receptors such as toll like receptors (TLRs) recognise pathogen 
associated molecular patterns (PAMPs) and trigger the production of pro-inflammatory 
cytokines.  Endogenous substances derived from dying tumour cells (DAMPs) can also 
act on many of these receptors.  These include DNA and RNA and their breakdown 
products (Xiao 2009), heat shock proteins (Feng, Zeng et al. 2002; Javid, MacAry et al. 
2007) and the nuclear protein high mobility group box-1 (HMGB1) (Tesniere, 
Schlemmer et al. 2009).  Immune activation by HMGB1 from tumour cells is dependent 
on TLR4.  The clinical relevance of this pathway has been demonstrated in 
anthracycline-treated breast cancer patients, where the presence of a variant, non-
functional TLR4 allelle significantly hastened the time to development of metastatic 
disease (Apetoh, Ghiringhelli et al. 2007). 
Uric acid is another inflammatory stimulator associated with cell damage, being 
produced from purine catabolism during DNA and RNA breakdown.  It is released from 
dying cells, stimulating DC maturation and enhancing cytotoxic CD8 responses to 
antigen in vivo (Shi, Evans et al. 2003).  Similarly, ATP is an intracellular molecule which 
within the extracellular environment is pro-inflammatory.  Cell death caused by a 
number of chemotherapeutic agents is associated with reduced intracellular and 
increased extracellular ATP levels (Martins, Tesniere et al. 2009).  ATP has a high 
affinity for the purinergic receptor, P2X7, on DCs, which results in IL-1B secretion .  IL-
1B plays a role in priming naive CD8 T cells into IFNg producing cells  and deficiency of 
this axis impaired the immune response to oxaliplatin treated tumour 
cells(Ghiringhelli, Apetoh et al. 2009). 
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A number of chemotherapy drugs have now been shown to induce tumour cell death 
in a way which looks dangerous to the immune system (Apetoh, Ghiringhelli et al. 
2007; Chaput, De Botton et al. 2007; Obeid, Tesniere et al. 2007; Ghiringhelli, Apetoh 
et al. 2009; Martins, Tesniere et al. 2009; Tesniere, Schlemmer et al. 2009).  In 
addition, augmenting the anti-tumour immune response through the local 
administration of agents providing danger signals has an established role in cancer 
ƚƌĞĂƚŵĞŶƚ ?ǁŝƚŚŚŝƐƚŽƌŝĐĂůƵƐĞŽĨŽůĞǇ ?ƐƚŽǆŝŶĂŶĚǁŝƚŚŝŶƚƌĂǀĞƐŝĐal BCG for bladder 
cancer.  Tumour regression was observed in mice following local injection of TLR 
agonists (Currie, van der Most et al. 2008).  Combining these local stimuli with systemic 
immunotherapy can generate systemic immune responses and regression of distal 
tumours in mice (Broomfield, van der Most et al. 2009).   
 
Antigen presenting cells  ? the gateway to immunity or tolerance to tumour antigens 
[Figure 1-1] 
Although T cell receptors bind with variable specificity and avidity to self and non-self 
antigens, T cells themselves do not have the capacity to discriminate dangerous from 
harmless antigen.  Antigen presenting cells, especially dendritic cells, fulfil this crucial 
role by acquiring antigens within tissues, responding to associated danger signals and 
subsequently displaying antigen to T cells (signal 1) with the appropriate information 
about the level of danger present (signal 2).  In addition helper (CD4+) T cells 
recognising antigen presented on MHC class II licence DCs, through co-stimulation, to 
ƉƌŽŵŽƚĞdĐĞůůĂĐƚŝǀĂƚŝŽŶ ?dŚƵƐƚŚĞŚĞůƉĞƌdĐĞůůŐŝǀĞƐĂ ?ƐĞĐŽŶĚŽƉŝŶŝŽŶ ?ƚŽƚŚĞƐŽ
that antigens which have previously been seen as dangerous and have hence 
generated memory responses are promoted as immunogenic.    
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Figure 1-1  Induction phase of anti-tumour CD8 cytotoxic T cells. 
Immature dendritic cells acquire antigen within the tumour and migrate to the draining lymph 
node.  Antigen is processed by the DC and presented to CD4 T cells on MHC class II molecules 
and cross-presented to CD8 T cells on MHC class I molecules.  DC activation is promoted by 
danger signals, IFNg and ligation of CD40 by helper T cells.  Upon activation DCs express co-
stimulatory molecules and cytokines, leading to activation of naive tumour antigen specific T 
cells. 
Legends in boxes indicate potential targets for therapeutic intervention. 
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All nucleated cells express MHC class I molecules and can display endogenously 
ĚĞƌŝǀĞĚĂŶƚŝŐĞŶďŽƵŶĚƚŽD,ĐůĂƐƐ/ŵŽůĞĐƵůĞƐƚŽ ?dĐĞůůƐ ?ďƵƚŽŶůǇ ?ƉƌŽĨĞƐƐŝŽŶĂů ?
antigen presenting cells can provide the additional co-stimulation needed to activate 
naive T cells.  Endogenous antigen is generated from self or viral proteins through the 
actions of proteosomes within the cytosol.  It is then transported to the endoplasmic 
reticulum (ER) in a process which is dependent on the Transporter associated with 
Antigen Processing (TAP), loaded onto MHC class 1 and trafficked to the plasma 
membrane.  In contrast, exogenous antigens, such as those from tumours, are taken 
up by antigen presenting cells into endosomes and loaded on MHC class II molecules 
within the endocytic compartment.  CD4 T cells are then able to bind antigen displayed 
on MHC class II molecules on the cell surface (Guermonprez, Valladeau et al. 2002).    
However, some dendritic cells are also able to present exogenous antigens on MHC 
class I molecules foƌƌĞĐŽŐŶŝƚŝŽŶďǇ ?dĐĞůůƐ ?ƚĞƌŵĞĚ ?ĐƌŽƐƐƉƌĞƐĞŶƚĂƚŝŽŶ ?(Albert, 
Sauter et al. 1998).   Cross presentation of tumour antigen bound to MHC class I is a 
constitutive feature during many types of tumour growth (Marzo, Lake et al. 1999; 
Robinson, Lake et al. 1999; Robinson, Scott et al. 2001) even in the absence of any 
antitumor CTL activity.  Cell bound antigen is presented more efficiently than soluble 
antigen (Li, Davey et al. 2001) and the degree of cross presentation is dependent on 
the amount of antigen present (Nelson, Bundell et al. 2000). Cross presentation is 
dependent on TAP, and hence it was initially thought that for cross presentation to 
occur, following cytosolic degradation by proteosomes, exogenous protein had to join 
the endogenous pathway in the ER (Brossart and Bevan 1997).  However recent work 
suggests that TAP is present in endosomes and transports antigen destined for cross 
presentation back into the endosome from the cytoplasm for loading onto MHC I 
(Burgdorf, Scholz et al. 2008). Interestingly, TAP levels in endosomes are regulated by 
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the TLR4-MyD88 pathway, implying that TLR danger signals can upregulate signal 1 on 
the DC as well as signal 2 (Burgdorf, Scholz et al. 2008).    
The fate of the T cell whose T cell receptor binds to cross presented antigen, and 
whether it becomes primed or inactivated as result of this encounter, is critically 
dependent on the state of maturation of the DC; activated DCs cross prime, whereas 
non-activated DCs cross tolerise.  Immature DCs are inefficient at cross presenting 
antigen and do not express the costimulatory molecules required to activate T cells.  
ĞŶĚƌŝƚŝĐĐĞůůŵĂƚƵƌĂƚŝŽŶŝƐŝŶŝƚŝĂƚĞĚďǇ ?ĚĂŶŐĞƌƐŝŐŶĂůƐ ?ĨƌŽŵƉĂƚŚŽŐĞŶƐŽƌĚĂŵĂŐĞĚŽƌ
dying cells and by inflammatory cytokines, including interferon gamma(Brossart and 
Bevan 1997).  In addition, ligation of CD40 on dendritic cells is a potent inducer of IL12 
secretion and increases their capacity to activate T cells (Cella, Scheidegger et al. 
1996).  CD40L is usually provided by helper T cells, consistent with the finding that 
CD40 activation circumvents the need for CD4 T cell help (Bennett, Carbone et al. 
1998; Nowak, Robinson et al. 2003).  DC maturation results in increased antigen 
uptake, upregulation of MHC expression (Cella, Engering et al. 1997), and expression of 
co-stimulators CD80(B7-1) and CD86(B7-2) (Rad, Pollara et al. 2003).  During 
maturation DCs migrate from tissues to draining lymph nodes, downregulating 
endocytic capacity and MHC class II synthesis en route, meaning that antigen 
presented to T cells is restricted to that which was internalised at the time any danger 
signal was encountered (Guermonprez, Valladeau et al. 2002). 
 
Promoting the CD8 T cell response  ? overcoming the reluctance of T cells to become 
activated and attack tissues. 
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Priming of CD8 T cells by mature DC in the draining lymph node requires several 
signals: T cell receptor binding to antigen coupled to MHC class 1, ligation of CD28 on 
the T cell by CD80 or CD86 on the DC and inflammatory cytokines such as IL-12 and 
type 1 interferons.  However, an effective anti-tumour response also requires that 
these cells proliferate, survive in the circulation, enter the tumour and fulfil their 
effector function (Lake and Robinson 2005). 
There is evidence that CD4+ cells play a critical role in this process.  The addition of 
tumour antigen specific CD4+ cells to a CD8+ adoptive transfer treatment strategy in 
mice led to sustained accumulation of tumour specific CD8+ cells in tumour and 
lymphoid tissues when compared with CD8+ transfer alone.  Cytotoxic activity of the 
CTLs was maintained and mice were protected from tumour growth (Marzo, Kinnear et 
al. 2000).  Persistent CD4+ help and  IL-2 secretion are required to maintain CD8 cell 
function and numbers (Antony, Piccirillo et al. 2005).  Direct cell  W cell contact from 
CD4 cells can also protect effector CD8 cells from activation induced cell death 
(Kennedy and Celis 2006).   
Help from CD4 cells during CD8 priming gives rise to CD8 cells that are not only able to 
function as effector CTL but on restimulation with antigen undergo further clonal 
expansion leading to the generation of memory cells (Janssen, Droin et al. 2005; 
Bannard, Kraman et al. 2009; Feau and Schoenberger 2009).  This is again dependent 
on IL-2 secretion (Williams, Tyznik et al. 2006), consistent with the finding that mice 
cured of tumour through the adoptive transfer of Th1 cells acquired immunological 
memory whereas those cured by transfer of Th2 cells did not (Nishimura, Nakui et al. 
2000).  In contrast those CD8 cells that do not receive CD4 help during priming die 
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following secondary contact with antigen, partly mediated by upregulation of the 
TRAIL receptor DR5 (Janssen, Droin et al. 2005).    
Although the role of CD4 helper cells in the activation and maintenance of CD8 T cells 
and the generation of memory is well established, less is known about their precise 
role following secondary encounter with antigen within the tumour.  Because CD4 cells 
enhance tumour CD8 infiltration (Marzo, Kinnear et al. 2000) it is assumed that 
through induction of co-stimulation plus cytokine and chemokine production, helper T 
cells facilitate secondary expansion and survival of CTLs (Kennedy and Celis 2008).  In a 
metastatic murine tumour model, the presence of memory CD4 cells enhanced 
secondary expansion of memory CD8 cells, increased tumour infiltration of activated 
CD8 cells, and controlled tumour growth (Hwang, Lukens et al. 2007). However, it is 
unclear whether this secondary help is mediated directly to CTLs or via further 
interactions with antigen presenting cells.   
 
Why does a strong T cell response still fail to eradicate tumours? [Figure 1-2] 
The importance of a robust effector T cell response in mediating successful outcomes 
to immunotherapy has been recently shown in a clinical human papillomavirus vaccine 
trial for pre-malignant vulval intraepithelial neoplasia, in which measured T cell 
responses strongly correlated with regression of lesions (Kenter, Welters et al. 2009).  
However, in other clinical trials of tumour vaccines against larger, invasive 
malignancies the effective generation of tumour antigen specific T cells in peripheral 
blood has not predicted clinical efficacy (Rosenberg, Sherry et al. 2005).  This disparity 
may reflect the weaker activity of T cells generated by vaccines targeting shared self 
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tumour antigens compared to those directed against viral neo-antigens.  It may also 
reflect the presence of a number of other barriers to effective immunotherapy in 
established invasive tumours compared to pre-malignant lesions. 
Figure 1-2    Effector phase of anti-tumour CD8 cytotoxic T cells 
Cytotoxic CD8 T cells (CTLs) need to exit the circulation and enter the tumour.  CD4 
cells facilitate tumour infiltration and may promote secondary expansion of CD8s, 
although it is unclear whether further contact with antigen presenting cells is 
necessary for this to occur.  Following recognition of their cognate antigen presented 
on MHC class I molecules by tumour cells, CTLs can effect tumour cell killing.  Local 
immunosuppressive mechanisms inhibit the anti-tumour response, including 
suppression by regulatory cells and inhibitory cytokines, loss of MHC class 1 expression 
by tumour cells and expression of PD-L1. 
Legends in boxes indicate potential targets for therapeutic intervention. 
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Tumour reactive CTLs may be ineffective because they remain in the periphery or the 
draining lymph node without actually infiltrating the tumour (Stumbles, Himbeck et al. 
2004), or they may disseminate to the tumour but display only weak anti-tumour 
activity.  This suggests that the anti-tumour T cell response can fail at a point 
downstream of the induction phase.  
Failure of activated T cells to continue to expand and maintain function 
T cell anergy can occur as a result of inadequate costimulation during priming, or can 
be acquired during later phases of clonal expansion after adequate initial activation 
(Deeths, Kedl et al. 1999; Mescher, Popescu et al. 2007).  Cells that become anergic 
may be able to fulfil effector functions but are unable to expand further or generate 
memory cells; this state can be reversed by IL-2, typically supplied by CD4 cells.  
Acquired anergy provides an inherent brake to the initial rapid CD8 T cell response 
which will recede after a few rounds of cell division unless further CD4 help is supplied.  
T cells may also become tolerised following persistent peripheral exposure to antigen, 
for example, in the setting of a growing tumour. This leads to a failure to proliferate 
and failure to produce IL-2 in response to antigen although cytotoxic activity may be 
retained (Tanchot, Guillaume et al. 1998; Ohlen, Kalos et al. 2002).  These findings are 
potentially relevant in human cancer, with Beyer identifying both tumour reactive and 
non tumour reactive T cell clones coexisting in cancer patients; non reactive cells had 
not simply been suboptimally activated but had altered molecular programs leading to 
division arrest anergy (Beyer, Karbach et al. 2009). 
Activated T cells may be switched off by some tumours 
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Inhibitory co-receptors, including CTLA4 and PD1, appear to play a major role in 
inducing and maintaining peripheral T cell tolerance.  They are expressed on activated 
T cells and interact with molecules of the B7 family which are found on APCs but are 
also expressed by many tumours (Zou and Chen 2008).  CTLA-4 is upregulated during T 
cell activation and causes competitive inhibition of B7-CD28 induced T cell activation, 
modulates intracellular signalling pathways and leads to decreased IL-2 production, 
impaired TCR signalling and cell cycle arrest, particularly in the early post-activation 
phase (Hodi 2007).  Anti CTLA-4 treatment has been trialled in melanoma and other 
cancers with evidence of clinical efficacy (Wolchok and Saenger 2008; Yuan, Gnjatic et 
al. 2008) and has recently been granted FDA approval for treatment of advanced 
melanoma (Hodi, O'Day et al. 2010).  
The expression of PD-L1 (B7-H1), a ligand for PD-1, is upregulated by IFNg (Blank, 
Brown et al. 2004) and has been observed in many tumour types, often being 
associated with a poor prognosis (Zou and Chen 2008).  PD-1/PD-L1 interactions impair 
antitumour T cell responses in mice, which is reversed in PD-1 deficient mice or by 
blocking PD-1 (Blank, Brown et al. 2004).  Mechanistically, expression of PD-L1 by 
tumours induces T cell apoptosis (Dong, Strome et al. 2002), induces production of IL-
10, and may mediate T reg suppressive activity (Zou and Chen 2008)).  PD-1/PD-L1 
inhibition strategies in patients with cancer are currently in early phase clinical trials.  
Although both CTLA-4 and PD-1 induced T cell tolerance in an autoimmune diabetes 
model, only PD-1was able to maintain tolerance after induction (Fife, Guleria et al. 
2006).  It is unclear whether this observation will be important in tumour models or 
clinical testing.  
Suppression by regulatory T cells 
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Regulatory T cells (Tregs) modulate the immune response and function by 
downregulating potentially harmful autoreactive T cells, and Treg defects are 
associated with the development of autoimmune disease (Costantino, Baecher-Allan et 
al. 2008; Poitrasson-Riviere, Bienvenu et al. 2008).  Although other types of 
suppressive cell have been identified, most regulatory T cells are characterised by 
expression of surface CD4, CD25 and by intracellular foxp3, a transcription factor that 
mediates many of their inhibitory capabilities (Fontenot, Rasmussen et al. 2005).  Tregs 
can inhibit effector T cell responses during both the induction (Darrasse-Jeze, Bergot et 
al. 2009) and the effector stage (Huehn, Siegmund et al. 2004; Sarween, Chodos et al. 
2004) by a number of mechanisms, such as direct competition for IL-2, ligation of 
CTLA-4 with CD80 or CD86 on effector T cells, by promoting the development of 
inhibitory DCs, or through the generation of inhibitory cytokines, TGFb and IL10 (von 
Boehmer 2005). The importance of this subset has been demonstrated in vivo, with T 
reg depletion mediating tumour regression in mice (Onizuka, Tawara et al. 1999; 
Rudge, Barrett et al. 2007). 
 Increased Treg infiltration has been demonstrated in many human tumour types, 
usually associated with decreased anti-tumour immune responses and worse 
prognosis (reviewed in (Beyer and Schultze 2006)).  However, Treg accumulation is not 
a universal feature of human cancer, implying a lack of immune response to the 
tumour or other means of regulation such as myeloid derived suppressor cells.  
Furthermore, in colorectal cancer, two independent cohorts demonstrated improved 
survival in patients with a high frequency of tumour infiltrating Tregs (Frey, Droeser et 
al. 2009; Salama, Phillips et al. 2009).  One explanation is that this finding actually 
reflects increased immunogenic stimuli within these tumours - either due to tumour 
antigens or due to gut pathogens - and a subsequent robust immune response. 
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The prognostic significance of Tregs in many human cancers, together with the success 
of Treg depletion in murine tumours, suggests Treg depletion may work as a clinical 
therapeutic strategy. This has been attempted through anti CD25 therapies, which 
have shown effective T reg depletion and enhanced CTL response to subsequent 
peptide vaccination (Rech and Vonderheide 2009).  However, a different T reg 
depletion strategy using the cytotoxic agent cyclophosphamide may be more readily 
translatable to the clinic.  At high doses cyclophosphamide is cytotoxic and causes 
immunosuppression but at low doses it preferentially depletes numbers of T regs 
(Ghiringhelli, Larmonier et al. 2004; Ghiringhelli, Menard et al. 2007; van der Most, 
Currie et al. 2009) and impairs T reg function (Lutsiak, Semnani et al. 2005).  A single 
dose of cyclophosphamide depleted T regs and when followed by an immunotherapy 
cured mice with established tumours (Ghiringhelli, Larmonier et al. 2004).  In humans 
low dose oral cyclophosphamide in patients with advanced cancer selectively depleted 
the T reg subset and enhanced the cytotoxic capacity of T and NK cells (Ghiringhelli, 
Menard et al. 2007).   
Immune escape within the tumour microenvironment 
Cytotoxic T cells recognise antigen bound to MHC class 1.  However reduced 
expression of MHC class 1, usually due to epigenetic regulation of TAP expression, has 
been observed in many tumour types and associated with a poor prognosis in patients 
with colorectal cancer (Watson, Ramage et al. 2006) ? ?ĂƌǁŝŶŝĂŶ ?ƐĞůĞĐƚŝŽŶŽĨƚŚĞƐĞ
resistant clones through intrinsic or therapeutic immune pressure may explain why 
some patients who initially respond to immunotherapy then subsequently relapse 
(Restifo, Marincola et al. 1996).   
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Changes in expression patterns of non-antigenic molecules may also alter traffic to the 
tumour. Villablanca et al showed that human and mouse tumours can subvert the 
migratory ability of mature dendritic cells by the expression of LXRa ligands 
(Villablanca, Raccosta et al. 2010).  LXRs bind to oxidised cholesterol and when 
activated on dendritic cells inhibited expression of CCR7, a chemokine required for DC 
migration to the draining lymph node.  This resulted in impaired DC migration to 
draining lymph nodes, reduced T cell priming and impaired antitumour activity.   
Immunosuppressive cytokines within the tumour also impair immune responses and 
transforming growth factor beƚĂ ?d'&ɴ ?ŚĂƐďĞĞŶŝŵƉůŝĐĂƚĞĚŝŶŵĂŶǇĚŝĨĨĞƌĞŶƚƚǇƉĞƐŽĨ
cancer (Elliott and Blobe 2005) ?d'&ɴŝŶĚƵĐĞƐĞǆƉĂŶƐŝŽŶ of Treg (Ghiringhelli, Puig et 
al. 2005) and inhibits T cell effector function (Ahmadzadeh and Rosenberg 2005).  
/ŶƚĞƌǀĞŶƚŝŽŶƐƚĂƌŐĞƚŝŶŐd'&ɴŚĂǀĞďĞĞŶƐŚŽǁŶƚŽƌĞĚƵĐĞƚƵŵŽƵƌŐƌŽǁƚŚŝŶǀŝǀŽ ?ĂŶĚ
to enhance the effectiveness of other immunotherapies (Marzo, Fitzpatrick et al. 1997; 
Kim, Buchlis et al. 2008).  Metabolic dysregulation also contributes to local 
immunosuppression.  The enzyme indolamine 2,3-dioxygenase (IDO) is expressed in 
numerous cancers (Uyttenhove, Pilotte et al. 2003).  It is upregulated by IFNg and 
causes tryptophan breakdown which leads to T cell apoptosis (Lob, Konigsrainer et al. 
2009).  Intervention aimed at silencing IDO expression have shown antitumour activity 
in a mouse melanoma model (Zheng, Koropatnick et al. 2006). 
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1.2 Helper T cell subsets and their role in antiȂtumour immunity 
 
1.2.1 CD4 subtypes and differentiation 
The ability of a subset of T cells expressing the marker CD4 to help promote CD8+ 
cytotoxic T lymphocyte responses has been known for over 30 years (Keene and 
Forman 1982).  CD4+ T cells recognise antigen presented on MHC class II complexes by 
antigen presenting cells, such as dendritic cells, macrophages and B cells.  CD4+ helper 
T lymphocytes can further differentiate into distinct subsets which have diverse effects 
on immunological function, mediated through the secretion of characteristic sets of 
cytokines.  The prototypic division of Th subsets was into Th1s, which produce IFNg, 
TNFa, IL-2 and promote inflammatory responses and cell mediated immunity, and 
Th2s, which secrete IL-4, IL-5, IL-13 and promote humoral responses (Mosmann, 
Cherwinski et al. 1986).  Recently Th17s, an IL-17 secreting CD4+ subset, have been 
identified (Harrington, Hatton et al. 2005; Park, Li et al. 2005).  Th17s appear to be 
involved in tissue responses to extracellular pathogens and have been implicated in 
many autoimmune diseases.  Th17s are found in highest concentration in lung and 
digestive mucosa. 
Activation of naive CD4+ T cells requires that T cell receptor on the CD4 cell binds to 
antigen presented by MHC class II on antigen presenting cells (signal 1) and that 
sufficient co-stimulation (signal 2) is provided, such as ligation of CD28 on the T cell by 
CD80/86 on the antigen presenting cell.  The subsequent differentiation of activated 
CD4+ cells into Th1, Th2 and Th17 subtypes is dependent on the presence of certain 
cytokines at the time of activation. 
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Th1 cell differentiation is induced by IL-12.  IL-12 is produced by activated dendritic 
cells (Cella, Scheidegger et al. 1996) and acts through the IL-12 receptor to drive STAT-
4 mediated activation of the Th1 transcription factor Tbet.  Interferon gamma can also 
act in an autocrine manner to further promote expression of Tbet through STAT-1 
(Kaiko, Horvat et al. 2008).   
Th2 differentiation is primarily driven by IL-4 which promotes expression of the 
transcription factor GATA-3 through STAT-6.  Other, non-cytokine related factors can 
also influence Th1/Th2 differentiation including the strength of TCR stimulus; with low 
level stimulation insufficient to induce differentiation, moderate stimulation favouring 
Th2 and a strong stimulus favouring Th1 differentiation (Rogers and Croft 1999).   
Th17 differentiation can be induced by a combination of IL-6 and TGFb.  Furthermore, 
IL-21 is produced by Th17 cells and can itself, in combination with TGFb, induce Th17 
cells.  In humans, IL-1B plus TGFb may also be able to induce Th17s.  Additionally, IL-23 
is important for the survival and activation of Th17 cells, although is not required for 
differentiation from naive T cells (Harrington, Hatton et al. 2005; Park, Li et al. 2005; 
Korn, Bettelli et al. 2009).  Following activation of CD4 cells in the presence of the 
necessary Th17 inducing cytokines, expression of ROR gamma is upregulated.  ROR 
gamma is required and sufficient for the expression of IL-17 and hence is the defining 
transcription factor for this lineage (Ivanov, McKenzie et al. 2006). 
Cytokines produced by helper subsets have antagonistic effects on the differentiation 
of other subsets, ensuring that once established, the polarity of the CD4 immune 
response is reinforced.  IFNg produced by Th1s antagonises Th2 development and 
conversely IL-4 antagonises Th1 differentiation (Gajewski and Fitch 1988; Chen and Liu 
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2009).  Th17 differentiation is inhibited both by IL-4 and IFNg (Harrington, Hatton et al. 
2005; Park, Li et al. 2005). 
Regulatory CD4+foxp3+ T cells can arise naturally in the thymus (nTreg), or may be 
converted peripherally from CD4+foxp3- cells (inducible Treg, iTreg)(Apostolou, 
Sarukhan et al. 2002; Apostolou and von Boehmer 2004).  Generation of iTregs in vivo 
and in vitro requires TCR stimulation, TGFb and IL-2 (Chen, Jin et al. 2003; Curotto de 
Lafaille and Lafaille 2009; Long, Rieck et al. 2011).  Both nTreg and iTreg constitutively 
express CD25, GITR and CTLA-4, and mediate suppressive functions in a contact 
dependent manner.  However the nTreg and iTreg populations may have differing 
roles as a result of their TCR repertoires.   nTregs are generated by high avidity 
interactions in the thymus with organ specific self antigens (Apostolou, Sarukhan et al. 
2002).  iTregs can be generated in the periphery from naive CD4 cells through contact 
with endogenously expressed or exogenously administered  antigens (Apostolou and 
von Boehmer 2004; Knoechel, Lohr et al. 2005) and as a consequence share a 
repertoire with the naive T cell population.  Therefore, it has been proposed that the 
role of nTregs is to prevent autoimmunity to self antigens whereas iTregs maintain 
tolerance at sites of foreign antigen, such as the gut (Curotto de Lafaille and Lafaille 
2009).  Since tumours express both self and foreign antigens this concept has 
relevance for tumour immunity.   However, it is unclear what proportion of Tregs react 
with specificity to tumour antigens (Wang, Peng et al. 2005), or whether they are 
recruited through the recognition of  shared self antigens that are co-expressed by 
tumour cells (Nishikawa, Kato et al. 2003; Darrasse-Jeze, Bergot et al. 2009).   
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1.2.2 Plasticity between CD4 subsets 
 
Despite the identification of distinct CD4 subtypes - Th1, Th2, Th17 and Treg - 
distinguishable by different cytokine secretion profiles and expression of specific 
transcription factors, it has long been recognised that a degree of plasticity exists 
between these lineages(Murphy and Stockinger 2010).   
Th1 and Th2 cells can be converted into the other subtype in the early stages of 
activation but not after prolonged stimulation (Murphy, Shibuya et al. 1996), 
suggesting that the number of rounds of cell division may impact on phenotypic 
stability.  Furthermore, the stability of Th1s and Th2s appears greater than that of 
Th17s and Tregs.   The differentiation pathways of both Th1 and Th2s contain positive 
feedback loops which reinforce expression of the transcription factors tbet and GATA-3 
respectively (Ouyang, Lohning et al. 2000; Mullen, High et al. 2001), providing 
phenotypic stability to the lineage.  In contrast, no reinforcing transcriptional circuits 
have been identified for RORg in Th17s or foxp3 in Tregs.   
Both Th17s and inducible T regs share common features in their differentiation 
pathway.  TGFb induces the expression of both RORg and foxp3, however the 
additional presence of inflammatory cytokines IL-6, IL-21 or IL-23 suppresses foxp3 
expression and enhances Th17 development (Bettelli, Carrier et al. 2006; Nurieva, Yang 
et al. 2007; Zhou, Lopes et al. 2008).  In contrast high levels of TGFb favour foxp3 
mediated suppression of RORg and induces T reg development (Zhou, Lopes et al. 
2008).  IL-2 further enhances Treg differentiation and inhibits Th17 generation 
(Kryczek, Wei et al. 2007).  As such the balance between Th17 and T reg differentiation 
is influenced by local concentrations of inflammatory cytokines and TGFb.   
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IFNg/IL-17 double producing cells are detectable in patients with chronic inflammatory 
conditions suggesting a possible relationship between Th1 and Th17 lineages 
(Boniface, Blumenschein et al. 2010).  Th17s convert into Th1s after exposure to IL-12 
and this is dependent on STAT-4/ tbet (Lee, Turner et al. 2009).  In vitro differentiated 
dŚ ? ?ƐĂůƐŽĐŽŶǀĞƌƚĞĚƚŽ/&EŐA? ?dŚ ?ůŝŬĞ ?ĐĞůůƐŝŶůǇŵƉŚŽƉĞŶŝĐĞŶǀŝƌŽŶŵĞŶƚƐ(Nurieva, 
Yang et al. 2009).  In another model, Th17 cells generated in vitro were readily 
converted into Th1s or Th2s by IL-12 or Il-4 respectively, however this was not the case 
for Th17 cells found in vivo, which maintained IL-17 expression despite culture ex vivo 
in these conditions (Lexberg, Taubner et al. 2008).  This suggests that In vitro 
differentiation conditions do not necessarily replicate those found in vivo.   A novel 
reporter mouse strain allowing fate tracking of cells which had previously expressed IL-
17 enabled Hirota et al to show that during experimental autoimmune encephalitis, 
inflammation was mostly mediated by cells which had produced IL-17 before their 
conversion to IFNg+ cells by IL-23 (Hirota, Duarte et al. 2011).  This only occurred 
under certain inflammatory stimuli, suggesting that the fate of Th17s is determined by 
distinct inflammatory conditions which drive Th17 plasticity into an IFNg secreting pro-
inflammatory effector cell. 
 
1.2.3 CD4 helper subtypes and anti-tumour responses 
 
CD4 cells provide help during both the induction and effector phase of the CD8 T cell 
response.  Ligation of CD40L on DCs with CD40 on CD4 cells provides an activating 
signal to the DC, stimulating the expression of costimulatory molecules, MHC 
expression and IL-12(Cella, Scheidegger et al. 1996).  Th cells also secrete cytokines 
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such as IL-2, important for the generation and survival of cytotoxic CD8s (Antony, 
Piccirillo et al. 2005) and for memory responses  (Janssen, Droin et al. 2005).  
Additionally CD4 helper T cells can promote anti-tumour responses mediated by innate 
immune cells, including macrophages, NK cells and granulocytes (Hung, Hayashi et al. 
1998; van den Broeke, Daschbach et al. 2003; Perez-Diez, Joncker et al. 2007; 
Heusinkveld, de Vos van Steenwijk et al. 2011).  CD4 cells can also exhibit direct 
cytotoxicity against tumour cells that express MHC class II molecules as a result of 
exposure to IFNg (Quezada, Simpson et al. 2010; Xie, Akpinarli et al. 2010). 
The role of regulatory T cells in suppressing anti-tumour immunity is well established 
and is discussed in section 1.1.   However the different ways that effector subsets 
influence anti-tumour immune responses is less clear.  Th1 cells have traditionally 
been thought to be the most important helper T cell in the context of anti-tumour 
immunity.   Rejection of tumour in a murine model was shown to correlate with a Th1 
response whereas tumour progression was associated with Th2 responses(Hamilton 
and Bretscher 2008).  Secretion of the Th1 cytokine IFNg has been found to be 
necessary for successful outcomes to a number of different immunotherapies 
(Murphy, Welniak et al. 2003; Moeller, Haynes et al. 2005; Muranski, Boni et al. 2008) 
and for CD4 mediated tumour elimination (Mumberg, Monach et al. 1999) and 
upregulates expression of MHC molecules by tumour cells (Quezada, Simpson et al. 
2010).  IFNg produced by Th1 CD4+ cells interacts with innate immune cells, stimulates 
production of reactive oxygen species by tumoricidal macrophages(Hung, Hayashi et 
al. 1998), converts tolerogenic M2 macrophages into inflammatory M1 macrophages 
(Heusinkveld, de Vos van Steenwijk et al. 2011)and is a key cytokine for NKT cell anti-
tumour immunity(Hong, Lee et al. 2006).  However, although important in initial anti-
tumour activity, IFNg has also been shown to impair T cell memory formation and 
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secondary immune responses to a later tumour rechallenge through induction of CD4 
T cell apoptosis (Berner, Liu et al. 2007).  It also upregulated expression of PD-L1 in 
squamous cell carcinomas and has negative effects on Th17 cells, suggesting that the 
balance between anti-tumour and tumour -promoting effects may be complex 
(Tsushima, Tanaka et al. 2006; Chen and Liu 2009). 
In contrast, an increased intratumoural Th2 infiltrate predicted a poor prognosis in 
patients with pancreatic cancer(De Monte, Reni et al. 2011).  However, despite being 
considered unhelpful in anti-tumour immune responses, when in vitro differentiated 
Th2 cells were adoptively transferred into tumour bearing mice, they mediated tumour 
rejection as effectively as Th1s through a CD8 dependent mechanism (Nishimura, 
Iwakabe et al. 1999).  However, only mice that received Th1 cells developed 
immunological memory and resisted rechallenge with tumour.  In another model 
maximal anti-tumour responses to a whole cell vaccine required both Th1s and Th2s to 
be present in the tumour microenvironment(Hung, Hayashi et al. 1998).  The Th2 
component of this response was mediated by IL-4 dependent recruitment of 
eosinophils to the tumour site, suggesting that eosinophils may a Th2 anti-tumour 
effector cell. 
Th17 cells normally constitute a small fraction of the CD4+ T cell population, but 
increased concentrations of Th17 cells have been found in the tumour 
microenvironment (Miyahara, Odunsi et al. 2008; Kryczek, Banerjee et al. 2009; Zhang, 
Yan et al. 2009) and the peripheral blood (Koyama, Kagamu et al. 2008; 
Derhovanessian, Adams et al. 2009; Horlock, Stott et al. 2009) of patients with a 
diverse range of cancers.  Their role in tumour responses is still controversial.  In 
hepatocellular carcinoma, tumour infiltration of Th17s correlated with poor prognosis 
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and with increased tumour angiogenesis (Zhang, Yan et al. 2009).  This is consistent 
with experimental models showing that IL-17 promotes angiogensis and tumour 
growth (Numasaki, Fukushi et al. 2003; Wang, Yi et al. 2009).  However in 201 ovarian 
cancer patients, tumour infiltrating Th17s correlated positively with the presence of 
effector cells and effector cytokines and were inversely associated with regulatory cells 
(Kryczek, Banerjee et al. 2009).  High levels of IL-17 in ascitic fluid predicted improved 
survival in this cohort.  Increased Th17 frequencies in peripheral blood has been 
associated with less advanced disease in small cell lung cancer(Koyama, Kagamu et al. 
2008) and with improved responses to treatment in prostate and breast cancer 
(Derhovanessian, Adams et al. 2009; Horlock, Stott et al. 2009).  
In animal models adoptive transfer of in vitro differentiated tumour antigen specific 
Th17 cells into lymphopenic(Muranski, Boni et al. 2008) and non-lymphopenic mice 
(Martin-Orozco, Muranski et al. 2009) has been shown to cause tumour rejection more 
effectively than in vitro differentiated Th1 cells.  The presence of lymphopenia appears 
to alter the behaviour of these cells following transfer.  In lymphopenic environments 
dŚ ? ?ƐĐŽŶǀĞƌƚŝŶƚŽ/&EŐƉƌŽĚƵĐŝŶŐ ?dŚ ?ůŝŬĞ ?ĐĞůůƐďƵƚ ƚŚŝƐĚŽĞƐŶŽƚŽĐĐƵƌŝŶŶŽƌŵĂů
hosts (Nurieva, Yang et al. 2009).  Consistent with this, in lymphopenic mice, tumour 
eradication was dependent on secretion of IFNg but not on IL-17 (Muranski, Boni et al. 
2008), suggesting that in the lymphopenic situation conversion of Th17s into IFNg 
producing cells is a critical component of their anti-tumour activity.  However Th17s 
have also shown anti-tumour activity in non-lymphopenic mice in  a model of 
metastatic  lung melanoma, where the Th17 phenotype was maintained in vivo 
(Martin-Orozco, Muranski et al. 2009).  Th17 cells caused increased DC infiltration of 
tumour and increased activation of tumour specific CD8s when compared with Th1 
cells.  This effect was compromised in IL-17 deficient mice but not by IFNg neutralising 
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antibodies, suggesting that, unlike in the lymphopenic situation, Th17s can mediate 
anti-tumour activity as a result of IL-17 production. 
 
1.3 The effects of chemotherapy on anti-tumour immunity 
 
Cytotoxic chemotherapy can cause lymphopenia and neutropenia and until recently 
the notion that chemotherapy could synergise with immunotherapy was not 
considered plausible.   However, it is now clear that chemotherapy can have 
immunostimulatory effects at a number of different points in the anti-tumour immune 
response: 
Removal of suppressive cells 
In causing lymphopenia, chemotherapy depletes regulatory T cells as well as those T 
cells which have been tolerised to tumour antigens.  Depletion of regulatory T cells by 
cyclophosphamide (Ghiringhelli, Larmonier et al. 2004; Lutsiak, Semnani et al. 2005; 
Ghiringhelli, Menard et al. 2007; van der Most, Currie et al. 2009) or depletion of 
myeloid derived suppressor cells with gemcitabine (Suzuki, Kapoor et al. 2005) can 
enhance antitumour activity through removal of negative regulation.  
Lymphodepletion in combination with adoptive immunotherapy has shown efficacy in 
mice (Dummer, Niethammer et al. 2002; Hu, Poehlein et al. 2002) and humans 
(Dudley, Wunderlich et al. 2002).   
Homeostatic proliferation 
Following chemotherapy-induced lymphopenia, T cell numbers can either be restored 
through thymic pathways by active thymopoiesis which producies naive T cells, or 
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through peripheral expansion of T cell clones, through homeostatic proliferation or 
antigen driven expansion (Mackall, Hakim et al. 1997).   In adults the thymus involutes 
with age, meaning the thymic pathway becomes compromised and the recovery of the 
naive T cell repertoire may remain diminished for many years.  In contrast homeostatic 
proliferation results in rapid expansion of the peripheral T cell pool.  Although the 
repertoire of the T cell pool which has regenerated through homeostatic and /or 
antigen driven proliferation is restricted, this environment may maximise the 
expansion of tumour reactive clones, improving anti-tumour immunity (Williams, 
Hakim et al. 2007).   Homeostatic proliferation is critically dependent on IL-7 (Tan, Dudl 
et al. 2001).  The IL-7 receptor is expressed at high levels on naive T cells, but is 
downregulated after activation, and is expressed at a low level on Tregs.   When 
lymphocyte numbers are depleted availability of IL-7 increases and T cells proliferate 
until IL-7 has been consumed, as illustrated by a dynamic, inverse relationship 
between serum IL-7 levels and T cell numbers observed in patients recovering from 
lymphopenia of varying etiology (Fry, Connick et al. 2001).  IL-7 administered to 
patients with melanoma increased circulating CD4 and CD8 T cells and decreased 
proportions of Tregs (Rosenberg, Sportes et al. 2006).  IL-7 also increases T cell 
trafficking to lymph nodes(Chu, Memon et al. 2004) and provides an anti-apoptotic 
signal to T cells (Li, Jiang et al. 2004). 
Immunogenic tumour cell death 
Additional mechanisms for immune modulation following chemotherapy include 
increased antigen release, and upregulation of immunogenic surface molecules. 
Apoptotic tumour cell death increases the quantity of antigen released and augments 
cross presentation by mature DCs (Rovere, Sabbadini et al. 1999).  Chemotherapy 
 43 
 
induced cell death can also be qualitatively immunogenic through upregulation of 
surface calreticulin (Chaput, De Botton et al. 2007; Obeid, Tesniere et al. 2007; 
Panaretakis, Joza et al. 2008) or release of intracellulaƌĚĞƌŝǀĞĚ ?ĚĂŶŐĞƌƐŝŐŶĂůƐ ?
(Apetoh, Ghiringhelli et al. 2007; Apetoh, Ghiringhelli et al. 2007; Ghiringhelli, Apetoh 
et al. 2009; Martins, Tesniere et al. 2009).  Treatment with gemcitabine results in 
increased antigen cross presentation and priming of tumour specific CD8 cells (Nowak, 
Lake et al. 2003).  Chemotherapy can also sensitise those cells not directly lysed by 
treatment to subsequent killing by immune cells, through upregulation of death 
receptors Fas (CD95) or TRAIL receptors (DR5) (Mattarollo, Kenna et al. 2006; van der 
Most, Currie et al. 2009) 
 
 
1.4 Combined chemo-immunotherapy  
 
The conventional oncology testing field for new treatments is metastatic disease which 
has failed multiple lines of therapy.  Such a high tumour burden with its associated 
levels of immunosuppression may be a too high a hurdle for immunotherapy alone to 
achieve clinically significant results.  Many murine studies have demonstrated 
responses to immunotherapy in very early tumours but fewer have demonstrated 
efficacy against larger, advanced tumours.  These very small tumours are unlikely to be 
representative of most human cancers.  However, murine studies have also shown that 
combining different types of immunotherapy, or combining immunotherapy with 
chemotherapy, can lead to responses against larger tumours and distal disease 
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(Jackaman, Bundell et al. 2003; Nowak, Robinson et al. 2003; Jackaman, Lew et al. 
2008; Broomfield, van der Most et al. 2009).   
A number of clinical trials of chemo-immunotherapy have been reported with some 
promising results, although larger randomised controlled trials are still required 
(reviewed in (Zitvogel, Apetoh et al. 2008)).  
 
1.5 Adoptive immunotherapy in the treatment of cancer 
 
The potential for adoptively transferred T cells, harvested from tumours and expanded 
in vitro in IL-2, to mediate tumour regression was first demonstrated in  murine 
models over 25 years ago (Rosenberg, Spiess et al. 1986).  Adoptive immunotherapy 
using tumour infiltrating lymphocytes (T.I.L.) expanded ex vivo and administered with 
high dose IL-2 has demonstrated reported response rates of 49-72% in advanced 
metastatic melanoma, with complete response rates of 12-40% (Rosenberg, Yang et al. 
2011).  Similar response rates were seen when CD8s were enriched from T.I.L. cultures 
prior to adoptive transfer (Dudley, Gross et al. 2011).  Other groups have generated 
tumour specific  CD8 T cell clones through in vitro peptide stimulation of CD8s isolated 
from peripheral blood and shown that these cells home to tumour sites, with variable 
clinical response rates observed (Mitchell, Darrah et al. 2002; Yee, Thompson et al. 
2002; Mackensen, Meidenbauer et al. 2006).  In all these techniques, CD8s were 
expanded in vitro with IL-2 and activating anti-CD3 antibody to obtain sufficient cell 
numbers (>1x10
10
) for adoptive transfer.  Following adoptive transfer, administration 
of high doses of IL-2 was also required for cells to survive in vivo, traffic to antigen 
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positive sites and elicit tumour specific responses.  In the absence of Il-2, transferred 
cells did not persist (Mitchell, Darrah et al. 2002; Yee, Thompson et al. 2002).   
Although animal models have demonstrated the potential benefit of using CD4 cells for 
adoptive immunotherapy(Muranski and Restifo 2009; Quezada, Simpson et al. 2010; 
Xie, Akpinarli et al. 2010), clinical experience of CD4 adoptive immunotherapy in 
humans is limited, although successful treatment of metastatic melanoma using 
autologous NY-ESO-1 specific CD4 clones has been reported (Hunder, Wallen et al. 
2008).  CD4 cells potentially offer benefits for adoptive immunotherapy, not only in 
providing help for CD8 T cells (Antony, Piccirillo et al. 2005) and through recruitment of 
innate immunity (Perez-Diez, Joncker et al. 2007) but CD4 cells may also exhibit direct 
cytotoxicity against tumour cells (Quezada, Simpson et al. 2010).  Perez-Diez et al 
directly compared the anti-tumour activity of adoptively transferred tumour specific 
CD4 and CD8 T cells against HY antigen expressing tumours and found CD4 cells to be 
more effective than CD8 cells, an effect which appeared to be due to interactions with 
NK cells.  Furthermore, since CD4 cells recognise antigen presented on MHC class II by 
antigen presenting cells, their anti-tumour activity is not directly dependent on antigen 
expression by tumours.  Downregulation of MHC class I molecules on tumours does 
not therefore lead to immune escape from CD4 cells as it does from CD8 T cells 
(Muranski and Restifo 2009). 
Adoptive immunotherapy protocols almost invariably have involved some form of 
preconditioning regimen to cause lymphodepletion prior to adoptive transfer.  
Myelosuppressive chemotherapy (Dudley, Wunderlich et al. 2002; Dudley, Wunderlich 
et al. 2005), total body irradiation (Wrzesinski, Paulos et al. 2011) and combined 
chemo-radiotherapy (Dudley, Yang et al. 2008) have all been employed to achieve this.   
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The beneficial effects of lymphodepletion include depletion of regulatory T cells 
(Antony, Piccirillo et al. 2005; Yu, Lee et al. 2005; Teng, Swann et al. 2010) and myeloid 
derived suppressor cells (Suzuki, Kapoor et al. 2005).  However non-myeloablative 
preconditioning was found to improve CD8 T cell reactivity even in the genetic absence 
of regulatory T cells, through removal of endogenous cells responsive to the  
homeostatic cytokines IL-7 and IL-15, thus increasing their availability for the 
adoptively transferred cells (Gattinoni, Finkelstein et al. 2005).   These observations 
siupport tŚĞĐŽŶĐĞƉƚƚŚĂƚůǇŵƉŚŽĚĞƉůĞƚŝŽŶĐƌĞĂƚĞƐ ?ƐƉĂĐĞ ?ĨŽƌĂĚŽƉƚŝǀĞůǇƚƌĂŶƐĨĞƌƌĞĚ
tumour reactive T cells to expand (Weber, Atkins et al. 2011).  Additionally total body 
irradiation also causes systemic inflammation and TLR mediated activation of innate 
immune cells due to translocation of gut microbial flora (Paulos, Wrzesinski et al. 
2007).  Increasing the intensity of irradiation increases the efficacy of adoptively 
transferred CD8 T cells in mice(Wrzesinski, Paulos et al. 2011) and humans (Dudley, 
Yang et al. 2008). 
 
1.6 Chemo-immunotherapy in malignant mesothelioma 
 
Mesothelioma is a malignant tumour of pleural and peritoneal surfaces that is 
associated with asbestos exposure in the vast majority of cases.   The boom in asbestos 
use during the latter half of the 20
th
 century has lead to an epidemic of asbestos 
related diseases.  A long latency exists between exposure and development of 
mesothelioma, such that although asbestos usage has been banned in the UK since the 
1980s, the incidence of mesothelioma is not expected to peak until 2015 (Hodgson, 
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McElvenny et al. 2005).  Asbestos use is still on the increase in many developing 
countries and a second global wave of asbestos related disease is predicted as a result. 
Mesothelioma is incurable and responds poorly to currently available treatments.   
Since mesothelioma grows as multifocal pleural nodules which encase the lung, it is 
generally not amenable to surgical resection.  Most patients present with advanced 
disease.  A combination of pemetrexed and cisplatin is the only treatment regimen 
proven to be beneficial, although the effects are modest, with a median prolongation 
of survival of 12 weeks (Vogelzang, Rusthoven et al. 2003).   Non-randomised studies 
have demonstrated individual responses to other agents, including gemcitabine 
(Nowak, Byrne et al. 2002). 
Several other treatment strategies have been tested in early phase clinical trials but 
with no proven benefit to date, including gene therapy (Sterman, Recio et al. 2007) 
and inhibition of growth factors and angiogenic pathways (Garland, Rankin et al. 2007).  
Immunotherapy has been trialled in mesothelioma in both the pre-clinical and the 
clinical setting.   Over 85% of patients with mesothelioma have an associated pleural 
effusion at the time of presentation, which potentially offers a route for local 
administration of therapeutic agents.  A number of early clinical studies examined the 
feasibility of intrapleural IL-2 administration, with response rates of up to 50% 
reported (Astoul, Picat-Joossen et al. 1998).  Intrapleural immunotherapy has also 
been trialled in the form of IFNb gene transfer using an adenoviral vector, with 
immune responses detected in 7 of 10 patients and clinical responses in 4 patients 
(Sterman, Recio et al. 2007).  In contrast, intrapleural administration of activated 
macrophages and IFNg demonstrated little anti-tumour activity against mesothelioma 
(Monnet, Breau et al. 2002). 
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Trials of tumour vaccines have been able to generate demonstrable T cell responses in 
patients with mesothelioma, but the effects of these interventions on survival are 
unknown.   When an autologous tumour cell lysate was administered intradermally 
with GM-CSF, 7 of 22 patients developed either cell-mediated or humoral immune 
responses (Powell, Creaney et al. 2006).  More recently, immune responses to a 
dendritic cell vaccine were detected in 10 of 10 patients and cytoxicity against tumour 
cells was seen in  4 of 8 patients  (Hegmans, Veltman et al. 2010).   Vaccination 
directed against Wilms tumour 1 (WT1) epitopes, which is highly expressed in 
mesothelioma, elicited T cell responses in 6 of 9 patients with mesothelioma (Krug, 
Dao et al. 2010).   
The effects of combining chemotherapy with immunotherapy were investigated in a 
murine model of mesothelioma (Nowak, Robinson et al. 2003) using an antibody which 
promotes activation of cellular immune responses through ligation of CD40.  This study 
demonstrated the potential for chemotherapy to synergise with immunotherapy and 
this approach is being translated into early phase clinical trials.  
 
1.7 The AB1-HA mesothelioma model 
 
The tumour cell line used in this model of malignant mesothelioma was generated by 
injecting mice intraperitoneally with crocidolite asbestos.  Around one third of mice 
develop tumours between 7 and 25 months later and these were confirmed to be 
mesothelioma on cytology and histology.  Tumour cells were harvested from ascites 
and passaged in vitro and in vivo until stable clonal cell lines were established (Davis, 
Manning et al. 1992).  AB1 was derived from a BALB/c mouse.  AB1 is a sarcomatoid 
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mesothelioma and has morphological and ultrastructural features similar to human 
mesothelioma on electron microscopy.  An inoculation of 5x10
5
 cells produces tumour 
in 100% of mice.   
AB1 cells expressing the influenza antigen haemagglutanin (AB1-HA) have been 
generated through transfection of AB1 with the HA gene derived from the Mt Sinai 
strain of the PR8 influenza virus (Marzo, Lake et al. 1999).  In this context HA acts as a 
tumour neo-antigen, but does not alter tumour morphology or MHC expression.   
The tumour microenvironment in this model has similarities and differences to that 
observed in human mesothelioma.  MHC class 1 is expressed by both human 
mesothelioma (Yamada, Oizumi et al. 2010) and AB1 (Leong, Marley et al. 1997).  MHC 
class 2 is not expressed, even after exposure to IFNg (Leong, Marley et al. 1997).   
Consistent with this, CD8 T cells have been shown to an important effector cell in 
human mesothelioma and in the AB1HA model (Rudge, Barrett et al. 2007; Currie, van 
der Most et al. 2008; Yamada, Oizumi et al. 2010).  Both human and Ab1Ha tumours 
are infiltrated with regulatory T cells (Hegmans, Hemmes et al. 2006; Rudge, Barrett et 
al. 2007; van der Most, Currie et al. 2009) and myeloid derived suppressive cells 
(Hegmans, Hemmes et al. 2006; Veltman 2010) and these cells were found to suppress 
immune responses in the AB1HA model (Rudge, Barrett et al. 2007; van der Most, 
Currie et al. 2009).   
In contrast to most human mesotheliomas and other murine mesothelioma cell lines, 
AB1 produces little TGFb (Maeda, Ueki et al. 1994; Kumar-Singh, Weyler et al. 1999; 
Suzuki, Kapoor et al. 2004).  As a result blockade of TGFb induced immunosuppression 
has little effect on AB1HA, when compared to TGFb secreting mesothelioma lines 
(Suzuki, Kapoor et al. 2004). 
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The AB1 and AB1HA model have been used extensively by a number of groups to study 
immune responses to mesothelioma (Nowak, Robinson et al. 2003; Hegmans, Hemmes 
et al. 2005; Rudge, Barrett et al. 2007; Darrasse-Jeze, Bergot et al. 2009; Bergot and 
Klatzmann 2010)   The presence of HA antigen in this model does not change the 
growth rate of tumour in nude mice, compared with the parent AB1 line.  In wildtype 
mice however, tumour growth is observed but is delayed in comparison to AB1 
(Marzo, Lake et al. 1999), demonstrating that HA antigen does induce an anti-tumour 
immune response, but that this is insufficient to mediate tumour rejection.  Depletion 
of Tregs led to higher rates of tumour rejection in mice inoculated with AB1HA than 
those receiving AB1, suggesting that this HA specific immune response is suppressed 
by regulatory T cells (Bergot and Klatzmann 2010).  However mice cured of AB1HA 
tumours were still able to reject subsequent challenge with AB1, demonstrating that 
even in the presence of the HA antigen, memory immune responses are generated to 
other non HA antigens (Nowak, Robinson et al. 2003; Bergot and Klatzmann 2010).  
Chemo-immunotherapy, in the form of gemcitabine and anti-CD40 antibody, was 
equally efficacious in AB1-HA and the parent line AB1, demonstrating that 
immunological eradication of tumour in this setting was primarily mediated by non-HA 
mechanisms (Nowak, Robinson et al. 2003). 
The advantage of using HA transfected cell lines are that the class I and class II 
epitopes are known and that anti-HA TCR transgenic mice are available and can be 
used to examine HA specific immune responses.  T cell receptors of CL4 mice are class I 
restricted and recognise residues PR/8 HA; 518-526 (sequence; IYSTVASSL) (Morgan, 
Liblau et al. 1996) and thus can be used a source of HA specific CD8 T cells.  T cells from 
HNT mice express a TCR which is class II restricted and recognises the epitope PR/8 HA; 
 51 
 
126-138 (sequence: HNTNGVTAACSHE) (Scott, Liblau et al. 1994), providing a source of 
HA specific CD4 T cells. 
Gemcitabine is used as the chemotherapeutic agent in this model.  Gemcitabine (2,2-
difluorodeoxycytidine) is a cytidine analogue and a cytotoxic  agent used to treat a 
wide variety of human cancers, including non small cell lung cancer, pancreatic cancer, 
bladder cancer and breast cancer.  Gemcitabine is a prodrug which is activated 
intracellularly by phosphorylation into gemcitabine diphosphate and triphosphate.  
Anti-tumour effects are mediated by a number of mechanisms, including inhibition of 
ribonucleoside reductase, resulting in depletion of deoxynucleotide pools necessary 
for DNA synthesis, and incorporation of gemcitabine triphosphate into DNA, resulting 
in DNA strand termination (Mini, Nobili et al. 2006).  Gemcitabine is eliminated 
through deamination into a uracil metabolite, which is excreted in the urine.  The half 
life of gemcitabine in mice is approximately 30 minutes in the plasma and up to 3 
hours in tissues (Shipley, Brown et al. 1992).   
Currently, pemetrexed is used as first line treatment in conjunction with cisplatin in 
patients with mesothelioma (Vogelzang, Rusthoven et al. 2003). The reasons 
gemcitabine is used instead of pemetrexed as the chemotherapeutic agent in this 
model are as follows:  1)  Pemetrexed is a multi-targeted folate antagonist which 
inhibits enzymes involved in purine and pyridamine synthesis.  In mice, plasma levels 
of folate and thymidine are around 10 fold higher than humans, meaning the activity 
of pemetrexed against mouse tumours is limited (van der Wilt, Backus et al. 2001);  2)  
The immuno-modulatory effects of gemcitabine have been well characterised and 
gemcitabine is known to synergise with immunotherapy (Nowak, Robinson et al. 
2003), whereas the effects of pemetrexed on the immune system are less well known;  
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3)  Since the clinical use of gemcitabine is much greater than that of pemetrexed, 
results are potentially translatable to more patients with a wider variety of tumour 
types.  
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1.8 Aims and hypotheses 
 
Based on an understanding of anti-tumour immune responses as outlined above, I 
made the following hypotheses: 
y The actions of CD4 T cells play a crucial role in orchestrating CD8 and other anti 
tumour immune responses and the balance between effector and suppressive 
CD4 subsets determines whether the immune system rejects or is tolerised to a 
tumour 
y CD4 T cells can be polarised in vitro into Th1, Th2, Th17 and Treg subsets.  
Adoptive transfer of in vitro differentiated tumour specific effector CD4 subsets 
will allow us to determine the optimal CD4 T cell anti-tumour response to 
mediate tumour rejection 
y The immunomodulating effects of cytotoxic chemotherapy mean that the post 
chemotherapy environment presents an optimal window for adoptive transfer 
of anti-tumour effector cells 
In order to investigate these hypotheses I had to establish a model in which the effects 
of different tumour specific CD4 subsets on anti-tumour immune responses could be 
studied.  Thus the aims of this project were: 
y To establish protocols for in vitro differentiations of tumour specific Th1s, Th2s, 
Th17s, Tregs  
y To investigate the activity of in vitro differentiated tumour antigen specific CD4 
cells against tumours in vivo in conjunction with cytotoxic chemotherapy 
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y To investigate the effects of cognate help provided by HA specific CD4 subsets 
on HA specific CD8 T cells during anti-tumour immune responses 
 
 
 55 
 
2            Materials and Methods 
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2.1 Tumour cell culture 
 
Cell lines were maintained in RPMI 1640 (invitogen) supplemented with 10% fetal calf 
serum, 20mM HEPES, 0.05mM 2-mercaptoethanol, 100U/ml penicillin, 50ug/ml 
gentamicin and Glutamax (Gibco) (R10: complete medium +10% FCS).  In addition the 
neomycin analogue geneticin was added at a concentration of 400ug/ml to all AB1-HA 
cell lines in order to suppress growth of non-HA expressing cells.  Cells were cultured 
at 37C in the presence of 5% CO2.  Cells were passaged when between 80-95% 
confluent. 
Cell passage was performed by washing the adherent monolayer of cells with PBS 
before incubating them with trypsin at 37C for 1 minute.  They were then resuspended 
in 10ml of complete media, centrifuged, resuspended in complete media and then a 
proportion of the cell suspension was added to new culture flasks. 
For long term storage cells were cooled and resuspended in cold media (R10) 
supplemented with an additional 20% FCS and 10% DMSO.  Cell suspension was 
aliquoted into cryovials and frozen at -80C for 24 hours.  Vials were then transferred 
for long term storage in liquid nitrogen. 
When reviving cells from liquid nitrogen they were gently rewarmed until just above 
melting point and then transferred into 10ml cold R10, centrifuged, resuspended in 
R10 supplemented with 10% FCS and transferred to tissue culture vial.  After 24 hours 
media was replaced with R10 containing 400ug/ml geneticin. 
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2.2 Mice 
 
Balb/c (H-2d) mice were purchased from the Animal Resources Centre (Perth, Western 
Australia) and housed in the University Department of Medicine.   
Transgenic mice (HNT and CL4, both Thy1.2+ve) were purchased from the ARC, Perth.  
HNT-Thy1.1+ve and CL4-Thy1.1+ve mice, which had been generated by backcrossing 
onto a Thy1.1 background, were purchased from ARC, Perth.  Transgenic mice had 
been typed individually prior to use by staining peripheral blood samples with anti CD8 
and anti VB8.1 for CL4 mice and for HNT mice by staining with anti-CD4 and anti-VB8.  
Thy1.1 and Thy1.2 homozygotes were identified by staining with anti Thy1.1 and 
Thy1.2 respectively. 
 
2.3 Tumour inoculations 
 
Tumour cells in an exponential phase of growth were trypsinised at between 80-95% 
confluence, washed three times with cold PBS and cells were counted.  Cells were 
resuspended in cold PBS at the appropriate concentration and between 5x10^5 and 
1x10^6 cells in 100ul were inoculated subcutaneously in the right hind flank. 
 
2.4 Monitoring of mice 
 
Once tumours became palpable they were measured using electronic callipers 3 times 
per week and then daily when they neared full size.  Tumour area was calculated as 
the product of the two largest, perpendicular diameters.  Mice were culled when 
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tumour area reached 100mm2 or if significant ulceration developed.  Mice were also 
culled if their body weight fell below 10% of its starting value or if they developed 
appearances of looking distressed such as disinterest, hunching or ruffled coat. 
 
2.5 Gemcitabine treatment 
 
Gemcitabine was made up in normal saline by the pharmacy department, Sir Charles 
Gairdner Hospital, Perth at concentrations of 240mg/ml or 480mg/ml.  Gemcitabine 
was injected intraperitoneally at a dose of 120ug/g or 240ug/g (equal to a volume of 
100ul for a 20g mouse). 
 
2.6 Anti-CD40 treatment 
 
Agonist Anti-Cd40 antibody (FGK-45) was purchased from Western Australia Institute 
of Medical Research (WAIMR) and 100ug of antibody was injected i.p. in 100ul of PBS. 
Standard treatment regimen was of 3 doses administered every 2 days. 
 
2.7 CD4 depletions 
 
Depleting anti-CD4 antibody (GK 1.5) was purchased from the Western Australia 
Institute of Medical Research and doses were administered in 100ul of PBS.  Injections 
were performed intravenously for the first dose and if subsequent doses were 
required these were given i.p. every 3 days for the duration of treatment.  CD4 
depletion was confirmed by FACS analysis of peripheral blood. 
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2.8 Preparing single cell suspensions 
 
2.8.1 Spleens and lymph nodes 
 
Organs were harvested into PBS containing 2% FCS and kept on ice.  Single cell 
suspensions were obtained by disaggregation of tissue by gentle mashing between 
frosted glass slides.  Where required, red blood cells in spleens were lysed by 
resuspending the sample in 2ml of BD Pharm Lyse solution for 2 minutes, followed by 
addition of 2ml FCS and 5 ml 2% FCS and then centrifugation and resuspension.  
Suspensions were then strained through 45uM mesh to remove debris before use. 
2.8.2 Tumours and other tissues 
 
Whole tissue was harvested into PBS containing 2% FCS and kept on ice.  Tissue was 
injected with 100ul of tumour digest solution (RPMI with 2% FCS(R2) containing 
1mg/ml collagenase (LS004176 Worthington Biochemical corporation), 0.1mg/ml 
DNase I (Roche Applied Sciences)).  Tissue was then finely minced using a scalpel and 
fragments were transferred to a 15ml tube with 1-2ml of tumour digest solution. 
Samples were digested for 1 hour on rollers at room temperature.  50ul of 0.1M EDTA 
was added per sample to break up DC-T cell rosettes and samples were left on rollers 
for a further 15 minutes.  Fragments were then allowed to settle and supernatant was 
strained and transferred into a fresh tube.  Samples were then underlayed with 1ml of 
cold FCS containing 0.01M EDTA and cells were recovered by centrifugation and 
resupended in PBS containing 2% FCS or media as appropriate. 
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2.8.3 Bleeds 
 
Where blood was required from culled mice, cardiac puncture was performed 
immediately after cervical dislocation.  Otherwise peripheral blood was obtained from 
tail veins by warming the mouse under a heat lamp and making a small nick in the vein 
with a scalpel.   Approximately 50-100ul of blood per mouse was collected into tubes 
containing 10ul of 1:1000 heparin to prevent coagulation. 
 
2.9 Restimulation of cells for determining cytokine expression 
 
Single cells suspensions were plated into 96 well plates and resuspended in complete 
media.  In some experiments cells were restimulated with PMA, Ionomycin in the 
presence of Brefeldin A (Leukocyte activation cocktail, BD at 2µl/ml).  In some 
experiments cells were restimulated with PMA 100ng/ml (Sigma-Aldrich P8139) and 
Ionomycin 2µM (Sigma Aldrich I3909) and Brefeldin A 10µg/ml (Sigma Aldrich B7651) 
was added after 1 hour.  Cells were stimulated for 5 hours at 37°C. 
Restimulation of cells with peptide was performed on HNT-thy1.1 +ve in vitro 
differentiated cells.  5x10
5
 splenocytes from a naive thy1.2+ balbc mouse were plated 
into a round bottom 96 well plate to provide antigen presenting cells.  These were 
cultured overnight in complete media with HNT peptide at 5ug/ml.  The following day 
wells were washed in media and 1x10
5
 Thy1.1 HNT cells added to wells.  Brefeldin A 
10µg/ml was added after 1 hour and wells were harvested after 5 hours.  Control wells 
were treated in the same way but were not pulsed with HNT peptide. 
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2.10   Cell staining 
 
For surface staining, single cell suspensions were plated into round bottom 96 well 
plates.  Cells were resuspended in 20ul of FACS buffer (PBS containing 2% FCS, 1% 
bovine serum albumin and 0.01% Sodium Azide) containing 1:200 anti CD16/32 
(Trustain, Biolegend) for 10 minutes at 4C, in order to reduce non specific binding.   
Cells were then resuspended in 20ul of FACS buffer containing fluorochrome labelled 
antibodies and kept in the dark at 4C for 30 minutes.  Cells were washed twice in FACS 
buffer and resuspended in fixative (BD stabilizing solution) prior to analysis. 
For intracellular staining, following surface staining of cells where necessary, cells were 
plated into 96 well plates, washed and resuspended in fixative (BD FACS lysing 
solution) for 15 minutes at room temperature.  Cells were washed once and if 
necessary were left overnight at 4C in FACS buffer at this point.  Cells were then 
permeabilized by resuspension in permeabilisation buffer (ebiosciences 
permeabilisation buffer) for 10 minutes.  Cells were then resuspended in 20ul of 
permeabilisation buffer containing fluorochrome labelled antibodies and left in the 
dark at 4C for 30 minutes.  Cells were washed once in permeabilisation buffer and 
twice in FACS buffer before being resuspended in fixative prior to analysis.  Where 
CD3, CD4 or CD8 staining was required alongside other intracellular markers, these 
were all stained together after permeabilisation.  Since cells downregulate surface CD4 
and CD8 expression during stimulation (Kemp and Bruunsgaard 2001), I found that 
following restimulation, intracellular staining of these markers gave better delineation 
of the positive population.  Likewise I found that thy1.1/1.2 staining could be 
performed intracellularly and gave a brighter signal than surface staining.  Other than 
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this, where other surface markers where stained alongside intracellular markers, 
surface staining was performed prior to fixation and permeabilisation. 
 
2.11    Flow cytometry 
 
All flow cytometry was performed on a FACS Canto (Becton Dickinson) except when 
blood samples were analysed for cell counts, which was performed on a Guava 
Easycyte Flow Cytometer (see section 2.13).  Data was analysed using Flowjo software 
(Tree star).  Compensation was performed using compensation beads (BD Comp 
beads).   
Fluorescence minus one stains (FMOs) were used as controls to set gates.  Control 
wells containing spleen, lymph node or tumour cells were stained with a cocktail of 
antibodies where one of the antibodies in the panel was omitted and substituted with 
the relevant isotype control.   Thus gates for each antibody could then be set against 
the FMO for that marker.   Examples of gating strategies are shown in the figures 
where relevant.    
To ensure that lymphocyte gates set on forward and side scatter included all 
lymphocytes of interest, including blasted cells, the population of cells being analysed 
(e.g CD4+, Thy1.1+ve) was selected from the total population and plotted on forward 
and side scatter plots.  The lymphocyte gate was then applied to this population and 
could then be adjusted to ensure it included all of the cells of interest. 
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2.12 Live cell counts 
 
Number and viability of cells in single cell suspensions was determined by staining cells 
with tryphan blue and counting with either a manual hemocytometer, or an 
automated cell counter (Countess, Invitrogen). 
 
2.13 Cell counts on blood samples and solid organs 
 
In order to perform cell counts on peripheral blood samples, 20ul blood was stained 
with antibodies to CD3, CD4 and CD8.  The volume was then made up to 200ul with BD 
FACS lysis solution and samples were immediately analysed on a Guava Easycyte flow 
cytometer.  Blood cell counts per ml were automatically generated by the Guava 
software. 
In order to perform cell counts on spleens and lymph nodes, single cells suspensions 
were prepared from organs as described in section 2.8.  Care was taken to rinse all 
slides and dishes thoroughly during preparation to minimise loss of cells.   The mashed 
organ was resuspended in a fixed volume (V ml) and 200ul  was pipetted into a 96 well 
plate for staining.  Thus each sample contained a known proportion of each solid organ 
= 0.2/V.   
Following staining, samples were then resuspended in 200ul and run on the flow 
cytometer (FACS Canto).  In order to calculate what volume of each sample had been 
analysed it was necessary to know the flow rate of the flow ctometer.  The exact flow 
rate of the flow cytometer was determined by resuspending a known number of beads 
(BD Trucount Tubes) in 500ul of buffer and running this for 3 minutes.  The flow rate at 
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each setting could therefore be calculated as [(number of beads processed/total 
number beads) X 500ul / 3].  To compensate for any day to day variation, flow rates 
were determined at the start and end of each analysis.  Day to day variability in flow 
rates was found to be less than 10% and was within the manufacturers reported 
values.  Samples were then run on the flow cytometer for a fixed period of time.  By 
multiplying the length of time that samples were run by the flow rate of the flow 
cytometer, the volume of each sample analysed could be calculated.  The number of 
cells in each organ could then be determined by dividing the number of cells counted 
in the sample by the proportion of each sample analysed and dividing this by the 
proportion of each organ per sample.  Thus the cell count per organ could be 
calculated as  
Cells per 200ul sample (A) = (Cell count) X (0.2ml/volume analysed)  
Total cells in organ = A X (V ml / 0.2 ml) 
Where V is the original volume into which the organ was resuspended. 
 
Since it was not possible to accurately compare absolute cell counts between tumour 
samples due to inconsistencies in the recovery of cells from digested tissue, an 
alternative method was needed to determine the concentration of tumour infiltrating 
lymphocytes such that the frequency of tumour infiltrating lymphocytes could be 
compared between different tumour samples.  This was done by counting the total 
number of tumour cells analysed per sample from forward and side scatter gates.  The 
 ?ƚŽƚĂůĐĞůůƐ ? gate was set to include all cellular events but excluded events lying on the x 
and y axis, likely to represent debris.  To enable comparsions between samples this 
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gate was fixed across all samples in an experiment.  The frequency of tumour 
infiltrating cells of interest could thus be expressed as a proportion of total tumour 
cells.  Examples of this gating strategy are shown in Figure 5-7A. 
 
2.14 Naive CD4 T cell isolations 
 
Spleens and lymph nodes were harvested from donor mice and single cell suspensions 
were prepared.  Cells were kept on ice throughout in PBS containing 0.5% bovine 
serum albumin and 2mM EDTA.  Cells were counted and CD62L+CD4+ T cells were 
purified using magnetic columns and a naive T cell isolation kit (Miltenyi Biotec no. 
130-093-227) as per manufacturers instructions:  Briefly, total CD4 T cells were isolated 
by negative selection by incubating cells with biotin labelled antibodies against CD8a, 
CD45R, CD11b, CD25, CD49b, TCRg/d and Ter-119 followed by incubation with 
antibiotin microbeads.  Cells were then passed through a magnetic column and eluted 
cells collected.  In most experiments, in order to improve purity, cells were passed 
through a second magnetic column at this stage. The elute obtained was then enriched 
by positive selection for CD62L+CD4+ cells by incubation with CD62L+ microbeads and 
passage through magnetic column.  The column was removed from the magnetic field 
and cells obtained by flushing the column three times with buffer.  The final product 
typically contained between 83-95% CD4 cells if one negative selection was performed 
and over 95% CD4 cells if two negative selections were performed.  These CD4 cells 
were 85-95% CD62L+ and contained between 0 - 0.5% CD25+ or CD8+ cells.   
 
 66 
 
2.15 In vitro CD4 T cell differentiations 
 
CD4+CD62L+ CD4 T cells were cultured in 48 well plates in RPMI 1640 supplemented 
with 10% fetal calf serum, 20mM HEPES, 0.05mM 2-mercaptoethanol, 100U/ml 
penicillin, 50ug/ml gentamicin, 1X non-essential amino acids (MEM-NEAA, Gibco) and 
1X Glutamax (Gibco).   
Cells were activated with plate bound anti-CD3 antibody (145.2C11, WAIMR, Perth) 
and soluble anti-CD28.  To precoat wells with anti-CD3, 500ul of PBS containing 5ug/ml 
anti-CD3 was incubated in wells at 4C overnight.  Before the addition of cells, this was 
aspirated and wells washed once in PBS taking care not to let the wells dry out.  
Soluble anti-CD28 (BD Pharminogen) at 1ug/ml was then added to culture media 
where activation was required. 
Other cytokines were added to culture media in order to generate different CD4 
subsets.  These were rmIL-12 (ebioscience 14-8121), rmIL-4 (ebioscience 14-8041), rm 
IL-6 (ebioscience 14-8061), rh TGFb (Peprotech 100-21), rm IL-23 (R+D systems 1887-
ML), rm IL-7 (R+D systems 407-ML), mIL-2 (Roche 11271164001).  Neutralising 
antibodies to IFNg (BD Pharminogen), IL-4 (BD Pharminogen) and IL-12 (BD 
Pharminogen) were added to cultures where stated.  Stimulating anti-ICOS antibody 
(Biolegend, clone 398.4A) was used in one experiment. 
Cells were split at a ratio of 1:2 or 1:3 on day 3 depending on the degree of 
proliferation. To do this, cells were transferred into conical tubes on ice and wells were 
rinsed with media which was added to the sample.  Cells were centrifuged and washed 
once with cold media before being resuspended in fresh media containing the 
appropriate cytokine/antibody cocktail and were plated into fresh wells.  Cells were 
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cultured for 5 or 6 days in total.  If media went yellow in between these times, 
approximately 50% of the media was aspirated, taking care not disturb the cells at the 
bottom of the well, and replaced with fresh media containing cytokines/antibodies.  At 
the end of the culture period cells were transferred into conical tubes and cell counts 
and viability were determined by tryphan blue staining and counting using an 
automated cell counter (Countess, Invitrogen).  Cells for in vitro restimulation and 
staining were washed once with media before use, whereas cells for adoptive transfer 
into mice were washed three times with cold PBS prior to transfer. 
 
2.16 Adoptive cell transfers 
 
In vitro differentiated cells were washed three times with cold PBS, counted and 
resuspended in PBS at between 5x10
6
 to 1x10
7
 cells per ml.  100ul (5x10
5
  W 1x106 cells) 
were injected iv. 
Lymphocytes from CL4 mice were obtained by harvesting axillary, inguinal, popliteal, 
cervical and mesenteric lymph nodes.  Single cells suspensions were prepared and cells 
were washed once in cold media and twice in cold PBS.  Cells were resuspended at 
1x10
7
/ml and 100ul (1x10
6
) was injected iv.  Where in vitro differentiated cells and CL4 
lymphocytes were co-transferred, cells were resuspended at double these 
concentrations and mixed at a ratio of 1:1 prior to transfer such that the final injection 
volume remained 100ul. 
For iv injections, mice were warmed under a heat lamp and gently restrained and 
100µl was injected iv into a tail vein. 
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2.17     Statistical analysis 
 
Statitical analysis was performed using Graphpad Prism software.  Students t test was 
used to compare means between groups.  Kaplan Meier survival curves were analysed 
using a Logrank test.  Growth curves were analysed using a 2 way ANOVA with 
repeated measures.  Statistical significance was determined at the level of p<0.05, 
p<0.01 and p<0.001 and these values are reported. 
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3  How gemcitabine 
chemotherapy affects the anti-
tumour T cell response 
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3.1 Introduction 
 
This chapter examines the interaction between chemotherapy and CD4 and CD8 T cells 
and is divided into two parts.  Initial experiments examined the effects of cytotoxic 
chemotherapy on CD4 and CD8 T cell populations.  Following this I looked to see how 
the presence or absence of CD4 cells influenced outcomes to combined treatment with 
chemotherapy and anti-CD40 directed immunotherapy. 
Gemcitabine induces a number of immunomodulatory effects, including lymphopenia, 
increased antigen cross presentation and cross priming, impairment of humoral 
immunity (Nowak, Lake et al. 2006), depletion of myeloid derived suppressor cells 
(Suzuki, Kapoor et al. 2005) and depletion of regulatory T cells (Rettig, Seidenberg et al. 
2010).  However, the effects of gemcitabine on other CD4 T cell subsets have not been 
well characterised.   My initial experiments suggested the possibility of immune 
mediated tumour regression after a single dose of gemcitabine.   I therefore examined 
whether the beneficial effects of gemcitabine on anti-tumour immunity were reflected 
in an altered balance between different CD4 subsets.  CD4 subsets were identified by 
intracellular flow cytometry.  Th1s, Th2s and Th17s were defined by functional 
expression of IFNg, IL-4 and IL-17 respectively, following ex vivo restimulation.  Tregs 
were defined by expression of the transcription factor foxp3, which is a highly specific 
marker for Tregs in mice (Fontenot, Rasmussen et al. 2005).  Since ex vivo 
restimulation alters the expression of many markers of activation, analysis of some 
phenotypic markers was restricted to foxp3+ (Treg) and foxp3- (nonTreg) subsets only. 
Having examined the effects of gemcitibine on CD4 cells I looked at the role CD4 cells 
play in mediating outcomes to gemcitabine combined with an immunotherapy.  
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Previous work using the AB1HA model has shown that gemcitabine synergises with 
agonist anti-CD40 antibody to cure a high proportion of mice with established 
tumours(Nowak, Robinson et al. 2003).  I examined whether CD4 cells were having an 
overall positive or negative effect on outcomes to treatment by removing total CD4 
cells in vivo using a CD4 depleting antibody.   Previous work showed that depletion of 
CD4s did not affect outcomes to gemcitabine and anti-CD40, suggesting that anti-CD40 
substitutes for CD4 help (Nowak, Robinson et al. 2003).  However, CD4 cells can help 
CD8 T cells at points downstream of the priming phase, such as through recruitment 
and expansion of CD8s at the tumour site (Marzo, Kinnear et al. 2000; Bos and 
Sherman 2010).  I therefore looked to see what the effects of removing CD4 cells were 
on outcomes to this treatment. 
In addition, work in other models has shown that the CD4 response is polarised in an 
effector or suppressive direction during the early stages of tumour emergence 
(Darrasse-Jeze, Bergot et al. 2009).  I hypothesised that induction of an effective CD8 T 
cell response may be dependent on the actions of CD4 cells during the early stages of 
tumour emergence.  I therefore looked to see whether removing CD4 cells prior to 
tumour inoculation affected the outcome to subsequent chemo-immunotherapy. 
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3.2 Results 
3.2.1 Gemcitabine causes transient lymphodepletion and can lead to 
regression of tumours 
 
Mice bearing 9 day old AB1HA tumours were treated with a single dose of 
gemcitabine.  Analysis of serial blood samples by FACS showed that numbers of CD4 
and CD8 T cells declined to around one third of baseline levels after 24 hours but had 
returned almost back to baseline 4 days later, indicating that gemcitabine causes 
lymphodepletion but that T cell numbers are rapidly restored within a few days (Figure 
3-1A). 
Untreated, AB1-HA tumours take between 17 and 23 days to grow to 100mm
2
.   When 
tumour bearing mice were treated with a single dose of gemcitabine, tumour 
regression and long term survival was seen in a small proportion (2 of 13) of mice.  
When growth curves were further analysed it was clear that tumour growth was being 
affected in two distinct phases (Figure 3-1B).  In all mice, within 3 days of 
administration, tumours regressed to a barely palpable size but then started to regrow 
at similar rates to that seen pre-treatment.  However secondary regression of tumour 
was seen in some mice between 7 and 12 days after gemcitabine administration.  In 
these mice, tumours rapidly regressed at this point from sizes of up to 15mm
2
.  Thus, 
in addition to immediate cytotoxicity, gemcitabine can cause a later anti-tumour effect 
and it is this secondary response which results in complete tumour eradication in a 
small proportion of mice.   This observation was suggestive of immunologically 
mediated tumour eradication following a single dose of gemcitabine. 
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Figure 3-1   Effects of gemcitabine on T cell populations 
A   Lymphodepletion in peripheral blood following single dose of gemcitabine.  Tail 
bleeds were performed on mice before, 1 day after and 4 days after 240ug/g 
gemcitabine i.p (n=5).  Cells were stained with antibodies to CD3, CD4, CD8 and cell 
counts performed using flow cytometry.  B  Tumour growth curves of individual mice 
inoculated with AB1-HA on day 0 and treated with 240ug/g gemcitabine i.p on day 9.  
Shows two independent experiments.  C  Schedule for harvests of mice treated with 
gemcitabine (n=8) and pretreatment (n=4) and untreated controls (n=4) and tumour 
size at harvest for each group.  D  CD4 and CD8 cell counts on DLN and spleen for 
groups described in C.  E  Tumour infiltrating CD3+CD4 and CD3+CD8 T cells expressed 
as a percentage of total cells, as determined from forward and side scatter plots as 
shown.   
 
 
 
3.2.2 Treatment with gemcitabine results in increased numbers of tumour 
DLN CD4 T cells and CD8 tumour infiltration7 days after treatment 
 
To examine whether the late response to gemcitabine was reflected in changes in T 
cell populations, I examined T cell populations in lymphoid organs and in tumours 7 
days after gemcitabine administration.  This timepoint was chosen as this was just 
prior to the point tumours started regressing, when immune responses were most 
likely to be observed but when tumours were still of sufficient size to harvest.  Mice 
were treated with a single dose of gemcitabine at day 9 (Figure 3-1C).  Organs were 
harvested at day 16 and analysed by FACS.  In order to control for both tumour size 
and duration of disease, harvests were also performed in a pre-treatment (size 
matched)control group, and in an untreated (time matched) control group at day 16, 
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when tumour sizes were larger than in the gemcitabine treated group (Figure 3-1C).  
Because tumours in the pre-treatment and gemcitabine treated groups were smaller 
than the untreated groups, in these groups tumours from 2 mice were pooled prior to 
staining in order to obtain enough cells for analysis. Thus the data for tumour harvests 
consists of 2 data points from 4 mice in the pre-treatment group, 4 data points from a 
total of 8 mice in the gemcitabine treated group and 4 data points from 4 mice in the 
untreated group. 
The number of total CD4 T cells, was found to be increased in the tDLN of gemcitabine 
treated mice (Figure 3-1D) 7 days after treatment, compared with untreated mice.  
Tumour sizes were larger in the untreated group, so the increase in CD4 T cells in the 
DLN of gemcitabine treated mice was seen despite an overall reduced tumour load.  
Cell counts were not available for the pretreatment group.  There was no change in the 
numbers of splenic CD4s or CD8s.  When tumour infiltrating T cells were examined, the 
frequency of CD4 cells within the tumour was not increased by gemcitabine.  In 
contrast, there was a large increase in the population of tumour infiltrating CD8 cells 
compared to both the pre-treatment and untreated controls (Figure 3-1E). 
 
3.2.3 Gemcitabine leads to a reduction in tumour infiltrating T regs and an 
increase in tumour infiltrating Th2 
 
To assess the effects of gemcitabine on T regs, samples were stained intracellularly for 
foxp3 expression (figure 3.2A).  Mice treated with gemcitabine had a reduced 
proportion of foxp3+ CD4 T cells in the DLN after 7 days compared with that seen pre-
treatment (figure 3.2B).  However there was no difference in proportions of foxp3+ 
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cells between the untreated and treated group at day 16, so the decline in foxp3+ cells 
in the DLN could have been a feature of prolonged disease duration rather than 
gemcitabine treatment.  In contrast, gemcitabine lead to a substantial reduction of 
foxp3+ CD4 T cells in the tumour at day 7 compared to both the untreated and the pre-
treatment group (figure 3.2B), demonstrating that this effect was not confounded by 
differing tumour sizes or disease duration.  In addition, gemcitabine had no effect on 
the proportion of foxp3+ CD4 cells in non tumour draining lymph nodes or the spleen, 
indicating that the reduction in Treg frequency was not a systemic effect but was 
localised to the tumour microenvironment. 
To assess whether the reduced frequency of Tregs seen post gemcitabine could have 
been due to alterations in proliferation of regulatory or effector subsets, cells were 
stained intracellularly for Ki67, a marker expressed by proliferating cells.  Overall, Ki67 
was expressed by a greater proportion of Tregs than non-Tregs (figure 3.2C) and 
demonstrated high rates of proliferation amongst intratumoural Tregs.   
In the tumour, gemcitabine led to a small but significant reduction of Ki67+ Treg cells 
compared to untreated animals (p<0.01) and a non-significant reduction when 
compared to the pretreatment group (p=0.08).  In contrast, the opposite effect was 
seen on the foxp3- (nonTreg) CD4 cells; during tumour growth the frequency of Ki67+ 
foxp3- CD4 cells within the tumour declines between the pretreatment and untreated 
group (p<0.01).  However treatment with gemcitabine reversed this decline, 
significantly increasing the frequency of Ki67+ foxp3- CD4 cells compared to untreated 
mice (p<0.01).  
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Figure 3-2  Effect of gemcitabine on T reg and non-Treg CD4+ cells 
A   Gating on foxp3+ and foxp3- CD4 cells and on CD4+foxp3+Ki67+ cells.  B  Proportion 
of foxp3+ CD4 cells in DLN, NDLN, spleen and tumour in pretreatment, untreated and 
gemcitabine treated groups described in figure 1.1C.  C  Ki67 expression on foxp3+ and 
foxp3- CD4 cells. 
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Although these differences were small, these results suggest that the reduction in the 
proportion of tumour infiltrating Tregs seen 7 days after gemcitabine treatment may in 
part be due to localised changes in the tumour microenvironment, resulting in both 
reduced proliferation of Tregs and increased proliferation of non-Treg CD4 T cells 
compared to untreated mice.   
To see whether gemcitabine causes any concomitant increases in CD4 Th1, Th2 or 
Th17 helper subsets, samples were restimulated ex vivo with PMA and ionomycin in 
the presence of brefeldin A and then stained intracellularly for IFNg, IL-4 and IL-17 
cytokine expression (Figure 3-3).  This showed that IFNg expression by CD4 cells 
declined in the spleen between days 9 and 16 of tumour growth (pretreatment vs 
untreated controls, p<0.01).  Treatment with gemcitabine had no effect on IFNg 
expression compared with untreated controls.  Similarly, frequencies of IL-4 producing 
CD4 cells, but not IL-17+ CD4+ cells, declined between pre-treatment and untreated 
groups in the DLN and spleen, although overall the frequency of these subtypes was 
low, at less than 1% of all CD4 T cells.  The tumour contained greater proportions of 
IFNg+, IL4+, and IL-17+ CD4 cells than were seen in either the spleen or the DLN at any 
timepoint.  Within the tumour, the frequency of IL-4 secreting Th2 cells was increased 
by gemcitabine, with no change in the frequency of Th1s or Th17s. 
These results indicate that there is a decline in tumour infiltrating Tregs 7 days after 
gemcitabine which is partially counterbalanced by an increase in tumour infiltrating 
Th2s. 
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Figure 3-3  Effects of gemcitabine on effector CD4 subsets 
Mice were treated with 240ug/g gemcitabine and harvests were performed as per 
schedule described in figure 1.1c.  Cells were restimulated ex vivo and expression of 
IFNg, IL-4 and Il-17 determined through intracellular flow cytometry.  A  Gating on 
IFNg+, IL4+ and IL-17+ CD4 cells.  B  Expression of IFNg, IL-4 and IL-17 on CD4 cells 
recovered from DLN, spleen and tumour. 
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3.2.4 The increase in tumour infiltrating CD8 T cells following gemcitabine 
treatment is not associated with increased intratumoural CD8 
proliferation 
 
CD8 T cells were examined in the same experiment at the time points indicated in 
Figure 3-1A.   In the draining lymph node and spleen 7 days after treatment, 
gemcitabine did not change the numbers of CD8 T cells when compared to untreated 
mice (Figure 3-1D).  However there was a significant increase in tumour infiltrating CD8 
T cells in comparison to pre-treatment and untreated controls (Figure 3-4A).  These 
cells were stained for Ki67 to determine whether this could be due to increased 
proliferation (Figure 3-4B).  Surprisingly, despite being present in greater quantities, 
the frequency of Ki67 expression on tumour infiltrating CD8 T cells from gemcitabine 
treated tumours was substantially less than that seen pre-treatment or in untreated 
tumours (Figure 3-4C).  This indicates that the accumulation of CD8 T cells in these 
tumours is unlikely to be due to increased local proliferation. 
The functional capacity of tumour infiltrating CD8 T cells was examined by 
restimulating cells ex vivo with PMA and ionomycin and staining for intracellular IFNg.  
There was no significant difference in the percentage of CD8 cells which produced IFNg 
between any of the groups.  In addition the proportion of IFNg producing CD8s 
expressed as a percentage of total tumour cells was no different between the groups 
(Figure 3-4D), showing that although gemcitabine causes increased CD8 accumulation 
within the tumour, the number of IFNg secreting CD8s did not increase.    
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Figure 3-4  Effects of gemcitabine on CD8 T cells 
Mice were treated with 240ug/g gemcitabine and harvests were performed as per 
schedule described in figure 3.1c and gating performed as shown in figure 3.1E.  A  
Tumour infiltrating CD8 T cells expressed as a percentage of total cells.  B  Gating of 
CD8+Ki67+ cells.  C  Ki67 expression on CD8s recovered from DLN, spleen and tumour.  
D  Proportion of IFNg+ CD8 cells, analysed by restimulation ex vivo and intracellular 
flow cytometry  W shown as a proportion of all CD8 cells and as a proportion of total 
tumour cells. 
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3.2.5 CD4 T cell depletion changes the efficacy of combination gemcitabine 
and agonist anti-CD40 treatment 
 
Although the above results suggest that gemcitabine alters the balance between 
effector and suppressive CD4 subsets within the tumour microenvironment and 
promotes CD8 infiltration of the tumour 7 days after administration, this is not 
sufficient to cure mice in the majority of cases.  I next investigated the role CD4 cells 
play during combination chemo-immunotherapy with gemcitabine and agonist anti 
CD40 antibody.  This combination was chosen as it has been previously shown to cure 
between 60-80% of mice with established tumours and provides one of the highest 
cure rates associated with this model.  I hypothesised that depleting CD4 cells would 
have a negative effect on outcomes to this treatment. 
We treated tumour bearing mice according to previously established protocols, with 5 
doses of gemcitabine followed by 3 doses of agonist anti-CD40 antibody.  CD4 cells 
were depleted in vivo by injection with GK1.5 antibody during two phases: an early 
phase from before tumour inoculation to the commencement of treatment and a late 
phase from the commencement to the end of treatment (Figure 3-5A).  By depleting 
CD4 cells I hoped to see what the overall effect of the total CD4 population was during 
these two phases and thus whether suppressive or effector CD4 subsets were likely to 
be dominant.  CD4 cells were depleted in these two phases in order to ascertain how 
the CD4 T cell response was polarised during the early stages of tumour emergence 
and whether this differed to what was seen during treatment with chemo- 
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Figure 3-5  The effects of CD4 depletion on outcomes to treatment with 
gemcitabine and agonist anti-CD40 
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A   Treatment schedule.  Mice were inoculated with AB1-HA on day 0 and treated 
where indicated with 5 doses of gemcitabine 120ug/g i.p. every three days 
commencing day 9, followed by 3 doses of anti-CD40 (FGK45) 100ug i.p. every two 
days commencing day 23.   ?ƐǁĞƌĞĚĞƉůĞƚĞĚĂƐŝŶĚŝĐĂƚĞĚŝŶĂŶ ?ĞĂƌůǇ ?ƉŚĂƐĞĨƌŽŵ
day - ?ƚŽĚĂǇ ?ĂŶĚĂ ?ůĂƚĞ ?ƉŚĂƐĞĨƌŽŵĚĂǇ ?ƚŽĚĂǇ ? ? ?ƚŚƌŽƵŐŚŝŶũĞĐƚŝŽŶŽĨĂŶƚŝ-CD4 
antibody (GK1.5) initially at 150ug iv and then 100ug i.p. every 3 days therafter.  B  
Confirmation of CD4 depletion by flow cytometry.  C  Survival curves and tumour 
growth curves of non-surviving mice (n=5 mice per group).   
 
 
 
immunotherapy.  The efficacy of CD4 depletion was confirmed by FACS analysis of 
peripheral blood samples (Figure 3-5B). 
 
3.2.6 Anti-CD40 delays tumour growth compared to gemcitabine treatment 
alone 
 
Following commencement of treatment with gemcitabine at day 9, tumours rapidly 
regressed from a size of around 2mm diameter to barely palpable.  However, 8 days 
after completion of gemcitabine, all tumours had started to regrow at a rate similar to 
that seen in untreated mice and there were no long term survivors (Figure 3-5C).  In 
mice that received anti-CD40 treatment following gemcitabine, tumour regrowth was 
significantly delayed by a further 10 days compared to those that received gemcitabine 
alone, although all eventually regrew tumours.  One mouse in this group died 
unexpectedly during treatment with no apparent cause evident on post mortem.   
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3.2.7 Early CD4 depletion improves survival whereas late CD4 depletion 
accelerates tumour growth in mice treated with gemcitabine and 
agonist anti- CD40 antibody 
 
In mice treated with gemcitabine and anti-CD40, depletion of CD4 cells prior to 
inoculation, but ceasing before commencement of treatment (early depletion) was 
associated with a small but significant improvement in survival (Figure 3-5C), indicating 
an overall suppressive effect of the CD4 population during this phase.  1 out of 5 mice 
in this group survived long term.   In contrast, CD4 depletion during treatment (late 
depletion) did not have any effect on survival, when compared with those treated with 
gemcitabine and anti CD40 alone, with 1 out of 5 mice remaining tumour free at the 
end of the study period.  However in those mice that did regrow tumour, late CD4 
depletion significantly hastened time to tumour regrowth compared with undepleted 
or early depleted groups (Figure 3-5C). 
 
3.2.8 Following early depletion, regenerating CD4 T cells are highly 
activated and contain increased frequencies of both Th1s and Tregs. 
 
In order to examine how T cell populations were affected by gemcitabine and anti-
CD40 and the effects of removing CD4 cells on CD8 T cells, we harvested tumour 
draining lymph nodes, non-tumour draining lymph nodes and spleens from mice at day 
0, day 8 (pre-treatment) and day 28 (post treatment) and analysed T cell populations 
by flow cytometry ( 
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Figure 3-6). 
 
 
Figure 3-6  Effects of CD4 depletion on CD4 T cells in mice treated with 
gemcitabine and anti-CD40 
A    ICOS expression;  B  foxp3 expression;  C IFNg expression on CD4 cells from mice 
treated according to schedule in figure 1.5A.  Harvests performed before tumour 
inoculation (day -1), before treatment commenced (day 8) and after treatment 
completed (day 28) in mice treated with gemcitabine and anti CD40 and depleted of 
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CD4 cells where indicated (NB - CD4 cells absent in early depleted mice at day 8 and in 
late CD4 depleted mice at day 28). 3 mice per group.   
The frequency of activated CD4 T cells, as determined by expression of ICOS, showed a 
progressive increase during tumour emergence and treatment in all compartments ( 
Figure 3-6A).  However, in mice that received early CD4 depletion, over 90% of the CD4 
cells which had regenerated by day 28 displayed an activated (ICOS+ve) phenotype. 
The frequency of foxp3+CD4+ cells within the DLN, NDLN and spleen did not 
significantly change during treatment with Gemcitabine and anti CD40 ( 
Figure 3-6B).  Likewise, the percentage of IFNg-expressing CD4 cells did not alter in the 
DLN or NDLN but was reduced in the spleen at day 28 ( 
Figure 3-6C).  However, in those mice that received early CD4 depletion, the frequency 
of both foxp3+ and IFNg+ CD4 cells was significantly increased at day 28 in all 
compartments compared with mice that did not receive CD4 depletion.   
  
 
3.2.9 CD8 T cells display a more activated phenotype when CD4 T cells are 
depleted 
 
Between day -1 and day 28, the expression of ICOS on CD8 cells increased significantly 
in the DLN and spleen, but not in the NDLN, of mice treated with gemcitabine and anti 
CD40 (Figure 3-7).  In mice that received CD4 depletion, a significant increase in the 
frequency of ICOS+ CD8 cells compared to undepleted mice was observed in the DLN 
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and NDLN following both early and late depletion.  In addition, the effects of early 
depletion on the frequency of ICOS+ CD8s persisted at day 28, 23 days after the last  
dose of depleting antibody.  In the spleen, early CD4 depletion increased the frequency 
of ICOS+ CD8s at day 8, but there was no difference at day 28 between undepleted, 
early depleted or late depleted groups.    
Overall, these results suggest that treatment with gemcitabine and anti-CD40 leads to 
increased activation of CD8 T cells.  Since removal of CD4s increases the frequency of 
ICOS expression by CD8 T cells, it would appear that CD4 cells are having a suppressive 
effect at the level of CD8 activation during both the early and the late (treatment) 
phases.   
However, despite the suppressive effect of CD4 T cells on CD8 priming, removal of 
CD4s during the treatment phase accelerated tumour growth, suggesting that during 
treatment CD4s are having additional, positive anti-tumour effects unrelated to CD8 
activation.   
  
 89 
 
 
 
Figure 3-7  Effects of CD4 depletion on CD8 T cells in mice treated with 
gemcitabine and anti-CD40 
ICOS expression on CD8 T cells in DLN, NDLN and spleen of mice treated according to 
schedule in figure 1.5A.  Harvests performed before tumour inoculation (day -1), 
before treatment commenced (day 8) and after treatment completed (day 28) in mice 
treated with gemcitabine and anti CD40 and depleted of CD4 cells at timepoints 
indicated.  3 mice per group. 
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3.3 Discussion 
 
This chapter examines the interaction between gemcitabine and T cell immunity.  It 
was clear from initial treatment experiments that a single dose of gemcitabine led to 
tumour regression which was not due to direct cytotoxicity on tumour cells.  This 
occurred after the period of lymphodepletion and homeostatic proliferation, which 
was shown to last around four days.  This suggests that during this initial window, 
gemcitabine could be priming an immune response, or removing a brake from a pre-
existing immune response, which was then able to lead to tumour regression some 7 
to 12 days later.  This would be consistent with the ability of gemcitabine to cause an 
immunogenic, apoptotic cell death, increase antigen presentation and cross priming 
and deplete suppressive cells.  To confirm that this response is immunologically 
mediated this experiment could be repeated in immunodeficient mice.  Another way 
of confirming the ability of gemcitabine to induce immunogenic cell death would be to 
immunise mice with gemcitabine treated AB1HA cells and then rechallenge mice with 
tumour after an interval, with tumour rejection indicating the induction of memory 
responses.  This could be compared to the immunity generated by other HA stimuli, 
such as influenza vaccines, or to responses to tumour cells treated by other 
chemotherapeutic agents known to induce immunogenic cell death (Tesniere, 
Schlemmer et al. 2009). 
I was interested to see if these responses were reflected by changes in T cell 
populations.  7 days after gemcitabine administration I found that there was an 
increase in total CD4 cells in the draining lymph nodes, but not in the spleen, of 
gemcitabine treated mice.  This could be due to increased antigen delivery to the 
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tumour draining lymph node as a result of gemcitabine induced tumour cell death.  In 
contrast numbers of CD8 T cells were not affected by gemcitabine treatment when 
compared to untreated controls.  In the tumour there was no change in the frequency 
of tumour infiltrating CD4 cells, however there was a substantial increase in CD8 
tumour infiltration following gemcitabine treatment.  These CD8s displayed reduced 
levels of proliferation compared to untreated mice, suggesting that increased 
trafficking into the tumour and/or improved survival was more likely to explain the 
increased infiltrate than in situ proliferation. 
CD4 cells have been shown to help CD8 infiltration of tumours and to virally infected 
tissues (Marzo, Kinnear et al. 2000; Nakanishi, Lu et al. 2009).  Although the increase in 
tumour infiltrating CD8 T cells could not be explained by increases in total CD4 
infiltration, when the composition of the intratumoural CD4 T cells was examined, a 
substantial reduction in the proportion of Tregs was observed.  This effect was 
localised to the tumour microenvironment.  The reduction in intratumoural Tregs 
observed following gemcitabine was associated with reduced rates of proliferation 
within the Treg population and increased proliferation of nonTreg CD4s compared to 
untreated controls.  In addition, in all treatment groups the Treg population contained 
much higher frequencies of proliferating cells than the non-Treg population, with the 
highest rates observed within the tumour.  Since gemcitabine targets proliferating 
cells, this disparity could explain how gemcitabine might preferentially deplete Tregs 
over non-Tregs.   This would be similar to the mechanism by which cyclophosphamide 
selectively depletes Tregs (van der Most, Currie et al. 2009).  
Gemcitabine did not increase the frequency of tumour infiltrating Th1s and Th17s, the 
two CD4 subsets believed to have the most potent anti-tumour activity.  Instead, an 
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increase in tumour infiltrating Th2s was observed.  It should be noted however that 
even after gemcitabine the frequency of intratumoural Th2s remained low, at less than 
5% of the total tumour infiltrating CD4s, whereas Th1s still constituted over 15% of the 
CD4 population.   
The effect of gemcitabine on the composition of CD4 subsets in peripheral blood has 
been examined previously.  Rettig et al found that gemcitabine lead to a brief, 
transient reduction in foxp3+ CD4 cells in peripheral blood of mice and patients after 
treatment with gemcitabine(Rettig, Seidenberg et al. 2010).  In contrast, Plate et al 
found no effect of gemcitabine on the frequency of circulating CD4+CD25+ cells, which 
are likely to be highly enriched for Tregs (Plate, Plate et al. 2005).   However the effects 
of gemcitabine on intratumoural CD4 populations have not been characterised.  A 
previous study using the same AB1HA model found that mice treated with 5 doses of 
gemcitabine had an increased histological total CD4 infiltrate compared with untreated 
mice (Nowak, Robinson et al. 2003).  My findings expand on this and suggest that 
gemcitabine induces localised changes within the tumour microenvironment resulting 
in a reduction in the frequency of tumour infiltrating Tregs.   
It is not possible to tell from these results whether gemcitabine acts on CD4s or CD8s 
directly or whether the changes in T cell populations observed result from other, 
indirect effects.   I did not examine tumours for myeloid derived suppressor cells 
(MDSC), which are known to be depleted by gemcitabine (Suzuki, Kapoor et al. 2005; 
Sinha, Clements et al. 2007).  MDSC have been shown to promote Treg development 
(Huang, Pan et al. 2006) and decrease macrophage production of type 1 cytokines, 
including IL-12 (Sinha, Clements et al. 2007), an effect reversed by gemcitabine.  
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Depletion of MDSCs by gemcitabine could be a mechanism which explains the 
observed changes in intratumoural T cell subsets. 
Although gemcitabine induced many localised changes to the tumour 
microenvironment which could be considered favourable to anti-tumour immune 
responses, it is important to note that in the majority of mice this was not sufficient to 
cure the tumour.  There are a number of reasons why this may the case.  The Tregs 
that remain after gemcitabine treatment may still be able to impair tumour rejection.  
In this model gemcitabine favoured an increased Th2 response which may not be the 
most favourable effector CD4 subset.  Additionally, although the CD8 infiltrate was 
increased overall, there was no increase in the numbers of IFNg secreting CD8s and the 
CD8s showed reduced proliferation in situ, suggesting that they may be functionally 
impaired (Plate, Plate et al. 2005).  Therefore there may still be factors limiting the 
effectiveness of the local immune response, despite the beneficial effects seen with 
gemcitabine.    
 
In the second half of this chapter I examined the effects of CD4 cells on outcomes to 
chemo-immunotherapy.  Gemcitabine combined with agonist anti-CD40 mAb 
improved survival in mice inoculated with the mesothelioma cell line AB1-HA.  
However, there were no cures with this treatment.  Previous published reports using 
this same model and treatment protocol have achieved cures in up to 80% of mice 
(Nowak, Robinson et al. 2003).  One possible reason for this discrepancy is due to the 
differences in growth rates of the tumour cells.  By day 9 the tumours in this study 
were slightly larger than those in previous studies, suggesting the line used here is 
more aggressive. 
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I found that prophylactic depletion of CD4 cells improved survival in this model.   This 
suggests that regulatory CD4 T cells are dominant over effector CD4 subsets during the 
period of tumour emergence, leading to overall suppression of anti-tumour responses 
by the CD4 T cell population.  In contrast, CD4 depletion during the treatment phase 
did not alter overall survival, although in those mice which regrew tumour, time to 
tumour outgrowth was hastened, suggesting there may be an overall positive CD4 
mediated anti-tumour effect during this phase.  These results require confirmation 
with a repeat experiment, which was not possible due to time constraints. 
These results are consistent with previous studies which have similarly demonstrated 
that prophylactic (Onizuka, Tawara et al. 1999; Teng, Swann et al. 2010), but not 
therapeutic (Quezada, Peggs et al. 2008), T reg depletion improves outcome.  Teng, 
Swann et al compared three different methods of prophylactic T reg depletion  W anti 
CD4 mAb, anti CD25 mAb and anti FR4 mAb - and found equivalent survival benefits, 
all of which were dependent on CD8 cells.  Darasse-Jeze et al specifically examined the 
kinetics of early effector T cell (Teff) and Treg responses following initial encounter 
with tumour antigen (Darrasse-Jeze, Bergot et al. 2009).  They found that Tregs 
expanded more rapidly and prevented activation of naive Teffs.  If memory Teffs were 
present, however, Tregs were unable to control Teff expansion and tumours were 
rejected.   This suggests that in naive mice without memory effector T cells, Tregs will 
be dominant during tumour emergence. 
Following early depletion, the CD4 cells which regenerated by day 28 displayed a 
highly active phenotype with higher proportions of both Foxp3 expressing and IFNg 
producing cells.  This is consistent with work in humans showing that homeostatic 
proliferation expands Treg cells, leading to increased proportions of CD4+CD25hi CD4 
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cells for up to 6 months following chemotherapy (Zhang, Chua et al. 2005).   In the 
early depleted group survival was improved despite the increased percentage of 
regulatory cells, indicating that the T regs may be ineffective or irrelevant at this later 
stage of the immune response, or that the positive effects of the observed increased 
population of IFNg secreting effector T cells outweigh the negative effects from Tregs.  
Reduced sensitivity of T cells undergoing homeostatic proliferation to inhibitory signals 
(Shvets, Chakrabarti et al. 2009) could also explain the improved outcomes seen 
despite the increased frequencies of Tregs. 
I examined the effects of CD4 depletion on CD8 activation and found that the 
frequency of activated CD8s was increased in the absence of CD4 cells at all points 
examined. This suggests there is a CD4 mediated impairment of CD8 T cell activation, 
which may explain in part how early CD4 depletion improves anti-tumour activity.  
However activated CD8s also increased to a similar level at day 28 in the late depleted 
group, where tumour growth was accelerated by CD4 depletion.  It is therefore 
possible that despite being activated these CD8s still require CD4 help to fulfil effector 
function.  This would be consistent with studies suggesting that CD4 cells are needed in 
the effector phase as well as the priming phase of the CD8 anti tumour response 
(Marzo, Kinnear et al. 2000; Nakanishi, Lu et al. 2009; Bos and Sherman 2010). 
This experiment shows that the overall tone of the CD4 response is suppressive at the 
time of initial tumour antigen encounter but may have positive anti-tumour effects 
during treatment with gemcitabine and anti CD40 mAb.   It should be acknowledged 
that although depletion of CD4s during early and late phases had a small impact on 
tumour growth, these effects were less than anticipated and did not substantially alter 
the number of mice cured.  As such it cannot be concluded from these results that CD4 
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T cells are a critical determinant of outcome in this model.  This could be because 
agonist anti-CD40 treatment replicates one of the main mechanisms by which CD4s 
provide help, masking the effects of CD4 depletion.  Or it could be that the opposing 
actions of effector and suppressive CD4 subsets mean that the net effect of removing 
total CD4 cells is attenuated.   Given that we observed tumour regression 7-12 days 
after a single dose of gemcitabine it is also possible that using a schedule whereby 
repeated doses of gemcitabine are given every 3 days may be depleting rather than 
enhancing the emerging CD4 response, minimising the effect of further CD4 depletion. 
 
The results described in this chapter provided a rationale for experiments described in 
the following chapters to see if we could take advantage of the immunological changes 
induced by gemcitabine to further skew the CD4 anti-tumour response in a way that 
achieved tumour rejection.  Since a single dose of gemcitabine was shown to stimulate 
anti-tumour immunity and due to the possible confounding effects of the combined 
gemcitabine and anti-CD40 schedule, in all future experiments mice were treated with 
a single dose of gemcitabine. 
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4 Establishing a model to study 
the anti-tumour effects of CD4 
subsets 
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4.1 Introduction 
 
I hypothesised that adoptive transfer of tumour specific CD4 subsets would promote 
tumour rejection.  This chapter describes the establishment of a model with which this 
hypothesis could be tested, by generating Th1, Th2, Th17 and Treg subsets in vitro and 
adoptively transferring them into tumour bearing mice.    
The first half of this chapter describes the optimisation of protocols for in vitro 
differentiation of CD4 subsets.  To achieve this, naive T cells require TCR activation 
with co-stimulation in the presence of the appropriate polarising cytokines.  Naive T 
cells express high levels of CD62L, meaning that that they can be isolated from bulk 
CD4 cells by positive selection using CD62L targeted antibodies.   I activated naive CD4 
cells with an activating anti-CD3 antibody.  CD3 is a transmembrane protein which 
associates with the T cell receptor to form the TCR complex.  Activating CD3 antibodies 
can mimic TCR activation signals in lymphocytes, leading to cell activation and 
proliferation (Wacholtz, Patel et al. 1989) and their use is well established in in vitro 
lymphocyte differentiation protocols (Zhang, Zhang et al. 2003; Harrington, Hatton et 
al. 2005).  Costimulation through CD28 activation is also required to ensure 
lymphocytes develop into effector cells, the absence of CD28 signalling leading to 
anergy or deletion (Appleman, Tzachanis et al. 2001).   
I then had to determine the optimal combination of cytokines for CD4 subset 
differentiation protocols.  Previous studies have shown that IL-12 is sufficient to induce 
Th1 differentiation and IFNg production by cells activated in vitro (Zhang, Zhang et al. 
2003) although IFNg itself also promotes Th1 differentiation (Kaiko, Horvat et al. 2008).  
IL-4 drives the formation of Th2 cells (Nishimura, Iwakabe et al. 1999), and Th2 
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differentiation can also be enhanced by IL-2 (Zhu, Cote-Sierra et al. 2003).  Th17 
differentiation requires TGFb and IL-6 (Harrington, Hatton et al. 2005; Park, Li et al. 
2005).  Tregs can be induced from naive precursors through activation in the presence 
of TGFb alone (Yang, Nurieva et al. 2008).   By activating naive CD4 cells in cultures 
supplemented with these cytokines I aimed to induce differentiation into each of these 
subsets. 
In order to generate HA specific CD4 subsets I then applied these protocols to naive 
CD4 cells harvested from HNT mice, which express a T cell receptor that recognises a 
class II restricted HA epitope.  I hypothesised that adoptive transfer of tumour (HA) 
specific CD4 subsets into mice bearing an HA expressing tumour mice would enable us 
to study the effects of different CD4 subsets on anti-tumour immunity.  Therefore it 
was important to determine how in vitro differentiated CD4 cells behaved in vivo after 
adoptive transfer into mice, whether these cells survived, were able to respond to 
tumour antigen and whether they retained the phenotype imposed on them during in 
vitro culture.   
The second part of this chapter describes experiments characterising the behaviour of 
in vitro differentiated cells in vivo following adoptive transfer.  To do this I made use of 
the fact that there are a number of different alleles of the thy 1 (CD90) lymphocyte 
marker in mice and for some of these alleles, thy1.1 and thy1.2, specific antibodies are 
available.  BALB/c HNT mice had been backcrossed onto a thy1.1 balb/c background.  
Homozygous thy1.1+HNT BALB/c mice were then used as the donor source for 
adoptively transferred CD4 cells.  Recipient mice were thy1.2+ balb/c, thus when mice 
were culled and recovered cells analysed by flow cytometry, adoptively transferred 
thy1.1+ cells could be identified from endogenous thy1.2+ cells by staining with an 
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anti-thy1.1 antibody.  This enabled me to track the fate, distribution and activity of the 
adoptively transferred in vitro differentiated CD4 subsets in vivo. 
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4.2 Results 
 
4.2.1 Generating in vitro polarised CD4 subsets 
 
Initial experiments were aimed at determining the optimal combination of cytokines 
and neutralising antibodies to drive the differentiation of naive CD4 T cells into helper 
T cell and T reg subsets.  These subsets were defined by expression of the signature 
cytokine  W IFNg for Th1s, IL-4 for Th2s, IL-17 for Th17s  W or by foxp3 expression in T 
regs, as determined by intracellular flow cytometry.  
Naive (CD62L+) CD4 cells were isolated from splenocytes using magnetic beads, 
through negative selection of CD4 cells followed by positive selection of CD62L+CD4+ 
cells.   A single negative selection of CD4s produced a purity of between 83-92% over a 
number of different experiments.  In order to optimise the purity of naive CD4+ cells 
for in vitro differentiation, cells were passed twice through the negative selection 
column, which produced a final population of >95% CD4+ cells which were >90% 
CD62L+ve with no detectable CD25+ or CD8+ contamination (Figure 4-1A). 
All cells were plated in 48 well plates at 3-5x10^5 cells per well and activated with 
plate bound anti-CD3 and soluble anti-CD28.  By day 3 the cells had proliferated to 
around 1-2x10^6 cells per well and required splitting at a ratio of between 1:2 and 1:3.  
If media went yellow in between these times, half the media was aspirated and 
replaced with fresh media containing cytokines. 
In initial experiments cells were activated continuously with anti CD3 and antiCD28 for 
the full 5 or 6 days of culture.  However it soon became clear that continuous 
activation adversely affected the viability of some of the subtypes and so I then tried 
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removing the activating stimulus at the day 3 split by washing them in media and 
plating them in cytokines without additional anti CD3 or anti CD28 for the remainder 
of the culture period.  Although these problems had to be addressed concurrently, I 
will discuss the issues involved in generating CD4 T helper phenotypes and in 
maintaining cell viability separately in the next two sections. 
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Figure 4-1 In vitro differentiation of CD4 subsets 
A  Isolation of naive CD4s from splenocytes.  Graphs show CD4, CD25, CD62L, CD8 
expression on cells before isolation (green line), after negative selection of CD4+ cells 
(blue) and after positive selection of CD4+CD62L+ cells (black).  Bold line and label 
indicate final percentages.   B  FACS plots of cells cultured in Th1, Th2, Th17 and Treg 
conditions with the addition of IL-2 or neutralising antibodies where indicated.  Cells 
restimulated with PMA and ionomycin prior to intracellular flow cytometry. Gated on 
CD4+ cells. 
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4.2.2 Generating phenotypes of in vitro differentiated CD4 subsets 
 
Th1s 
IL-12 promotes Th1 differentiation by STAT-4 mediated activation of t-bet.  In, addition 
IFNg acts in an autocrine fashion to further promote tbet expression, however IL-12 
alone is sufficient to cause Th1 development in vitro cultures (Zhang, Zhang et al. 
2003).  I compared different concentrations of IL-12 and found that 5ng/ml was 
sufficient to induce around 60% IFNg expression in cells activated with anti-CD3 and 
anti-CD28 for 5-6 days.  The addition of neutralising anti-IL-4 antibodies further 
increased the percentage of cells expressing IFNg (Figure 4-1B).   
Th2s 
Th2 differentiation is driven by IL-4 but is inhibited by IFNg.  When naive CD4 T cells 
were activated with anti CD3 and anti CD28 in the presence of IL-4 and neutralising 
anti-IFNg for 5 or 6 days a proportion of cells (between 0.5-50% over a number of 
different experiments) stained intracellularly for IL-4 (Figure 4-1B).   IL4 expression was 
higher if cells were stimulated for 6 days than if stimulation was removed after day 3, 
however the viability of the cells deteriorated if the stimulation was continued beyond 
day 3 (see section 4.2.3).   
The addition of IL-2 increased the percentage of IL-4 producing cells when stimulation 
was removed after 3 days but had no effect on IL-4 expression when cells were 
stimulated for the full culture period (Figure 4-1B), suggesting that exogenous IL-2 can 
compensate in part for the loss of CD3 and CD28 stimulation on Th2 differentiation, 
but is superfluous in the presence of continued activation. 
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In some experiments a small percentage of cells activated in Th2 culture conditions 
expressed IFNg after restimulation.  IFNg antagonises Th2 development and so it was 
important to remove any factors which may be driving a Th1 rather than a Th2 
phenotype.  I therefore tried adding neutralising anti-IL-12 antibodies to Th2 cultures, 
however this did not improve the yield of IL-4 +ve cells (Figure 4-1B). 
Studies using splenocytes pulsed with TCR specific peptide to activate CD4 cells in vitro 
have been able to generate higher levels of intracellular IL-4 than I was able to 
achieve(Nishimura, Iwakabe et al. 1999).  It was possible that antigen presenting cells 
within these cultures may be delivering signals through receptors other than CD3 and 
CD28 which may promote Th2 development.  ICOS is a costimulatory molecule of the 
CD28 family that is expressed on activated T cells and stimulation through ICOS has 
been shown to favour Th2 development (Shilling, Clay et al. 2009).  Therefore I tried 
adding stimulating anti-ICOS antibody to Th2 cultures.  However this also had no effect 
on yield of IL-4 producing cells (Figure 4-1B). 
Lack of detection of IL-4 on intracellular staining could be due to inadequate 
production, or it could be due to inadequate detection methods.   I restimulated cells 
with plate bound anti-CD3 and soluble CD28 in the presence of Brefeldin-A, but levels 
of IL-4 induced by this were comparable to PMA and ionomycin stimulation.  I also 
stained cells for IL-5 expression in addition to IL-4 but this did not substantially 
increase the identification of Th2 cells (Figure 4-1B). 
In summary, I was only able to detect high frequencies (over 15%) of IL4 producing 
cells if cells were stimulated continuously for 5 to 6 days, however, as discussed in 
section 4.2.3, this resulted in unacceptable levels of cell death.   
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Th17s 
Th17 cells can be derived from naive precursors through TCR stimulation in the 
presence of TGFb and IL-6.  I was able to induce between 20-50% of cells to produce IL-
17 by stimulation with plate bound anti-CD3 and soluble anti-CD28 for 5 or 6 days in 
the presence of 2.5ng/ml TGFb and 20ng/ml IL-6 (Figure 4-1B).  IL-23 is not required 
for Th17 differentiation but has been shown to be an important survival factor for 
Th17s and was therefore included in culture conditions. 
Other factors have also been shown to promote IL-17 expression in CD4 T cells, 
including the type of media used.  Veldhoen et al found that CD4 T cells activated in 
Th17 polarising conditions in IMDM produced more IL-17 secreting cells than those 
grown in RPMI and this was due to the presence of AhR ligands in IMDM media 
(Veldhoen, Hirota et al. 2009).  Similarly I found that IL-17 expression was 
approximately 2 fold higher in Th17 cultures grown in IMDM than RPMI, whereas the 
choice of media did not make any difference to the other subsets. 
T regs 
In mice foxp3 is a highly specific marker for the regulatory T cell subset (Fontenot, 
Rasmussen et al. 2005).  Foxp3+ CD4 T cells can be induced from naive precursors by 
TCR activation in the presence of TGFb.  I found that 10ng/ml of TGFb in addition to 
neutralising IFNg antibodies and CD3/CD28 activation produced between 50-90% 
foxp3 + cells (Figure 4-1B).   
Th0s 
In order to provide a control for later experiments I also generated CD4 T cells which 
had been activated in the same way as the other CD4 subsets but had not been 
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differentiated into specific subsets.  This was done by activating naive CD4 T cells with 
anti CD3 and anti CD28 for three days and then removing the activation and adding IL-
2 for the remaining two days.  Neutralising anti IFNg and anti IL-4 antibodies were 
added to inhibit differentiation into Th1 or Th2 phenotypes.  These cells proliferated to 
a similar extent as the other subtypes and cultures typically contained less than 10% 
IFNg+ cells and less than 1% IL-4, IL-17 or foxp3+ cells. 
 
4.2.3 Maintaining cell viability of in vitro differentiated CD4 subsets 
 
It was clear from these early attempts at CD4 differentiation that although it was 
possible to induce variable proportions of IFNg, IL-4, IL-17 or foxp3 expressing cells 
(Figure 4-2A), the viability of these cells was often poor at the end of the culture 
period.  When cells were activated continuously, viability of Th1s, Th2s and Tregs 
deteriorated following splitting of cells on day 3 and harvesting on day 5 or 6.  
However this was not observed with Th17s, which maintained viability despite 
continual activation for the full 5 or 6 days of culture (Figure 4-2B).   
IL-2 is a cytokine which promotes T cell survival and proliferation.  I therefore looked at 
the effects of IL-2 on viability of Th1, Th2 and Treg cultures.  In addition it was possible 
that other unknown autocrine factors that were important for survival may have been 
secreted by the cells into the culture media and were being removed during the 
ƉƌŽĐĞƐƐŽĨƐƉůŝƚƚŝŶŐƚŚĞĐĞůůƐ ?/ƚŚĞƌĞĨŽƌĞƚƌŝĞĚ ?ƐƉůŝƚƚŝŶŐ ?ƚŚĞĐĞůůƐďǇƚƌĂŶƐĨĞƌƌŝŶŐƚŚĞŵ
with their media into larger wells and adding new media on top.  However, neither of 
these interventions improved cell viability. 
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Figure 4-2 The effects of the duration of activation on in vitro differentiated CD4 
subsets 
A    Cells were cultured for 5 days in Th1, Th2, Th17 and Treg conditions and were 
stimulated with antiCD3 and anti-CD28 from days 0-3 or 0-5 before restimulation and 
analysis by intracellular flow cytometry on day 5.  B   Tables showing percentage 
expression of the phenotypic marker for each subset  W IFNg for Th1s, IL-4 for Th2s, IL-
17 for Th17s and foxp3 for Tregs  W and percentage viability at the end of 5 days culture 
in cells stimulated for 3 days (black symbols) or 5 days (red symbols). 
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Activation induced cell death occurs when T cells are exposed to repeated TCR 
stimulation and this appeared likely to explain the fall in viability between day 3 and 6.  
In contrast to the other subsets, the viability of Th17s remained high despite 5-6 days 
continual stimulation, which is consistent with the finding that Th17s are less 
susceptible to AICD than Th1s (Yu, Iclozan et al. 2009).  I therefore examined viability 
and phenotypic expression in Th1s, Th2s, Th17s and Tregs after removing aCD3 and 
aCD28 stimulation from day 3 onwards compared with stimulation for the entire 
period of culture.  I found that removing stimulation at day 3 and adding IL-2 for the 
remainder of culture resulted in improved viability of the Th1, Th2 and Treg subsets, 
which were generally maintained at over 90%, compared with cells grown with 
continued stimulation (Figure 4-2B).   
Removing stimulation at day 3 improved viability but was associated with a slight 
decrease in the percentage of IFNg expressing cells in Th1 cultures and a more marked 
decrease in IL4 +ve cells in Th2 cultures.  When stimulation was removed from Th17 
cultures at day 3 the percentage of IL17 +ve cells dropped to less than 2% by day 5 or 
6.  Removing stimulation from Treg cultures improved both the viability and the 
percentage of foxp3 +ve cells (Figure 4-2B). 
Therefore, to generate cells which were both differentiated into the appropriate 
phenotype and sufficiently viable for adoptive transfer into mice it was clear that 
activation needed to be removed from Th1, Th2 and Treg cultures at day 3.  For Th1 
and Th2 subsets the improvement in viability came at the expense of reduced 
expression of IFNg and IL-4 respectively.  For Th17 cells continued activation was 
necessary to maintain the IL-17+ve phenotype and did not worsen viability.  For Tegs 
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both viability and phenotype were improved by withdrawal of activation at day 3.  
Final culture conditions are summarised in Table 4-1. 
 
Subset 
Activation 
aCD3, aCD28  
Polarising 
cytokines IL-2 / IL-23 
Neutralising 
antibodies 
Th1 Day 0-3 IL-12 (5ng/ml)  IL-2  day 3-5 anti IL4  
Th2 Day 0-3 IL-4 (10ng/ml)     IL-2 day 3-5 anti IFNg  
Th17 Day 0-5 
TGFb (2.5ng/ml) 
IL-6 (20ng/ml)  
IL-23 day 0-5 
anti IL-4 
anti IFNg  
Treg  Day 0-3 TGFb (10ng/ml)  IL-2 day 3-5 anti IFNg  
Th0  Day 0-3 Nil  IL-2 day 3-5 
anti IFNg  
anti IL4 
 
Table 4-1 Summary of final culture conditions 
 
 
 
 
4.2.4 CD4 subsets generated from HNT CD4 T cells maintain ability to 
recognise HA antigen after in vitro differentiation 
 
Having established conditions for optimal differentiation of CD4 subsets I applied these 
protocols to naive CD4+ T cells harvested from HNT mice.  CD4 T cells from HNT mice 
express a TCR which recognises the class II restricted HNT epitope in haemaggluttinin 
(HA).  It was important that these in vitro differentiated CD4 cells retained the ability 
to respond to HNT peptide after 5 days of culture.  I therefore compared IFNg, IL-4 and 
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IL-17 expression on CD4 T cell subsets after restimulation with PMA / ionomycin or 
peptide pulsed splenocytes (Figure 4-3).  This showed that expression of IFNg and IL-4 
was similar with HNT peptide to PMA/ionomycin.  Il-17 expression was slightly reduced 
in the peptide stimulated cells.  Together this demonstrates that in vitro differentiated 
HNT CD4+ subsets retain the ability to recognise and respond to HNT peptide. 
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Figure 4-3  In vitro differentiated HNT CD4 subsets retain the ability to respond to 
HNT peptide 
CD4 subsets were generated from thy1.1+HNT CD4 cells.  At the end of 5 day in vitro 
culture cells were restimulated with PMA/ionomycin or HNT peptide loaded 
splenocytes from a thy1.2+ balb/c mouse, in the presence of brefeldin A.  A  shows 
gating of Thy1.1+ve cells in mixed thy1.1/thy1.2 cultures.  B  shows cytokine 
expression profiles on restimulated Thy1.1+ cells.  Representative of 3 independent 
experiments. 
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4.2.5 In vitro differentiated Th1s and Th2s are more stable than Th17s and 
T regs in vitro 
 
Although the above conditions generated a population of cells which appeared to have 
differentiated into Th1s, Th2s, Th17s and Tregs, it was important to know how stable 
these phenotypes were once cells were removed from their differentiation conditions.  
I generated Th1, Th2s, Th17s and Tregs and activated each subtype for 2 further days 
in each of the alternative differentiation conditions (Th1, Th2, Th17, Treg, Th0) as well 
as in media only (Figure 4-4).   
This showed that Th1 cells were stable in all conditions except Th2, where IFNg 
expression was substantially reduced.   
Th2 cells were stable in all conditions except in media only.  Interestingly, despite 
negligible expression at day 5, increased IL-4 expression was seen after 2 further days 
culture in all conditions containing CD3 and CD28 stimulation, irrespective of the 
cytokines added.  
Th17s and Tregs were less stable. A proportion of cells became IFNg and IL-4 secreting 
in Th1 and Th2 conditions with loss of IL-17 and foxp3 expression.  Th17s required 
TGFb (Treg and Th17 conditions) to maintain substantial levels of Il-17 expression, 
whereas high levels of foxp3 expression amongst Tregs was maintained in Treg 
conditions only.  
  
 114 
 
 
Figure 4-4 In vitro differentiated Th1s and Th2s are more stable than Th17s and 
Tregs 
Th1s, Th2s, Th17s and Tregs were generated in vitro over 5 days and then cultured for 
a further two days in the presence of anti-CD3 and anti-CD28 in each of the alternative 
polarising conditions described in Table 4-1 (nil=media only).  On day 7 cells were 
harvested and restimulated with PMA and ionomycin and analysed by FACS.  
Representative of two independent experiments. 
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4.2.6 In vivo behaviour of in vitro differentiated CD4 subsets following 
adoptive transfer 
 
In order to confirm that in vitro differentiated CD4 cells survive in vivo following 
adoptive transfer, 5x10^5 in vitro polarised HNT Thy1.1+ CD4 cells were injected iv into 
non-tumour bearing Thy1.2+ mice and spleens and lymph nodes harvested 2 , 7 and 21 
days later (Figure 4-5A).  Adoptively transferred thy1.1+CD4 cells were identified by 
flow cytometry (Figure 4-5B).   
Survival and homing of cells to lymphoid compartments was found to vary between 
subsets (Figure 4-5C).   Initial homing of cells to lymph nodes was highest in Th1 and 
Treg subsets, however by day 7 Th2s were found in lymph nodes in equivalent 
proportions.    Th1s, Th2s and Tregs were found in equivalent quantities in the spleen 
at day 2, however by day 7 Tregs had started to disappear in both the spleen and 
lymph node.  Th17s were found in a very low frequency in the spleen only at day 2 and 
had almost completely disappeared in all compartments thereafter.  By day 21, the 
numbers of Th1s had declined with only Th2s surviving long term, at levels unchanged 
from that seen at day 2. 
In summary persistence of adoptively transferred cells in the spleen and lymph node 
varied between different subsets with Th17s essentially disappearing post transfer and 
Th2s displaying the most longevity.   
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Figure 4-5 Recovery of in vitro differentiated CD4 subsets following adoptive 
transfer into naive mice 
Thy1.1+ Th1s, Th2s, Th17s and Tregs were differentiated in vitro and 5x10
5
 cells were 
injected iv into recipient thy1.2+ balb/c mice.  Harvests were performed 2, 7 and 21 
days later as in schedule in A.  Gating on CD4+Thy1.1+ve cells is shown in B.  Recovery 
of CD4+Thy1.1+ve cells from lymph nodes and spleen is displayed in C.  Experiment 
performed once. 
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CD62L is a cell surface marker expressed by naive T cells and central memory subsets 
which facilitates entry of circulating T cells into lymph nodes.  I therefore analysed 
expression of CD62L on the differentiated CD4 subsets at the end of the in vitro 
differentiation period (Figure 4-6).  This showed that the level of CD62L expression was 
consistently highest on Th1s and Tregs, the two subsets found in the greatest 
frequency in lymph nodes at day 2, suggesting that differences in baseline CD62L 
expression may explain the variable initial lymph node trafficking seen between 
subsets.   
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Figure 4-6  Initial homing of CD4 subsets to lymph nodes correlates with 
expression of CD62L 
A  CD62L expression was analysed on in vitro differentiated CD4 subsets at the end of 5 
days culture.  Results from 3 independent cultures are shown in B.  The recovery of 
thy1.1+CD4 cells from the experiment described in Figure 4-5 is shown in C  for 
comparison. 
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4.2.7 Survival and behaviour of CD4 subsets following adoptive transfer into 
tumour bearing mice 
 
It was important to determine how the presence of tumour affected the behaviour of 
adoptively transferred CD4 subsets.  The presence of AB1-HA tumour could potentially 
provide HA antigen and therefore drive proliferation of HNT CD4 cells but malignancy 
can also invoke a number of immunosuppressive mechanisms which might impair 
survival or proliferation of the adoptively transferred cells. 
CD4 subsets were generated from thy1.1+ HNT cells and adoptively transferred into 
Thy1.2 mice bearing 8 day old AB1HA tumours.  Organs were harvested 2 and 7 days 
after transfer.  It was not possible to examine later time points due to outgrowth of 
tumours.  Similar to that seen in non-tumour bearing mice, Tregs and Th1s were found 
in the greatest frequency in lymph nodes at day 2 (Figure 4-7A).  In addition, the 
presence of tumour favoured accumulation of Th1 and Treg subsets in the draining 
node compared to the non draining node, whereas no difference was seen for Th2s 
and Th17s.  The frequency of Tregs in the DLN two days after adoptive transfer was 
now four-fold higher than that seen for Th1s.   This suggests that the presence of 
AB1HA tumour provides a favourable environment for initial accumulation or 
proliferation of HA specific Tregs in the DLN. 
At day 2 Tregs were seen at the greatest frequency in all compartments, however 
consistent with results in naive mice, they had disappeared by day 7 (Figure 4-7B).  In 
contrast Th1s and Th2s expanded in the DLN or spleen between day 2 and day 7.  Since 
expansion of these subsets had not been observed in non tumour bearing mice during 
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this period, proliferation could be attributed to the presence of the HA expressing 
tumour.  
Again the quantity of Th17s that could be found at any time point was around 10 fold 
lower than that seen in other subsets indicating that the presence of cognate antigen 
did not improve the survival of these cells.  It was possible that Th17s may be homing 
to peripheral tissues rather than lymphoid compartments.  I therefore harvested lungs 
from mice alongside other organs and analysed recovered cells by flow cytometry 
(Figure 4-7C).  The frequency of each subset in the lung was similar to that seen in the 
spleen, indicating that there was no preferential accumulation of Th17s in the lung.  
Since Th17s were activated for 5 rather than 3 days, I also tried removing activation 
from Th17s after 3 days, in case the Th17s were undergoing activation induced cell 
death after adoptive transfer.  However this did not improve recovery of Th17 cells 2 
days after adoptive transfer (data not shown). 
These results indicate that the presence of AB1HA tumour favours early accumulation 
of Tregs in the DLN and spleen (but does not prevent their disappearance by day 7), 
promotes expansion of adoptively transferred Th1 and Th2s between days 2 and 7, but 
does not improve survival of Th17s. 
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Figure 4-7  Recovery of in vitro differentiated CD4 subsets following adoptive 
transfer into tumour bearing mice. 
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Thy1.2+ balb/c mice bearing 8 day old AB1-HA tumours received adoptive transfer of 
5x10
5 
in vitro differentiated Thy1.1+ Th1s, Th2s, Th17s or Tregs.  Harvests were 
performed 2 and 7 days later and recovered thy1.1+CD4 cells were identified by FACS, 
as shown in Figure 4-5B.  A  Initial accumulation of thy1.1+CD4 cells in DLN and NDLN 2 
days after adoptive transfer, statistical comparisons performed using paired T test.  B   
Recovery of thy1.1+ CD4 cells from DLN, NDLN and spleen at 2 and 7 days after 
transfer.  Statistical comparisons performed using unpaired t test with significant 
differences between values obtained on day 2 and day 7 for each organ shown.  A and 
B show results from two independent experiments (total 6 mice per group).   C  
Recovery of thy1.1+ CD4s from lung tissue 2 days after adoptive transfer. 
 
 
 
 
4.2.8 Th1s and Th2s are able to infiltrate tumours 
 
Although Th1 and Th2 cells were found to proliferate in lymphoid compartments in the 
presence of AB1HA tumour, this did not necessarily mean that these cells were able to 
infiltrate tumours and effect anti-tumour activity.  I therefore looked for the presence 
of adoptively transferred thy1.1 CD4 cells in tumours harvested 7 days after adoptive 
transfer.  Single cells suspensions were prepared and cells analysed by flow cytometry 
( 
Figure 4-8A).  The proportion of tumour infiltrating CD4 cells which consisted of 
adoptively transferred Thy1.1 HNT cells was determined.  In addition, in order to 
account for any effects the HA specific CD4 cells may have had on the total infiltrating 
CD4 population, the proportion of infiltrating thy1.1+ve cells was also expressed as a 
percentage of total tumour cells, as gated from forward and side scatter plots ( 
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Figure 4-8A). 
This showed that adoptively transferred Thy1.1+ve Th1s infiltrated the tumour in the 
greatest abundance, composing between 3-20% of all tumour infiltrating CD4s.  
Thy1.1+ve Th2s were also found in the tumour at a slightly lower proportion but 
Thy1.1+ve Tregs and Thy1.1+ve Th17s were not detected. 
 
 
Figure 4-8 Ability of CD4 subsets to infiltrate tumours 
Tumours from mice treated as described in Figure 4-7 were harvested 7 days after 
adoptive transfer and recovered cells analysed by flow cytometry.   A shows example 
of gating  W total cells were determined from forward and side scatter plots such that 
all lymphocytes were included but events lying on the axis were excluded, and thy1.1+ 
CD4 cells were identified as shown.   B  Recovery of thy1.1+ CD4 cells from tumours, 
expressed both as a percentage of total tumour infiltrating CD4 cells and as a 
percentage of total cells. 
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4.2.9 Stability of polarised phenotype in vivo 
 
The phenotypic expression of Thy1.1+ve HNT CD4 subsets after adoptive transfer into 
tumour bearing mice was determined by harvesting organs and restimulating cells with 
PMA and ionomycin ex vivo.  Expression of IFNg, IL-4, IL-17 and foxp3 on recovered 
cells was analysed by intracellular staining and flow cytometry.   
Expression of IFNg, Il-4, Il-17 and foxp3 on recovered Thy1.1+ Th1s, Th2s, Th17s and 
Tregs is shown in Figure 4-9A.  Compared to levels of IFNg expression on the cells prior 
to adoptive transfer, Th1s showed a small decrease in the proportion of IFNg-
expressing cells by day 2 suggesting either early death of some overstimulated cells 
through activation induced cell death or loss of IFNg expression by some cells (Figure 
4-9B).  However between day 2 and day 7 the proportion of IFNg secreting cells 
remained stable, indicating that in vitro differentiated Th1s maintain their phenotype 
in vivo. 
Interestingly, when Thy1.1+ve Th2s were recovered there was a marked increase in 
the proportion of cells which expressed IL-4 compared to that seen at the end of their 
5 day in vitro culture before transfer.  This mirrors the in vitro data described in section 
4.2.5, where restimulation of cells for a further two days increased the percentage of 
IL-4+ve cells.  Unlike Th1s, IL-4 expression was much higher in the spleen than the DLN 
at day 2, suggesting either that IL-4 negative cells preferentially track to lymph nodes 
or that IL-4 expression was being suppressed in the DLN.  Between days 2 and 7 levels 
of IL-4 expression declined in the spleen but were maintained in the DLN. 
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Although few Thy1.1+ve Th17s were found at any time point, those that were 
detectable did contain a proportion of IL-17 secreting cells, and this proportion was 
higher in the spleen than the DLN. 
Recovered Thy1.1+ve Tregs showed an initial loss of foxp3 positive cells.  Levels of 
foxp3 expression were stable thereafter. 
Overall these results indicate that for all subsets, the proportion of recovered cells 
expressing the phenotype imposed in vitro was generally comparable, or increased in 
the case of Th2s, to that seen pre-transfer.  This suggests that the phenotype imposed 
during in vitro culture is maintained by a similar proportion of cells in vivo. 
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Figure 4-9 Ex vivo phenotypic expression on CD4 subsets recovered 2 and 7 days 
after adoptive transfer 
Thy1.1+ CD4 cells were recovered 2 and 7 days after adoptive transfer into tumour 
bearing mice, as described in Figure 4-7, and restimulated ex vivo with PMA and 
ionmycin.  Thy1.1+CD4+ cells were identified by flow cytometry as shown in Figure 
4-5B.   A  Expression of IFNg, IL-4, IL-17 and foxp3 on Thy1.1+CD4+ cells.   B  Percentage 
of recovered Th1s, Th2s, Th17s and Tregs expressing IFNg, IL-4, IL-17 and foxp3 
respectively, compared to baseline (pretransfer) levels.  Shows results from 2 
independent experiments (n=6 at each timepoint) (3 data points missing from Th1, Th2 
and Th17 day 2 graphs due to failed restimulation). 
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4.2.10    Some adoptively transferred Th2s and Th17s Ǯ ?ǯer 7 
days in vivo in tumour bearing mice 
 
Although a proportion of in vitro differentiated CD4 cells maintained expression of 
their phenotypic markers in vivo, it was clear from this experiment that 7 days after 
adoptive transfer, amongst recovered thy1.1+ve Th2, Th17 and Treg populations there 
was an additional population of IL-4, IL-17 and foxp3  negative cells which had become 
IFNg secreting (Figure 4-10A).   In contrast there was no detectable IL-4, Il-17 or foxp3 
expression on recovered thy1.1+ve Th1s (data not shown).    
Prior to adoptive transfer the proportion of IFNg secreting cells in Th2, Th17 and Tregs 
was low and typically between 0-5%.  At day 2 levels of IFNg were still low in the DLN 
ĂŶĚƚŚĞƐƉůĞĞŶ ?ŚŽǁĞǀĞƌďǇĚĂǇ ?ĂƌŽƵŶĚ ? ?A?ŽĨƌĞĐŽǀĞƌĞĚƚŚǇ ? ? ?A?ǀĞ ?dŚ ?Ɛ ?ĂŶĚ ? ?A?
ŽĨƌĞĐŽǀĞƌĞĚƚŚǇ ? ? ?A?ǀĞ ?dŚ ? ?Ɛ ?ǁĞƌĞ/&EŐƉŽƐŝƚŝǀĞŝŶƚŚĞƐƉůĞĞŶ ?tŚĞŶƚƵŵŽƵƌ
infiltrating thy1.1+ve  ?Th2s ? were examined the proportion of IFNg secreting cells rose 
further to almost 40% (Figure 4-10B). 
These results indicated the tumour environment in this model favours the 
ĚĞǀĞůŽƉŵĞŶƚŽĨĂŶ/&EŐA? ?dŚ ? ?ƉŚĞŶŽƚǇƉĞĂŵŽŶŐƐƚa proportion of the adoptively 
transferred CD4 cells. 
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Figure 4-10 Plasticity of CD4 subsets in vivo 
Cells were recovered from DLN, spleen and tumour 2 and 7 days after adoptive 
transfer of 5x10
5
 in vitro differentiated Thy1.1+ CD4 subsets and restimulated ex vivo 
with PMA and ionomycin, as described in Figure 4-7.  Thy1.1+CD4+ cells were 
identified by flow cytometry as shown in Figure 4-5B.   A  Expression of IFNg on thy1.1+ 
Th2, Th17 and Treg subsets recovered from DLN and spleen was determined by flow 
cytometry.  B  Expression of IFNg on tumour infiltrating thy1.1+ Th1s and Th2s 7 days 
after adoptive transfer, shows analysis of pooled tumours from 3 mice. 
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4.3 Discussion 
 
The first part of this chapter describes the optimisation of protocols for differentiating 
naive CD4 T cells into Th1, Th2, Th17 and Treg subsets.   Initially I was mainly 
concerned with maximising the proportion of cells which expressed the appropriate 
phenotype.  Based on reports in the literature I found that IL-12 induced Th1 
differentiation, IL-4 induced Th2 differentiation, IL-6 and low dose TGFb induced Th17 
differentiation and high dose TGFb induced Treg differentiation.  In addition I found 
that adding neutralising antibodies to IFNg and IL-4, where appropriate, further 
increased the proportion of phenotype positive cells. 
To activate cells I used anti-CD3 and anti CD28 antibodies.  This method is well 
described (Zhang, Zhang et al. 2003; Harrington, Hatton et al. 2005; Nurieva, Yang et 
al. 2009), although other methods of activating cells with peptide loaded antigen 
presenting cells have also been commonly reported (Nishimura, Iwakabe et al. 1999; 
Park, Li et al. 2005; Lexberg, Taubner et al. 2008; Martin-Orozco, Muranski et al. 2009).  
I found that the duration of the activating stimulus had a profound effect on the 
phenotypic expression and viability of in vitro differentiated cells, consistent with cells 
undergoing activation induced cell death with prolonged activation.  For Th1s and 
Th2s, continuous activation for 5 days produced high frequencies of IFNg and IL-4 
positive cells respectively but at the expense of cell viability.  To preserve viability I had 
to settle for a shorter activation period with a reduced frequency of phenotype 
positive cells at the end of the culture period.  Th17s however appeared more resistant 
to activation induced cell death and indeed required continual activation to maintain 
their phenotype. 
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These results suggest that the culture conditions can have a marked effect on the 
quality of the in vitro differentiated CD4 cells which are produced.  As a consequence 
comparisons between studies which use markedly different protocols for in vitro 
activation and differentiation of CD4 cells need to be made cautiously.  Other 
investigators have also reported removing activation from aCD3, aCD28 activated Th1 
and Th2 cultures after 3 days (Zhang, Zhang et al. 2003) whereas this was not reported 
for cells activated by peptide loaded irradiated APCs (Park, Li et al. 2005; Lexberg, 
Taubner et al. 2008; Martin-Orozco, Muranski et al. 2009).  It could be that the 
strength of the TCR stimulus from peptide loaded APCs is weaker or declines naturally 
during culture such that removal of the activating stimulus is not necessary. 
To investigate the degree of plasticity of in vitro differentiated CD4 cells I tried to 
repolarise them into each of the other subsets.  This showed that Th1s and Th2s were 
more stable than Th17s and Tregs.  This is consistent with previous studies and is 
consistent with the theory that Th1s and Th2s are a more terminally differentiated CD4 
cell than Th17s or inducible Tregs (Murphy and Stockinger 2010).  Interestingly 
however when I examined the stability of the CD4 cells in vivo in tumour bearing mice, 
I found that Th1s were highly stable but that after 7 days a proportion of recovered 
thy1.1 cells from Th2, Th17 and Treg cultures had become IFNg secreting.  This was 
most pronounced amongst tumour infiltrating cells.  This suggests that the 
microenvironment in AB1-HA tumour bearing mice favours Th1 polarisation.  Since the 
transferred population contained both phenotype positive and negative cells, it is 
unclear whether the Th2, Th17 or Treg cells which had become IFNg +ve had arisen 
from the original positive or negative population. 
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Although the populations of each CD4 subset at the end of the culture period 
contained both phenotype positive and negative cells, it is interesting to note that the 
negative population still display some features of fully differentiated cells.  In the Th2 
cultures, despite >99% of cells being IL-4 negative at the end of 5 days in vitro 
differentiation, these cells were still highly resistant to repolarisation into other 
subtypes in vitro.  Furthermore, higher frequencies of IL-4+ cells were detected after a 
further 48 hours exposure to TCR stimulation, which was observed following two days 
in vitro culture and after recovery ex vivo.  These findings suggest that despite the lack 
of IL-4 expression initially, these cells still display some degree of Th2 differentiation.  
In addition, the Th17 cultures contained around 60-70% IL-17 negative cells yet 
recovery of Th17s following adoptive transfer was over ten-fold lower than other 
subtypes, suggesting that the survival and/or homing of the IL-17 negative population 
mirrors that of the IL-17 positive cells rather than the negative population from other 
subtypes.   
These findings suggest that the population of negative cells in CD4 subset cultures are 
not simply undifferentiated CD4 cells but in a number of respects behave similarly to 
their phenotype positive counterparts, despite the lack of expression of the signature 
cytokine.  It is possible, therefore, that intracellular cytokine detection by flow 
cytometry may be an insensitive method of detecting polarisation of some CD4 
subsets.   
Following adoptive transfer into mice, trafficking and survival of in vitro differentiated 
CD4 cells differed between subsets.  Initial homing of cells to lymph nodes was highest 
in Th1s and Tregs.  This can be explained by their higher expression of CD62L, a cell 
surface marker expressed by naive and central memory cells that facilitates entry into 
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lymph nodes.  In contrast CD62L expression on Th17s was consistently low and was 
variable on Th2s.  The presence of AB1HA tumour favoured the early 
accumulation/expansion of Tregs in the DLN and spleen over the other subsets, 
suggesting that the tumour environment may promote initial Treg homing, survival 
and/or proliferation over effector subsets. 
In naive mice Th2s displayed the greatest longevity but other subsets had started to 
decline in frequency by day 7.  However, the presence of an HA expressing tumour led 
to the expansion of antigen specific Th1s and Th2s in vivo, with substantial tumour 
infiltration by the Th1 subset.  This confirms that the observed ability of HA specific 
CD4 subsets to respond to HA peptide in vitro is mirrored in vivo by expansion of cells 
in the presence of HA antigen.  In contrast Tregs had disappeared 7 days after adoptive 
transfer in both naive and tumour bearing mice.  Surprisingly I could recover very few 
Th17s from lymph nodes and spleens at any timepoint following adoptive transfer.  
This was despite these cells being over 90% viable prior to transfer.   Furthermore 
removing the activating stimuli from Th17 culture at day 3 did not improve recovery of 
Th17s, suggesting activation induced cell death was not the cause of the lower 
recovery compared to other subsets.  In addition I looked for Th17s in peripheral 
tissues and could not find evidence of preferential homing of Th17s to other, non-
lymphoid sites.   
These results demonstrate that the behaviour of in vitro differentiated CD4s following 
adoptive transfer differs markedly between subsets.  As such, differential in vivo 
activity of in vitro differentiated CD4s may not only result from the specific set of 
cytokines produced by each subset but may also be due to differential homing and 
survival.  The failure to find Th17s after adoptive transfer is striking and contrasts to 
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other studies where Th17s were found to have a survival advantage over Th1s in 
lymphopenic hosts (Muranski, Boni et al. 2008) and a similar survival capacity to Th1s 
in non-lymphopenic mice (Martin-Orozco, Muranski et al. 2009).  It is unclear why 
Th17s did not survive in this model, however these studies used peptide loaded APCs 
to stimulate cells during in vitro culture as well as different mouse strains.  Balb/c mice 
are reported to favour Th2 differentiation when compared to C57BL/6 mice (Arimura, 
Kato et al. 2002), so it is possible that T cells from these strains may respond 
differently to in vitro polarisation protocols.   
 
In summary, this chapter demonstrates that naive HA specific CD4 cells can be 
polarised in vitro into Th1s, Th2s, Th17s and Tregs.   These subsets demonstrate 
variable homing, survival and plasticity in vivo but Th1s and Th2s are able to expand in 
vivo and infiltrate AB1HA tumours.   Based on these results I went on to examine the 
anti-tumour activity of these cells against AB1-HA tumours. 
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5 Using in vitro differentiated 
CD4 cells to treat tumours 
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5.1 Introduction 
 
Having established protocols for in vitro differentiation of HA specific CD4 subsets, I 
next examined whether these cells had anti-tumour activity in vivo against AB1-HA 
tumours.   CD4 cells can mediate anti-tumour effects through a number of 
mechanisms, but it is the provision of help to tumour specific CD8 T cells which is 
widely regarded as their primary mode of action (Lake and Robinson 2005; Kennedy 
and Celis 2008).   Therefore it was important to ensure that there was an adequate 
precursor frequency of HA specific CD8s available so that the help provided by HA 
specific CD4s would be apparent, and also so that any differences in outcome between 
mice receiving different CD4 subsets could be attributed to the CD4 cells themselves 
and not due to differences in the availability of CD8 effectors.   
CL4 mice express a T cell receptor which recognises a class I restricted HA epitope.  I 
therefore opted to co-transfer HA specific CD8 T cells harvested from a naive thy1.1+ 
CL4 mouse alongside the HNT CD4 cells.  In early experiments I transferred unsorted 
CL4 lymphocytes, however in later experiments, due to a limited supply of CL4 mice, I 
sorted CD8 T cells from CL4 lymph nodes and spleens through magnetic column 
separation and transferred an equivalent number of CD8 T cells.  Since thy1.1+ CL4 
CD8s could be identified ex vivo with flow cytometry, I was able to track the activity of 
the HA specific CD8 cells and hence determine the effects of cognate help provided by 
each HA specific CD4 subset to HA specific CD8s. 
I first examined the anti-tumour activity of in vitro differentiated CD4 cells in a 
prophylactic treatment setting, where HA specific T cells were injected prior to 
inoculation with AB1-HA.  Due to the absence of established tumour-induced 
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ŝŵŵƵŶŽƐƵƉƉƌĞƐƐŝŽŶĂŶĚƚŚĞůŽǁĞƐƚƚƵŵŽƵƌůŽĂĚ ?ƚŚŝƐĐŽƵůĚďĞĐŽŶƐŝĚĞƌĞĚĂ ?ďĞƐƚĐĂƐĞ
ƐĐĞŶĂƌŝŽ ? ?ǁŚĞƌĞĂŶƚŝ-tumour activity of adoptively transferred T cells is likely to be 
maximal.    
I then looked at the effects of adoptive transfer of CD4 subsets against established 
tumours.  In chapter 3, I demonstrated that gemcitabine causes lymphodepletion 
followed by homeostatic proliferation and leads to a reduction in tumour infiltrating 
Tregs 7 days after treatment.  I hypothesised that treatment with gemcitabine would 
provide a favourable window for adoptive transfer.  The plasma half life of gemcitabine 
in mice is around 30 minutes (Shipley, Brown et al. 1992), therefore I opted to transfer 
cells 24 hours after gemcitabine administration, to ensure the transferred cells were 
not affected by the drug. 
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5.2 Results 
5.2.1 Titrating the number of HA specific CD8 T cells for co-transfer with in 
vitro differentiated CD4 subsets 
 
In order to ensure that there were an adequate number of HA specific CD8 T cells in 
our tumour model, such that the availability of tumour specific CD8 T cells was not 
going to limit the effects of the adoptively transferred CD4 subsets, HA specific CD8 T 
cells from a naive CL4 mouse were co-transferred alongside the HNT CD4 subsets. 
Transfer of large numbers (10
7
) of naive CL4 lymphocytes has been shown to mediate 
tumour rejection in a high proportion of mice in the AB1-HA model (Marzo, Lake et al. 
1999).  We therefore titrated the number of transferred CL4 cells to try to find the 
tipping point at which there were likely to be enough HA specific CD8 cells available to 
mediate the effects of the adoptive transferred CD4 cells, but not so many that they 
would themselves substantially delay tumour growth.  CL4 lymphocytes were injected 
intravenously alongside naive HNT lymphocytes and 1 day later mice were challenged 
with AB1-HA.  There were no cures with these treatments, but in mice that received 
both lower (5x10
4
) and higher (5x10
5
) numbers of HNT cells, tumour growth was 
delayed when more than 1x10
6 
CL4s were used (Figure 5-1).  With 1x10
6 
CL4s a small 
but significant prolongation of survival was seen.  Therefore in future treatment 
experiments we elected to co-transfer 1x10
6
 CL4 lymphocytes alongside the in vitro 
differentiated CD4 subsets. 
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Figure 5-1 Titrating numbers of HA specific CD8s for co-transfer with HA specific 
CD4s 
Mice were injected i.v. with naive HNT CD4 cells in combination with CL4 lymphocytes 
on day -1 and challenged with 5x10
5
 AB1-HA cells at day 0.  Tumour growth and 
survival curves are shown.  Kaplan Meier plots were analysed by log rank test and 
significance is shown in comparison to mice receiving HNT cells only. 
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5.2.2 Th1s mediate tumour rejection in a prophylactic treatment model 
 
The anti-tumour activity of in vitro differentiated CD4 subsets was first examined in a 
prophylactic treatment setting, as this could be considered the most optimal situation 
to see anti-tumour activity.  Th1, Th2, Th17, Treg and Th0 subsets were generated in 
vitro (Figure 5-2A) and were injected intravenously with
 
CL4 lymphocytes.  1 day later 
mice were challenged with AB1HA.  Survival and tumour growth was compared to 
control mice that received CL4 cells alone (Figure 5-2B).  This showed that only Th1 
cells provided a significant survival advantage, with 2 of 5 mice rejecting tumours and 
surviving long term.  In addition, in the mice which did not survive, only Th1s led to a 
significant delay in rate of tumour growth (Figure 5-2B).   Although no significant 
differences in growth rates were observed with any of the other CD4 subsets, tumours 
were noted to grow most quickly in mice that received adoptive transfer of Tregs. 
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Figure 5-2 Prophylactic treatment with HA specific CD4 subsets  
A   Th1, Th2, Th17, Treg and Th0 HNT CD4 subsets were differentiated in vitro.  B   Mice 
received intravenous adoptive transfer of 5x10
5
 HNT cells and 1x10
6
 CL4 lymphocytes, 
1x10
6
 CL4 lymphocytes alone or no adoptive transfer on day -1 and inoculation of 
5x10
5
 AB1-HA subcutaneously on day 0.  Survival curves and tumour growth curves in 
non surviving mice are shown.  Significance compared to mice receiving CL4 cells 
alone.  5 mice per group. 
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5.2.3 Adoptive transfer of in vitro differentiated CD4 subsets does not 
improve outcomes following treatment with gemcitabine 
 
Experiments described in chapter 3 demonstrated that a single dose of gemcitabine 
caused transient lymphodepletion, reduced the frequency of regulatory CD4 T cells 
within the tumour and substantially increased CD8 tumour infiltration.  However this 
was not sufficient to cure tumours in the majority of cases.  I therefore examined 
whether adoptive transfer of in vitro differentiated CD4 subsets, in conjunction with 
tumour specific CD8 T cells, in the immediate post chemotherapy setting could 
enhance the anti-tumour immune response, and whether this would be sufficient to 
cure mice with established tumours. 
Mice bearing 9 day old AB1HA tumours were treated with a single dose of 
gemcitabine.  24 hours later mice received an intravenous injection of in vitro 
differentiated Th1, Th2, Th17, Treg or Th0 cells, plus CL4 cells (Figure 5-3A).  Control 
groups received CL4 cells alone or no adoptive transfer.  In contrast to the prophylactic 
setting, adoptive transfer of tumour specific CD4 subsets did not improve survival 
(Figure 5-3B) or delay tumour growth (data not shown) compared to mice that 
received transfer of CL4 cells alone.  In all groups a small percentage of mice were 
cured of their tumour, however this appeared to be simply an effect of gemcitabine 
treatment. 
Since gemcitabine on its own was capable of eradicating tumours, I repeated this 
experiment with a reduced the dose of gemcitabine.  However, transfer of CD4 subsets 
on day 12 following a lower dose of gemcitabine on day 9 still had no effect on survival 
or tumour growth (Figure 5-3C). 
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Figure 5-3 Treatment of established tumours with gemcitabine followed by 
adoptive transfer of CD4 subsets 
A   Th1, Th2, Th17, Treg and Th0 HNT CD4 subsets were differentiated in vitro.  B + C  
Mice bearing 9 day old AB1-HA tumours were treated with 240ug/g gemcitabine (B) or 
120ug/g gemcitabine (C) followed by i.v. adoptive transfer on day 10 (B) or day 12 (C ) 
of 5x10
5
 HNT cells and 1x10
6
 CL4 lymphocytes, 1x10
6
 CL4 lymphocytes alone or no 
adoptive transfer.  Between 5-7 mice per group. 
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5.2.4 Gemcitabine does not deplete cells transferred 24 hours later 
 
Although the plasma half life of gemcitabine is around 30 minutes, the half life in 
tissues can be longer (Shipley, Brown et al. 1992).  Thus it was important to ensure 
that the adoptively transferred cells were not being killed by residual gemcitabine not 
cleared from tissues at the time of transfer.  I therefore injected non-tumour bearing 
mice with a single dose of 240 ug/g of gemcitabine 1 day, 2 days and 3 days prior to 
adoptive transfer of in vitro differentiated Th1s and counted thy1.1+CD4 cells 
recovered from spleens 48 hours later (Figure 5-4).  This showed that cells transferred 
24 hours after gemcitabine were not being depleted compared to control mice.   
 
 
 
Figure 5-4 Effects of timing of gemcitabine on recovery of adoptively transferred 
cells 
Mice were treated with 240ug/g gemcitabine 1, 2 or 3 days before receiving adoptive 
transfer of 1x10
6
 in vitro differentiated thy1.1+ HNT Th1s.  2 days later spleens were 
harvested and thy1.1+ CD4 cells identified by flow cytometry. 
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5.2.5 Increasing the number of adoptively transferred CD4 subsets or 
tumour specific CD8 T cells does not improve outcomes 
 
In the previous experiments, because of difficulties generating large numbers of 
polarised CD4 cells in vitro, mice were treated with 5x10
5
 HNT CD4 cells.  This is fewer 
than many other investigators have used in similar experiments (Nishimura, Iwakabe 
et al. 1999; Muranski, Boni et al. 2008), where up to 2x10
7
 cells were transferred.  
Since the effects of adoptive transfer in treatment experiments had been minimal, 
these experiments were repeated using an increased number of CD4 cells (Figure 5-5).  
Mice were treated in both the prophylactic and the post-gemcitabine situation with 
2.5x10
6
 in vitro differentiated HNT CD4 cells and 1x10
6
 CL4 cells.  However, even 
though cell number was increased five-fold, no improvement in numbers of surviving 
mice was observed.  Surprisingly, we found that the number of survivors from theTh1 
treated group in the prophylactic experiment was less than that seen in the original 
experiment (Figure 5-5B).  Despite this, the same trend was observed  W that only Th1s 
were able to significantly improve survival in the prophylactic setting compared to 
mice who received CL4 cells alone.   
In the post-gemcitabine setting, adoptive transfer of five-fold more CD4 cells did not 
generate any long term survivors, but there was a small delay in the rate of tumour 
growth with Th1 and Th2 cells (p<0.05), suggesting some limited anti-tumour activity 
(Figure 5-5C). 
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Figure 5-5 Treatment experiments using increased numbers of HA specific CD4 
subsets 
A)  Th1, Th2, Th17, Treg and Th0 HNT CD4 subsets were differentiated in vitro.   B+C)  
Mice received adoptive transfer of 2.5x10
6
 HNT CD4 cells with 1x10
6
 CL4 lymphocytes 
1 day before tumour inoculation (B), or 1 day after treatment with 240ug/g 
gemcitabine (C). 6 mice per group.  Graphs show survival curves and tumour growth in 
non-surviving mice.  Significance compared to mice receiving CL4 cells alone. 
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Since increasing the number of tumour specific CD4 cells did not improve overall 
survival, it was important to ensure that there were no other factors which could have 
been limiting the activity of the adoptively transferred CD4 cells.  Although I had 
previously attempted to titrate the number of CL4 lymphocytes transferred in 
conjunction with naive HNTs, it was still possible that inadequate numbers of tumour 
specific CD8 T cells could explain the lack of effectiveness of the CD4 cells.  Whether 
this might be the case was examined by repeating the prophylactic treatment 
experiment using only the Th1 subset.  Increasing numbers of CL4 lymphocytes were 
co-transferred in order to ascertain if there was a CD8 dose dependant effect (Figure 
5-6).  With low (5x10
5
) and high (1x10
6
) numbers of Th1s transferred, increasing the 
number of CL4 cells by a factor of 10 had no significant effect on survival.  In all groups 
we found that, similar to previous experiments, approximately 40% of mice rejected 
tumour.  This suggests that the availability of HA specific CD8 T cells was not a limiting 
factor in the model. 
  
 147 
 
 
Figure 5-6 Treatment experiments using increased numbers of HA specific CD8s 
Mice received adoptive transfer of HNT Th1s and CL4 lymphocytes in the doses 
indicated at day -1 and were challenged with 5x10
5
 AB1-HA on day 0.   
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5.2.6 In vitro differentiated HA specific CD4 subsets fail to provide help to 
HA specific CD8s in mice with established tumours 
 
The above experiments suggested that the anti-tumour activity of HA specific CD4 and 
CD8 T cells was not limited by the absolute number of cells transferred.   I next 
investigated whether there could be a functional problem with the cognate help 
provided in vivo by the HA specific CD4 cells to HA specific CD8 T cells.  Thy1.1+ HNT in 
vitro differentiated CD4 subsets were transferred along with Thy 1.1+ CL4 lymphocytes 
into mice bearing established 9 day tumours.  Organs were harvested and recovered 
cells were analysed by flow cytometry 7 days after adoptive transfer (Figure 5-7A).  The 
effects of each HA specific CD4 subset on recovery of HA specific Thy1.1+CD8+  T cells 
could thus be determined and compared to mice that received CL4 cells without HNT 
cells (Figure 5-7B). 
Similar to the experiments described in chapter 4, at 7 days after adoptive transfer 
Th1s, Th2s and Th0s could be recovered from DLN, spleen and tumour whereas Th17s 
and Tregs were not found at this timepoint.  It was also clear that compared to the 
group that received no CD4 cells (Nil), adoptive transfer of Th1s, Th2s, Th17s or Th0s 
did not have any effect on the numbers of HA specific CD8 T cells recovered from the 
draining lymph node, spleen or tumour.  This suggests that these HA specific CD4 cells 
did not help cognate CD8 T cells to expand within lymphoid organs or to infiltrate 
tumours.   
In contrast, transfer of Tregs alongside CL4s led to a significant reduction in CL4 
frequency in the spleen and tumour, but not the DLN, 7 days after transfer.  This was 
despite the fact that the Tregs themselves had disappeared by this timepoint.   
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Figure 5-7 The effects of HA specific CD4 help on recovery ex vivo of HA specific 
CD8s 
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Mice bearing 9 day old AB1-HA tumours received adoptive transfer of 1x10
6
 CL4 
lymphocytes with 5x10
5
 in vitro differentiated HNT Th1s, Th2s, Th17s, Tregs, Th0s or 
no CD4s.  7 days later DLN, spleen and tumour were harvested and thy1.1+ CD4 and 
CD8 cells identified by flow cytometry.  A   gating on thy1.1+CD4 and thy1.1+CD8 cells 
in DLN and tumour.  B Recovery of adoptively transferred thy1.1+CD4 cells and 
thy1.1+CD8 cells, expressed as a percentage of total CD4s/CD8s and additionally for 
tumour samples, as a percentage of total cells.  * denotes significance at p<0.05 
compared to mice receiving no CD4s (Nil). 
 
In addition to analysing the effects of CD4 subsets on cognate CD8 numbers, I also 
looked to see if the provision of CD4 help could be altering the function of HA specific 
CD8 cells.  To do this I looked for expression of a positive marker of activation, ICOS, 
and expression of a negative regulator of function, PD-1 on recovered Thy1.1+ve CD8 
cells (Figure 5-8A).  The frequency of ICOS+ thy1.1+CD8 was very high in the DLN and 
tumour, between 80-100%, consistent with the cells being activated by the presence of 
HA antigen.  ICOS expression was lower in the spleen.  The frequency of ICOS+ thy1.1+ 
CD8s was not affected by the presence of any of the CD4 subsets, indicating that they 
had not changed the activation status of HA specific CD8 cells (Figure 5-8B).   
Expression of PD-1 on Thy1.1+ve CD8 cells was very high in the tumour, but was 
expressed at a much lower level in the DLN and there was minimal expression in the 
spleen (Figure 5-8B).  Expression of PD-1 on HA specific (thy1.1+ve) tumour infiltrating 
CD8 cells was substantially higher than on the endogenous (thy1.1-) CD8 cells (Figure 
5-8C).  This suggests that it is the HA expression within the tumour microenvironment 
which promotes expression of PD-1 on HA specific CD8 cells.  Again, the presence of 
HA specific CD4 subsets did not alter PD-1 expression on Thy1.1+ve CD8s in any 
compartment.   
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Figure 5-8 The effects of HA specific CD4 help on ICOS and PD-1 expression on HA 
specific CD8s 
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Mice bearing 9 day old AB1-HA tumours received adoptive transfer of 1x10
6
 CL4 
lymphocytes with 5x10
5
 in vitro differentiated HNT Th1s, Th2s, Th17s, Tregs, Th0s or 
no CD4s (Nil).  7 days later DLN, spleen and tumour were harvested and expression of 
ICOS and PD-1 on thy1.1+ CD8 cells was examined by flow cytometry.  Thy1.1+CD8+ 
cells wre identified as shown in Figure 5-7A.  A   Gating of ICOS and PD-1 on thy1.1+ 
CD8 cells, on thy1.1- CD8 cells and on FMO control.  B  Effects of different HNT CD4 
subsets on ICOS and PD-1 expression on thy1.1+ CD8 cells recovered from DLN, spleen 
and tumour. C  Expression of ICOS and PD-1 on endogenous (thy1.1-) cells. 
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5.3 Discussion 
 
The experiments described in this chapter tested the hypothesis that adoptive transfer 
of HA specific in vitro differentiated CD4 subsets alongside HA specific CD8 cells could 
enhance rejection of an HA expressing tumour.   The only situation in which any of the 
treatment groups caused permanent rejection of tumour was with Th1s cells in the 
prophylactic setting.  Amalgamating all experiments which used variable numbers of 
HA specific CD4 and CD8 cells, 15 out 43 (35%) mice treated prophylactically with Th1 
cells survived long term, whereas we saw no survivors in mice who received any of the 
other subsets.  Increasing either the quantity of transferred CD4 or CD8 cells did not 
increase numbers of survivors suggesting that cell number was not a limiting factor. 
The finding that Th1s possess anti-tumour activity is well established.  Adoptive 
transfer of large numbers (10
7
) of Th1 polarised tumour specific CD4 cells caused 
rejection of established subcutaneous tumours in one model (Nishimura, Iwakabe et 
al. 1999).  This study also showed that in vitro differentiated Th2 cells can have anti-
tumour activity, although Th2 cells are usually considered to be a suppressive subtype 
in tumour immunity (De Monte, Reni et al. 2011).  In contrast to my findings, in vitro 
differentiated Th17 cells have recently been shown to be superior at mediating tumour 
rejection than Th1s in a subcutaneous melanoma model (Muranski, Boni et al. 2008) 
and in a melanoma lung metastasis model (Martin-Orozco, Muranski et al. 2009).  The 
lack of efficacy of the Th17s in our model is not unexpected given that they were only 
found in low frequencies in lymphoid and non-lymphoid organs after adoptive transfer 
(section 4.2.7).  In addition, treatment models involving Th17 cells have used 
preconditioning irradiation to induce complete lymphodepletion prior to adoptive 
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transfer (Muranski, Boni et al. 2008).  In a lymphopenic environment, Th17s have been 
shown to convert into a IFNg-ƐĞĐƌĞƚŝŶŐ ?dŚ ?-ůŝŬĞ ?ĐĞůů(Nurieva, Yang et al. 2009), which 
is consistent with the finding that the anti-tumour activity of Th17s in lymphopenic 
mice was critically dependant on IFNg and not IL-17 (Muranski, Boni et al. 2008).  It is 
possible that Th17 cells in this model may have better survival and anti-tumour activity 
if complete lymphablation had been induced prior to adoptive transfer. 
In the post gemcitabine setting, there was little effect from adoptive transfer of CD4 
subsets.  There was no improvement in numbers of mice surviving long term and even 
when high numbers of cells were transferred, there was only a small delay in tumour 
outgrowth seen with Th1 and Th2 subsets only.  As such experiments described in this 
chapter reject the hypothesis that adoptive transfer of in vitro differentiated CD4 
subsets can mediate rejection of established tumours in the post gemcitabine setting. 
 
I therefore investigated possible reasons for the lack of efficacy of in vitro 
differentiated CD4 subsets against established tumours.   Importantly, I excluded the 
possibility of any direct toxicity from residual gemcitabine on the adoptively 
transferred cells.   In chapter four I demonstrated that in vitro differentiated Th1s and 
Th2s survived in vivo, expanded between days 2 and 7 post adoptive transfer, and 
were able to infiltrate established tumours.   Additionally the experiments described in 
this chapter demonstrate that increasing the number of cells does not improve 
outcomes.  It therefore seemed unlikely that an insufficient number of cells or an 
inability to infiltrate the tumour was limiting.  As such, it was important to consider 
other reasons which may have explained the poor efficacy of the adoptively 
transferred cells against established tumours.  I therefore looked to see if there was a 
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functional problem with the help these cells were able to provide to HA specific CD8s.  
This experiment showed that none of the helper CD4 subsets appeared to be able to 
provide help to cognate CD8s.  I found no evidence of increased expansion/survival of 
CD8s in any compartment compared to mice that did not receive CD4s. 
In contrast to the effector CD4 subsets, I found that Tregs did appear to be negatively 
impacting on CD8 expansion/survival and tumour infiltration.  This was despite the fact 
that the Tregs themselves had disappeared by day 7.  In chapter 4, I found that 
adoptively transferred Tregs accumulate in abundance in the DLN and spleen at day 2 
but do not survive until day 7.   In addition, I did not find Tregs in the tumour, 
suggesting that the negative effect of Tregs on CD8 accumulation in the spleen and 
tumour seen at day 7 is likely to be a consequence of inhibitory activity in the DLN or 
spleen that occurs during the first few days after adoptive transfer, before the Tregs 
themselves have disappeared. 
In addition there was no change in activation status or expression of PD-1 on HA 
specific CD8s in the presence of helper CD4 cells.   PD-1 expression was highly 
upregulated on tumour infiltrating Thy1.1+ CD8s compared to that seen in the DLN or 
spleen, suggesting that the HA specific CD8s within the tumour are susceptible to 
negative regulation.  Additionally PD-1 expression was higher on tumour infiltrating HA 
specific CD8s than on the endogenous CD8 cells, suggesting that this was not simply a 
global effect of the tumour microenvironment on all CD8s but was likely to be an effect 
of interactions between HA antigen and cognate CD8 cells.   Ahmadzadeh et al found 
high levels of PD-1 expression on tumour infiltrating CD8s and this correlated with an 
exhausted phenotype and impaired effector function (Ahmadzadeh, Johnson et al. 
2009).  In viral models CD8 T cells primed in the absence of CD4 help were found to 
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excessively upregulate PD-1 (Fuse, Tsai et al. 2009) and this effect was also replicated 
by an absence of CD40-CD40L interactions (Dias, Giannoni et al. 2011).  It is possible 
therefore that the HA specific CD8s within the tumour could have been functionally 
impaired as a result of ineffective CD4 help during priming. 
Thus, the failure of CD4 helper subsets to provide help to CD8s in mice with 
established tumours could explain the lack of efficacy of the CD4 subsets in this 
setting.  Potential reasons for this inability to help were considered:  
1) Uncoupling of HA-HNT specificity.   
Expression of HA on tumour cell lines was confirmed by others in the lab on frequent 
occasions by real time PCR (unpublished data - Amanda Cleaver).  As reported in 
chapter 4, in vitro differentiated HNT CD4 cells retained the ability to respond to HA 
when restimulated with peptide in vitro and also expanded in vivo in the presence of 
HA expressing tumours, suggesting that loss of HA specificity on the adoptively 
transferred cells or loss of HA antigen expression on tumours was unlikely to be a 
factor.  In addition work by others in the lab demonstrated that CFSE labelled HNT cells 
proliferated in vivo in the presence of AB1HA, demonstrating that host antigen 
presenting cells were able to process and present HA antigen (personal 
communication, Prof Richard Lake). 
2) Overriding suppression from endogenous immunity.   
Although we consistently saw survivors in Th1 treated mice in the prophylactic group, 
this was not replicated in established, gemcitabine treated tumours.  It is noteworthy 
that following gemcitabine treatment at day 9, tumours rapidly regress to barely 
palpable by day 12 such that the overall tumour burden in the post gemcitabine 
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setting was not macroscopically dissimilar to that seen immediately following tumour 
inoculation.  This suggests that there may be reasons other than increased tumour 
load to explain the differences in efficacy between the prophylactic and the treatment 
setting.   Mice treated with gemcitabine at day 9 will have already established an 
immune response to tumour antigens, which is not the case in mice treated 
prophylactically.  Daresse-Jeze et al showed that after first encounter with tumour 
antigens, regulatory T cells proliferate more rapidly than naive effector CD4 cells and 
suppress effector responses, but if effector memory T cells were present first then 
Tregs were unable to control responses (Darrasse-Jeze, Bergot et al. 2009).  This 
suggests that the presence or absence of established regulatory cells at the time of 
adoptive transfer could determine outcome.  Although gemcitabine does cause 
lymphodepletion, this is not complete, meaning that established regulatory T cells 
could still be suppressing the actions of adoptively transferred cells.  Supporting this 
hypothesis was my finding that in established tumours, adoptively transferred Tregs 
had a negative impact on CD8 tumour infiltration, suggesting an environment which 
favoured the activity of suppressive subsets and not effector subsets. It was possible 
therefore that in the treatment model established endogenous Tregs were suppressing 
the activity of the adoptively transferred helper CD4 T cells. 
3) >ĂĐŬŽĨ ?ƐƉĂĐĞ ?ĨŽƌĂĚŽƉƚŝǀĞůǇƚƌĂŶƐĨĞƌƌĞĚĐĞůůƐƚŽĞǆƉĂŶd 
In addition to depleting suppressive cells, lymphodepletion prior to adoptive transfer 
ŝŶĚƵĐĞƐŚŽŵĞŽƐƚĂƚŝĐƉƌŽůŝĨĞƌĂƚŝŽŶĂŶĚƉƌŽǀŝĚĞƐ ?ƐƉĂĐĞ ?ĨŽƌĂĚŽƉƚŝǀĞůǇƚƌĂŶƐĨĞƌƌĞĚĐĞůůƐ
to expand (Weber, Atkins et al. 2011).  Most adoptive transfer protocols employ some 
form of preconditioning to induce homeostatic proliferation of transferred cells.  
However, since Th1s were able to cause tumour rejection in the prophylactic model, 
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ĚĞƐƉŝƚĞƚŚĞĂďƐĞŶĐĞŽĨůǇŵƉŚŽĚĞƉůĞƚŝŽŶ ?ƚŚĞƌĞƋƵŝƌĞŵĞŶƚĨŽƌ ?ƐƉĂĐĞ ?ĐĂŶŶŽƚďĞ
considered necessary for their efficacy and does not in itself explain why these cells 
were ineffective when given after gemcitabine. 
4) Lack of helper function on adoptively transferred CD4 subsets 
Although Th1, Th2, Th17 and Treg cells are generally defined by expression of IFNg, IL-
4, IL-17 and foxp3 respectively, CD4 cells provide help to other immune cells by a 
number of mechanisms.  Despite having the appearance of fully differentiated and 
functional CD4 helper cells, in vitro differentiated HA specific CD4 cells did not provide 
help to HA specific CD8s.  Two of the most important mechanisms by which CD4 cells 
provide help are through activation of DCs through CD40-CD40L interactions and 
through production of IL-2 (Wilson and Livingstone 2008).  It was therefore important 
to further define the phenotype of in vitro differentiated CD4 subsets and determine 
whether they were functionally able provide help to CD8 T cells through these 
mechanisms.   
 
In summary the experiments described in this chapter show that only Th1 polarised 
CD4 cells have significant anti-tumour activity in vivo and that this is only in the 
prophylactic setting.  The lack of effect against established tumours even after 
gemcitabine treatment could be explained by the apparent lack of help given to 
cognate CD8s.  These results led me to investigate i) whether there were functional 
deficiencies in in vitro differentiated CD4 cells which limited the help they could 
provide and ii) whether removing the endogenous, suppressive CD4 repertoire prior to 
treatment would improve the capacity of adoptively transferred Th1s to eradicate 
established, gemcitabine treated tumours. 
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6 Ǯǯ
functions of in vitro 
differentiated CD4 cells 
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6.1 Introduction 
 
The experiments described in this chapter follow from the discussion at the end of 
chapter five.  The lack of activity of in vitro differentiated CD4 cells against established 
tumours, and the inability of these cells to mediate expansion and tumour infiltration 
of HA specific CD8 T cells in mice with established tumours, suggested the CD4 cells 
ǁĞƌĞĨĂŝůŝŶŐƚŽƉƌŽǀŝĚĞĞĨĨĞĐƚŝǀĞ ?ŚĞůƉ ?ƚŽ,ƐƉĞĐŝĨŝĐ ?Ɛ ? 
I therefore examined the CD4 subsets for expression of markers associated with CD4 
help, including CD40L (CD154) and IL-2.  CD40L expressed on helper T cells ligates CD40 
on dendritic cells, leading to dendritic cell activation and upregulation of co-
stimulatory molecules and expression of IL-12 (Cella, Scheidegger et al. 1996; 
Schoenberger, Toes et al. 1998).   IL-2 is a T cell growth factor which is important for 
sustaining CD8 T cell expansion, function and memory formation (Antony, Piccirillo et 
al. 2005; Janssen, Droin et al. 2005).  A deficiency in either CD40L expression (Shah, 
West et al. 2009) or IL-2 production (Antony, Piccirillo et al. 2005) impairs the ability of 
CD4s to promote CD8 expansion or tissue infiltration. 
I then tried to see if altering the culture conditions could alter the phenotype of the in 
vitro differentiated cells, with aim of improving their ability to provide help.  Since Th1s 
were the only CD4 subset which had anti-tumour activity in the prophylactic setting, in 
these experiments I concentrated on this subtype.  In some experiments I tried 
culturing Th1 cells in IL-7 rather than IL-2.  IL-7 is a member of the common gamma 
chain family of cytokines and signals through the IL-7 receptor (CD127), which is 
expressed on naive T cells and on some effector T cells destined to become memory 
cells (Mackall, Fry et al. 2011).  IL-7 was superior to IL-2 for the ex vivo expansion of 
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tumour specific T cells and produced cells with greater in vivo anti-tumour activity 
(Caserta, Alessi et al. 2010; Cha, Graham et al. 2010).   
Once I had adjusted the culture conditions to produce Th1 cells which displayed a 
phenotype in vitro that might be associated with an improved ability to provide help to 
CD8 T cells, I adoptively transferred these cells into gemcitabine treated tumour 
bearing mice, and the effect on tumour growth and on the expansion and tumour 
infiltration of HA specific CD8s was analysed. 
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6.2 Results 
 
6.2.1 In vitro differentiated helper T subsets express variable levels of 
CD40L, IL-2 and PD-1 
 
Since the in vivo activity of in vitro differentiated CD4 T cells subsets had been weak 
and I had found no evidence that they had been able to help HA specific CD8s to 
expand or infiltrate tumours I looked to see whether these cells expressed markers 
associated with T cell help and also whether they may be susceptible to negative 
regulation.  I examined expression of CD40L, IL-2 and PD-1 on the CD4 subsets at the 
end of the 5 day culture period (Figure 6-1).   
CD40L expression was high on Th1 subsets, lower on Th0s and Th17s and minimally 
expressed on Th2s and Tregs.  When cells were restimulated and analysed for 
expression of IL-2 by intracellular flow cytometry, surprisingly Th1s and Th2s produced 
no IL-2, whereas it was produced in abundance by Th17s, Tregs and Th0s.  PD-1 was 
expressed most highly on Th17s with the lowest levels being seen on Tregs and Th0s, 
suggesting that Th17s had the greatest potential to be inhibited through ligation of PD-
1. 
These results indicated that an inability to provide help through CD40-CD40L 
interactions or through the production of IL-2 may have explained the lack of anti-
tumour activity of the CD4 subsets.  No cell type expressed both high levels of CD40L 
and IL-2.   Loss of IL-2 expression was particularly surprising on the Th1 subset, since 
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this is often considered a Th1-type cytokine.  I therefore went on to look at the kinetics 
of expression of CD40L and IL-2 during the whole of the 5 day culture period. 
 
 
 
 
 
Figure 6-1 Expression of CD40L (CD154), IL-2 and PD-1 on CD4 subsets at the end 
of 5 day in vitro culture.    
In vitro differentiated CD4 subsets were analysed for expression of CD40L and PD-1 by 
flow cytometry and are shown compared to the FMO control (unfilled histogram).  IL-2 
expression was analysed by intracellular flow cytometry after restimulation with PMA 
and ionomycin in the presence of brefeldin A.  All plots gated on CD4+ cells.  Plots 
representative of duplicate samples.   
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6.2.2 CD40L expression declines during in vitro culture in all CD4 subtypes 
except Th1 
 
CD4 cells were differentiated in vitro into Th1, Th2, Th17, Treg and Th0s over 5 days in 
accordance to the protocols established in chapter 4.  On days 0, 1, 2, 3 and 5 samples 
of cells were stained for expression of CD40L (Figure 6-2).  This showed that CD40L was 
highly upregulated on Th1s, Th2s and Th0s after 24 hours activation but had declined 
in Th2s by day 3.  Th0s lost CD40L between day 3 and day 5, whereas Th1s were the 
only subset to maintain CD40L throughout the 5 day culture.  In contrast Th17s and 
Tregs expressed much lower levels after 24 hours of activation and this was lost by day 
2 of culture. 
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Figure 6-2 Kinetics of CD40L expression during 5 day in vitro differentiation on 
CD4 subsets.  
Expression of CD40L was determined by flow cytometry on day 0, 1, 2, 3 and 5 of in 
vitro differentiation.  Gate set against FMO control. 
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I then looked to see if Th1s maintained expression of CD40L in vivo following adoptive 
transfer into gemcitabine treated tumour bearing mice.  Expression of CD40L on 
adoptively transferred Th0s was also examined as a comparison.  AB1-HA tumour 
bearing mice were injected with 5x10
5
 in vitro differentiated HNT-Thy1.1 Th1s or Th0s 
and DLN and spleen were harvested 48 hours later.  The frequency of CD40L+ 
Thy1.1+ve CD4 cells was determined by flow cytometry (Figure 6-3).  This showed that 
although CD40L was expressed by a high proportion of Th1s before adoptive transfer, 
after two days in vivo less than 5% of cells recovered from the DLN or spleen still 
expressed CD40L and CD40L expression was now similar to that observed on Th0s, 
both in the DLN (p=0.11) and in the spleen (p=0.95).   
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Figure 6-3 Ex vivo expression of CD40L on adoptively transferred Th1s and Th0s 2 
days after adoptive transfer.   
Mice bearing AB1-HA tumours which had been treated with a single dose of 240ug/g 
gemcitabine on day 9 received adoptive transfer of 5x10
5
 HNT Th1s or Th0s on day 11.  
DLN and spleen were harvested 48 hours after adoptive transfer and recovered cells 
analysed by flow cytometry.  A Gating on CD4+Thy1.1+ cells and on CD40L+ (filled 
histogram) which are shown alongside FMO control (unfilled).  B Proportion of CD40L+ 
cells amongst Thy1.1+CD4+ cells before adoptive transfer, and when recovered from 
the DLN and spleen 2 days after transfer (n=3 per group) 
 
Thy1.1+ve CD4s
Th1Th0 Th1Th0 Th1Th0
0.0
2.5
5.0
NS
20
40
60
%
 
CD
40
L+
v
e
DLN Spleen
A
B
Day 2 post transfer
Pretransfer
 169 
 
6.2.3 In vitro differentiated Th1s and Th2s lose IL-2 expression by day 3 of 
culture 
 
Expression of IL-2 by in vitro differentiated CD4 cells was examined by intracellular 
flow cytometry on cells restimulated with PMA and ionomycin on day 0, 1, 2, 3 and 5 
of culture.  Comparison of IL-2 expression with expression of IFNg, IL-4, IL-17 and foxp3 
on each respective subtype is shown in Figure 6-4.  IL-2 expression is high 24 hours 
after activation in all subtypes, but in Th1s and Th2s it has disappeared by day 3.  
Interestingly this is at the point that expression of IFNg and IL-4 appears, such that 
there is only a short window where IFNg/IL-4 and IL-2 are both expressed.  In Th17s, 
Tregs and Th0s, however, IL-2 expression is maintained throughout in vitro culture, 
indicating that the loss of IL-2 production by in vitro cultured Th1s and Th2s is specific 
to the Th1 and Th2 differentiation pathways. 
 
 
 
 
Figure 6-4 Kinetics of IL-2 expression on in vitro differentiated CD4 subsets.   
In vitro differentiated cells were restimulated with PMA and ionomycin and analysed 
by intracellular flow cytometry at each indicated timepoint.  Expression of IL-2 
alongside IFNg for Th1s and Th0s, IL-4 for Th2s, IL-17 for Th17s and foxp3 for Tregs is 
shown.  Data is representative of two independent experiments for Th1, Th2 and Th0 
subsets and 1 experiment for Th17s and Tregs.  Missing data is due to failed 
restimulation at one of the timepoints in one experiment. 
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I next examined whether the lack of IL-2 expression on in vitro differentiated Th1s 
persisted in vivo after adoptive transfer into tumour bearing mice.  IL-2 and IFNg 
expression on Thy1.1+ HNT Th1 cells recovered from AB1-HA tumour bearing mice, 
was determined by ex-vivo restimulation with PMA and ionomycin and intracellular 
flow cytometry (Figure 6-5A).  After 7 days in vivo, around 40% of Th1 cells recovered 
from the spleen and tumour had regained the capacity to produce IL-2 but this was 
seen in only 10% of Th1 cells recovered from the DLN (Figure 6-5B).   
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Figure 6-5 Ex vivo IL-2 and IFNg expression on recovered Th1s 7 days after 
adoptive transfer.  
 AB1HA tumour bearing mice received adoptive transfer of 1x10
6
 HNT Th1s.  DLN, 
spleen and tumour were harvested 7 days later and cells restimulated ex vivo with 
PMA and ionomycin in the presence of brefeldin A and analysed by intracellular flow 
cytometry.  A  Gating on CD4+thy1.1+ cells. IFNg and IL-2 gates were set against FMO 
and unstimulated controls.  B  Expression of IFNg and IL-2 on recovered CD4+thy1.1+ve 
cells.  (N=12 and shows pooled data of recovered thy1.1+CD4 cells from all treatment 
groups in experiment described in Figure 7-3.) 
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6.2.4 IFNg and IL-2 expression by in vitro differentiated Th1s resembles 
that seen in endogenous CD4s recovered from tumours but not the 
DLN 
 
Although differentiating CD4 cells in vitro may not replicate what happens when CD4 
cells differentiate in vivo, I was interested to see if there was any suggestion that CD4 
cells primed in vivo also go through stages of differentiation involving differential 
expression of IL-2 and IFNg, similar to that seen in vitro.  The in vitro data suggested 
that IL-2 is expressed in the early phases of Th1 differentiation and IFNg appears later, 
as IL-2 production is lost.  I therefore re-examined the data obtained from the 
experiment described in Figure 5-7, where tumour bearing mice had received adoptive 
transfer of CD4 subsets, but gated on endogenous (thy1.1-ve) CD4 cells.  IFNg and IL-2 
expression on endogenous CD4 cells recovered from the DLN (the site of priming), the 
spleen and the tumour (the effector site) was analysed (Figure 6-6).  This showed that 
CD4 cells in the DLN and spleen predominately produce IL-2, whereas CD4 cells in the 
effector site predominately produce IFNg.  The proportion of IFNg+IL2+ double positive 
cells was lowest in the DLN but higher in the spleen and tumour.   
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Figure 6-6 IL-2 and IFNg expression on endogenous CD4+ cells in mice bearing 
AB1HA tumours.   
Mice bearing AB1HA tumours received adoptive transfer of 1x10
6
 thy1.1+HNT in vitro 
differentiated CD4 cells and 1x10
6
 CL4 lymphocytes on day 9 after tumour inoculation 
and were culled on day 16, as described in Figure 5-7.  Cells recovered from DLN, 
spleen and tumour were restimulated with PMA and ionomycin in the presence of 
brefeldin A and analysed by intracellular flow cytometry.  IFNg and IL-2 expression on 
endogenous CD4+ (thy1.1-ve) cells was determined as shown. N=18. 
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lack of help provided by in vitro differentiated CD4 cells to CD8s could be due to an 
inability to produce IL-2 in the DLN during CD8 priming. 
 
 
6.2.5 Ǯǯ1s in IL-7 maintains IL-2 and IFNg 
expression 
 
Since IL-2 expression was progressively lost during the activation phase of Th1 cultures, 
I tried to see if I could preserve the IL- ?ƉƌŽĚƵĐŝŶŐƉŚĞŶŽƚǇƉĞŽĨ ?ĞĂƌůǇ ?dŚ ?ƐďǇ
removing the activation stimulus after 24 hours.  IL-2 and IL-7 are cytokines which have 
been used for in vitro expansion of tumour specific T cells and IL-7 produced cells with 
greater anti-tumour activity than IL-2 (Caserta, Alessi et al. 2010).   I therefore tried 
expanding Th1 cells which had been activated for only 24 hours in either IL-2 or IL-7 for 
the remaining 4 days of culture in the presence of IL-12 but without anti CD3/CD28.  
For comparison, Th0s were treated in an equivalent way, without the addition of IL-12 
to media (Figure 6-7A). 
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Figure 6-7 The effects of expanding 1 day activated Th1s and Th0s in IL-2 and IL-7.  
A  HNT CD4 cells were activated with anti-CD3 and anti-CD28 for 24 hours under Th1 
and Th0 polarising conditions.  Cells were then washed and plated in fresh media 
containing IL-12 and anti-IL-4 for Th1s, or anti-IL4 and anti-IFNg for Th0s, in the 
absence of activation for a further 4 days.  IL-2 at 50U/ml or IL-7 at 25ng/ml was added 
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separately to individual wells after plating.  Samples of cells were restimulated and 
analysed at day 1 and day 5 for expression of IFNg and IL-2 and unstimulated cells 
were analysed for expression of CD62L, CD40L and PD-1.  Data shown is representative 
of two independent experiments.  B  Cells were treated as A, but after 24 hours 
activation Th1 cells were plated in media containing IL-12 and anti-IL4 only and 
analysed on day 5.  C  Cells were activated for 48 hours and 72 hours before being 
treated as described in A and analysed at day 5.  B and C were performed once. 
 
 
The phenotypes of Th1s and Th0s were similar at 24 hours, with high levels of IL-2 but 
little IFNg production.  Th1 cells expanded for a further 4 days in IL-2 produced little IL-
2 but contained a high proportion of IFNg secreting cells, similar to that seen 
previously when Th1 cells were activated for the full 3 days.  In contrast, Th1 cells 
which were cultured in IL-7 following initial activation displayed slightly lower levels of 
IFNg expression, but produced large amounts of IL-2, with around 20% of cells positive 
for both IFNg and IL-2 (Figure 6-7A).  The amount of proliferation was reduced in the 
IL-7 cultured cells, which expanded between 4.5 - 7 fold between day 1 and day 5, 
compared to a 16 fold expansion of the IL-2 cultured cells.  This experiment was 
repeated comparing the effects of IL- ?ŽŶ ?ĞĂƌůǇ ?dŚ ?ƐƚŽƚŚĞĞĨĨĞĐƚƐŽĨƐŝŵƉůǇƌĞƐƚŝŶŐ
the cells in media containing IL-12 and anti-IL4 but without any other cytokines (Figure 
6-7B).  This showed that IL- ?ĂŶĚ/&EŐƉƌŽĚƵĐƚŝŽŶǁĂƐƐŝŵŝůĂƌŝŶĐĞůůƐ ?ƌĞƐƚĞĚ ?ĨŽƌ ?days 
to cells cultured in IL-7, however these cultures produced only a 2 fold expansion of 
ĐĞůůƐ ?dŚƵƐŝƚĂƉƉĞĂƌĞĚƚŚĂƚĐƵůƚƵƌŝŶŐ ?ĞĂƌůǇ ?dŚ ?ĐĞůůƐŝŶ/>-7 had the dual effect of 
preserving IL-2 production whilst expanding cells to sufficient numbers for adoptive 
transfer into mice.  
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/ŶĐŽŶƚƌĂƐƚ ? ?ĞĂƌůǇ ?dŚ ?ƐŵĂŝŶƚĂŝŶĞĚƐŝŵŝůĂƌůĞǀĞůƐŽĨ/>-2 production after expansion for 
4 days in either IL-2 or IL-7 (Figure 6-7A).  Again this indicated that the loss of IL-2 
production by Th1s in IL-2 driven cultures was specific to the Th1 differentiation 
pathway.   Th0s cultured in IL-2 expanded 21 fold between days 1 and 5, whereas 
those cells cultured in IL-7 expanded 4.1 fold.   
Removing the activating stimuli from Th1s after 48 and 72 hours and then culturing 
them in IL-2 or IL-7, induced cells that produced little IL-2 at the end of 5 days culture 
(Figure 6-7C) irrespective of whether IL-2 or IL-7 was added to the culture, indicating 
ƚŚĂƚƚŚĞĂďŝůŝƚǇƚŽƉƌĞƐĞƌǀĞƚŚĞ ?ĞĂƌůǇ ?/>-2 producing phenotype of Th1s does not 
persist once cells have been activated for longer than 24 hours. 
Examination of other phenotypic markers showed that expression of CD62L, CD40L 
and PD-1 was similar between IL-7 and IL- ?ĞǆƉĂŶĚĞĚ ?ĞĂƌůǇ ?dŚ ?ƐĂŶĚdŚ ?Ɛ ?ǁŝƚŚǀĞƌǇ
high levels of CD62L and low levels of CD40L and PD-1 (Figure 6-7A).   Thus Th1 cells 
activated for only 24 hours and then cultured with IL-7 and IL-12 display a phenotype 
which suggests that they may have the potential to traffic to lymph nodes in vivo and 
produce both IL-2 and IFNg.  Expression of IFNg, IL-2, CD40L and CD62L on Th1s 
activated for 24 and 72 hours and on Th1s activated for 24 hours and expanded in IL-7, 
is summarised in Table 6.1.  
Since expanding 1 day activated Th1s in IL-7 preserved the high levels of IL-2 
production seen ŝŶƚŚĞĞĂƌůǇƐƚĂŐĞƐŽĨdŚ ?ĚŝĨĨĞƌĞŶƚŝĂƚŝŽŶ ?/ůĂďĞůůĞĚƚŚĞƐĞĐĞůůƐ ?ĞĂƌůǇ
dŚ ?Ɛ ? ?ǁŚĞƌĞĂƐĐĞůůƐĂĐƚŝǀĂƚĞĚĨŽƌ ?ĚĂǇƐĂŶĚĞǆƉĂŶĚĞĚŝŶ/>- ?ĂƌĞƌĞĨĞƌƌĞĚƚŽĂƐ ?ůĂƚĞ
dŚ ?Ɛ ? ? 
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 Naive 
CD4 cells 
After 24 hours in 
vitro activation 
Activated 24 hours 
IL-7 expanded day 1-5 
 ?Early dŚ ?Ɛ ?
Activated 72 hours 
IL-2 expanded day 3-5 
 ?Late dŚ ?Ɛ ?
IFNg - - ++ +++ 
IL-2 + +++ +++ - 
CD40L - +++ + ++ 
CD62L +++ - +++ + 
 
Table 6-1 Summary of characteristics of Th1 cells activated for 24 hours and 
expanded in IL-7or activated for 72 hours and expanded in IL-2. 
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6.2.6 1 day activated, IL- ?Ǯǯ ?
produce IL-2  
 
I next examined the behaviour of 1 day activated, IL- ?ĞǆƉĂŶĚĞĚ ?ĞĂƌůǇ ?dŚ ?Ɛ in vivo, to 
determine if the adjustment in polarising conditions had altered their behaviour in vivo 
following adoptive transfer. 
Mice bearing 14 day old AB1-HA tumours were treated with a single dose of 240ug/g 
gemcitabine and 48 hours later received adoptive transfer of 5x10
5
 1 day activated, IL-
 ?ĞǆƉĂŶĚĞĚ ?ĞĂƌůǇ ?dŚ ?Ɛ ? ?ĚĂǇĂĐƚŝǀĂƚĞĚIL-2 expanded  ?ůĂƚĞ ?dŚ ?ƐŽƌdŚ ?Ɛ ? An equal 
number of thy1.1+ CL4 CD8 T cells were transferred at the same time.  Larger tumours 
were used so that at the time of harvest tumours would still be of sufficient size to 
yield adequate numbers of cells for analysis.   DLN, spleen and tumour were harvested 
2 days and 7 days and cells analysed by flow cytometry (Figure 6-8).   
Analysis of recovered thy1.1+ve CD4 cells revealed ƚŚĂƚ ?ĞĂƌůǇ ?dŚ ?ƐĂŶĚ ?ůĂƚĞ ?dŚ ?ĂƌĞ
found in equal proportions in the spleen at day 2 following adoptive transfer.  
,ŽǁĞǀĞƌ ?ĐŽŶƐŝƐƚĞŶƚǁŝƚŚƚŚĞŝƌŚŝŐŚ ? ?>ĞǆƉƌĞƐƐŝŽŶ ? ?ĞĂƌůǇ ?dŚ ?ƐĂĐĐƵŵƵůĂƚĞŝŶ
greater quantities in the DLN at day 2 (p<0.05) (Figure 6-8A), ƐƵŐŐĞƐƚŝŶŐƚŚĂƚ ?ĞĂƌůǇ ?
Th1s may be quantitatively more able to provide help to HA specific CD8s in the DLN 
ƚŚĂŶ ?ůĂƚĞ ?dŚ ?Ɛ.  Th0s did not survive well after adoptive transfer and few cells were 
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Figure 6-8 dƌĂĐŬŝŶŐŽĨ ?ůĂƚĞ ?dŚ ?Ɛ ? ?ĞĂƌůǇ ?dŚ ?ƐĂŶĚdŚ ?ƐĨŽůůŽǁŝŶŐĂĚŽƉƚŝǀĞ
transfer into tumour bearing mice treated with gemcitabine.   
Mice bearing 14 day old AB1-HA tumours were treated with 240ug/g gemcitabine.  48 
hours later mice received transfer of 5x10
5
 ƚŚǇ ? ? ?A?,Ed ?ůĂƚĞ ?dŚ ?Ɛ ? ?ĞĂƌůǇ ?dŚ ?ƐŽƌdŚ ?Ɛ
with 5x10
5
 thy1.1+CL4 CD8 T cells.  At 2 and 7 days after adoptive transfer mice were 
culled and cells recovered from DLN, spleen and tumour were analysed by flow 
cytometry (3 mice per group).  Cells were gated on CD4+Thy1.1+ cells as per figure 4.5.  
Cell counts were determined as described in materials and methods.  A  Recovery of 
DLN Thy1.1 Cd4s
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Thy1.1+CD4+ cells as a percentage of total CD4 cells.  B  IFNg and IL-2 expression on 
Thy1.1+CD4+ cells recovered 2 days after adoptive transfer and from the DLN and 
spleen and restimulated with PMA and ionomycin and analysed by intracellular flow 
cytometry.  C  Frequency of Thy1.1+CD4+ cells in tumour at day 7 expressed as 
percentage of total CD4 cells and also as percentage of total cells, gated from forward 
and side scatter plots as illustrated in figure 5-7.  Experiment performed once, 3 mice 
per group. * denotes significance at p<0.05. 
 
The phenotype of the cells was examined 2 days after adoptive transfer, cells were 
restimulated with PMA and ionomycin and expression of IFNg and IL-2 was 
characterised by flow cytometry (Figure 6-8B).  This showed that after 2 days in vivo, 
the adoptively transferred cells retained the phenotype they possessed at the end of in 
vitro culture.  A high proportion of  ?ĚĂǇĂĐƚŝǀĂƚĞĚ ? ?ůĂƚĞ ?dŚ ?ƐĞǆƉƌĞƐƐĞĚ IFNg but few 
produced IL-2; Th0s made IL- ?ďƵƚĚŝĚŶŽƚĞǆƉƌĞƐƐ/&EŐĂŶĚ ?ĚĂǇĂĐƚŝǀĂƚĞĚ ? ?ĞĂƌůǇ ?
Th1s expressed high levels of both IFNg and IL-2. 
Tumour infiltrating thy1.1 CD4s were not detected 2 days after adoptive transfer, 
although tumour sizes were small (10-20mm
2
) at this point.  However by 7 days after 
adoptive transfer, tumour infiltrating thy1.1+ve CD4s could be detected.  This showed 
ƚŚĂƚŽŶůǇ ?ĚĂǇĂĐƚŝǀĂƚĞĚ ? ?ůĂƚĞ ?dŚ ?ƐŝŶĨŝůƚƌĂƚĞĚƚƵŵŽ ƌƐ in any great quantity at this 
time point, where they comprised 1 -6 % of the total CD4 population (Figure 6-8C), 
ĂůƚŚŽƵŐŚĚŝĚŶŽƚƌĞĂĐŚƐŝŐŶŝĨŝĐĂŶĐĞĐŽŵƉĂƌĞĚƚŽ ?ĞĂƌůǇ ?dŚ ?Ɛ ?ƉA? ? ? ? ? ?. 
Thus  ?ĞĂƌůǇ ? (IL-7 expanded) Th1s preferentially accumulate in the DLN, where they are 
able to produce IL-2, but they do not infiltrate the tumour ? ?LĂƚĞ ?dŚ ?Ɛhome to the 
ƚŚĞƚƵŵŽƵƌĂŶĚĂƌĞĂďůĞƚŽƉƌŽĚƵĐĞ/&EŐ ? ?>ĂƚĞ ?dŚ ?Ɛwhich do make it into the DLN 
are unable to produce IL-2.   
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6.2.7 The post gemcitabine environment does not favour survival of in vitro 
differentiated Th1s beyond day 2 after adoptive transfer 
 
hŶĞǆƉĞĐƚĞĚůǇ ?ďĞƚǁĞĞŶĚĂǇ ?ĂŶĚ ?ŶƵŵďĞƌƐŽĨďŽƚŚ ?ůĂƚĞ ?ĂŶĚ ?ĞĂƌůǇ ?dŚ ?ƐĚĞĐůŝŶĞĚŝŶ
ƚŚĞƐƉůĞĞŶĂŶĚ ?ĞĂƌůǇ ?dŚ ?ƐĂůƐŽ declined in the DLN (Figure 6-8A).  This is in contrast to 
results presented in section 4.2.7, where a 3 fold expansion of Th1s in untreated 
tumour bearing mice was observed during the same period.  Since gemcitabine was 
not directly killing the adoptively transferred cells, the differences observed between 
untreated and gemcitabine treated mice indicate that the post gemcitabine 
environment did not favour the expansion of the transferred HA specific cells. 
In chapter 5 it was demonstrated that cells adoptively transferred 24 hours or more 
after gemcitabine were not killed by the gemcitabine.   Failure of the adoptively 
transferred cells to expand in the post gemcitabine setting suggested that these cells 
did not undergo either antigen driven proliferation or homeostatic proliferation, as 
seen in the endogenous lymphocyte population following gemcitabine (see Figure 
3-1A).   This could have been due to reduced ability to respond to cytokines such as IL-
7 or IL-2, or reduced availability of these cytokines.  I therefore compared expression 
of CD25 (IL-2 receptor) and CD127 (IL- ?ƌĞĐĞƉƚŽƌ ?ŽŶ ?ĞĂƌůǇ ?dŚ ?Ɛ ? ?ůĂƚĞ ?dŚ ?ƐĂŶĚŶĂŝǀĞ 
(CD62L+) CD4 cells (Figure 6-9).   
Naive cells express high levels of the IL-7 receptor, but undetectable levels of the IL-2 
ƌĞĐĞƉƚŽƌ ? ?>ĂƚĞ ?dŚ ?ƐĞǆƉƌĞƐƐĞĚǀĞƌǇŚŝŐŚůĞǀĞůƐŽĨƚŚĞ/>-2 receptor but lower levels of 
IL- ?ƌĞĐĞƉƚŽƌ ? ?ĂƌůǇ ?dŚ ?ƐĞǆƉƌĞƐƐĞĚǀĞƌǇůŽǁůĞǀĞůƐŽĨƚŚĞ/>-7 receptor and although 
CD25 was deƚĞĐƚĂďůĞŝŶƚŚĞŵĂũŽƌŝƚǇŽĨ ?ĞĂƌůǇ ?dŚ ?Ɛ ?ƚŚŝƐǁĂƐŵŽƐƚůǇĂƚĂŶŝŶƚĞƌŵĞĚŝĂƚĞ
rather than high level of expression.  Thus during a period of homeostatic, IL-7 driven, 
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proliferation, in vitro differentiated cells may be at a disadvantage to naive 
endogenous cells due to lower levels of expression of the IL-7 receptor, which may 
explain the reduced expansion and survival observed. 
 
 
 
Figure 6-9  ? ?ĂŶĚ ? ? ?ĞǆƉƌĞƐƐŝŽŶŽŶŶĂŝǀĞ ?ĐĞůůƐ ? ?ĞĂƌůǇ ?dŚ ?ƐĂŶĚ ?ůĂƚĞ ?
Th1s.   
Naive CD4+CD62L+ cells were isolated by magnetic column separation of HNT 
ƐƉůĞŶŽĐǇƚĞƐ ? ?ĂƌůǇ ?ĂŶĚ ?ůĂƚĞ ?dŚ ?ƐǁĞƌĞŐĞŶĞƌĂƚĞĚŽǀĞƌ ?ĚĂǇƐŝŶǀŝƚƌŽ ?ĂƐĚĞƐĐƌŝďĞĚŝŶ
Figure 6-7. CD25 and CD127 expression was determined by flow cytometry.  Plots 
show CD25 and CD127 expression (filled histograms) and FMO control (unfilled).  
Performed once. 
 
  
 ?Ɛ ? ?ĞĂƌůǇ ?dŚ ?ƐĂŶĚ ?ůĂƚĞ ?dŚ ?Ɛ
CD25
CD127
Naive  ?>ĂƚĞ ?dŚ ?Ɛ ?ĂƌůǇ ?dŚ ?Ɛ
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6.2.8  ?Ǯǯ ?
transferred after gemcitabine 
 
I hypothesised that the inability of in vitro differentiated Th1s to produce IL-2 in the 
DLN could explain the lack of help provided to CD8s and the lack of efficacy of these 
cells against established tumours.  I therefore compared the anti-tumour activity of 3 
day activated, IL- ?ĞǆƉĂŶĚĞĚdŚ ?Ɛ ? ?ůĂƚĞ ?dŚ ?Ɛ ? ?ǁŚŝĐŚĚŽŶŽƚŵĂŬĞ/>-2, with 1 day 
activated, IL- ?ĞǆƉĂŶĚĞĚdŚ ?Ɛ ? ?ĞĂƌůǇ ?dŚ ?Ɛ ? ?ǁŚŝĐŚŵĂŬĞ/>-2, as well as with Th0s 
(make IL-2).  Additionally, since it was possible that optimal anti-tumour responses 
ŵŝŐŚƚƌĞƋƵŝƌĞďŽƚŚ ?ĞĂƌůǇ ?/>-2 producing Th1s in the DLN ĂŶĚ ?ůĂƚĞ ?/&EŐƉƌŽducing 
Th1s at the effector site, I also looked at the effects of transferring  ?ůĂƚĞ ?dŚ ?ƐŵŝǆĞĚĂƚ
Ă ? P ?ƌĂƚŝŽǁŝƚŚĞŝƚŚĞƌ ?ĞĂƌůǇ ?dŚ ?ƐŽƌdŚ ?Ɛ ?As before, all groups additionally received 
adoptive transfer of HA specific CD8s cells.  
Mice bearing 9 day old AB1-HA tumours were treated with a single dose of 
gemcitabine followed 48 hours later by adoptive transfer of 5x10
5
 CL4 CD8 T cells in 
conjunction with 5x10
5
 in vitro differentiated thy1.1 HNT CD4s.  The CD4s consisted of 
ĞŝƚŚĞƌ ?ůĂƚĞ ?dŚ ?Ɛ ? ?ĞĂƌůǇ ?dŚ ?Ɛ ?dŚ ?Ɛ ? ?ůĂƚĞ ?dŚ ?ƐƉůƵƐ ĞĂƌůǇ ?dŚ ?Ɛ ?Žƌ ?ůĂƚĞ ?dŚ ?ƐƉůƵƐ
Th0s  
There was no significant difference in tumour growth or survival between any of the 
groups (figure 6-10).  No long term survivors were seen. 
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Figure 6-10 Effects of  ?ĞĂƌůǇ ?ĂŶĚ ?ůĂƚĞ ?dŚ ?ƐŽŶĂďŝůŝƚǇŽĨŵŝĐĞƚŽƌĞũĞĐƚƚƵŵŽƵƌ
following gemcitabine 
Mice bearing 9 day old AB1-HA tumours were treated with 240ug/g gemcitabine i.p. 
and 48 hours later received intravenous injection of 5x10
5
 CL4 CD8 T cells alone or of 
5x10
5
 CL4 CD8 T cells with 5x10
5
 in vitro differentiated HNT CD4 cells - consisting of 
 ?ůĂƚĞ ?dŚ ?Ɛ ? ?ĞĂƌůǇ ?dŚ ?Ɛ ?dŚ ?Ɛ ? ?ůĂƚĞ ?dŚ ?ƐŵŝǆĞĚ ? P ǁŝƚŚdŚ ƐŽƌ ?ůĂƚĞ ?dŚ ?ƐŵŝǆĞĚ ? P ?
 ?ĞĂƌůǇ ?dŚ ?Ɛ ? ?ŵŝĐĞƉĞƌŐƌŽƵƉ ?ǆƉĞƌŝŵĞŶƚƉĞƌĨŽƌŵĞĚŽŶĐĞ ? 
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The lack of effect of any of the CD4 subsets on tumour growth is reflected in a lack of 
positive effects of any of the CD4 combinations on the recovery of HA specific CD8s.  
Recovery of thy1.1+ CD8s from the DLN and spleen was not altered by co-transfer of 
any of the CD4 subtypes  (Figure 6-11A).  Thy1.1 CD8 cells were detectable in the 
tumour at day 7, however again the presence of any of the different types or 
combinations of CD4 cell did not increase HA specific CD8 tumour infiltration 
compared to mice that received CL4 CD8 cells alone (Figure 6-11B).    
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Figure 6-11 Tracking of CL4 Thy1.1+CD8s injected alongside HNT CD4 cells.   
Mice were treated as described in Figure 6-10, receiving 5x10
5 
CL4 thy1.1+CD8s along 
with 5x10
5
 ŝŶǀŝƚƌŽĚŝĨĨĞƌĞŶƚŝĂƚĞĚ,Ed ?ůĂƚĞ ?dŚ ?Ɛ ? ?ĞĂƌůǇ ?dŚ ?Ɛ ?dŚ ?Ɛ ?ŽƌŶŽ,Ed ?Ɛ ?
In addition, two further groups of mice received 5x10
5 
CL4 Thy1.1+CD8s alongside 
2.5x10
5
  ?ůĂƚĞ ?dŚ ?ƐŵŝǆĞĚǁŝƚŚĞŝƚŚĞƌ ? ? ?ǆ ? ?5  ?ĞĂƌůǇ ?dŚ ?ƐŽƌǁŝƚŚdŚ ?Ɛ ?,ĂƌǀĞƐƚƐŽŶ
mixed groups were only performed at day 7.  A  Recovery of thy1.1+CD8+ cells from 
DLN and spleen expressed as percentage of total CD8s.  B  Recovery of thy1.1+CD8+ 
DLN Thy1.1 CD8s
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cells from the tumour 7 days after adoptive transfer, expressed both as a percentage 
of total CD8s and of total cells.   
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6.3 Discussion 
 
In this chapter I examined the expression of two important mediators of CD4 T cell 
help on in vitro differentiated CD4 subsets - CD40L and IL-2.  I found that on 5 day in 
vitro differentiated cells, CD40L was only expressed at high levels on Th1s.  This could 
potentially have explained the anti-tumour activity of Th1s seen in the prophylactic 
situation and the absence of activity of other subsets.  When I examined the kinetics of 
CD40L expression during the 5 day period of activation and expansion of CD4 subsets I 
found that Th1s, Th2s andTh0s initially express high levels of CD40L whereas Th17s and 
Tregs express lower amounts, suggesting that expression of CD40L following initial 
activation is not consistent between different CD4 differentiation pathways.  
Furthermore only Th1s maintained high levels of CD40L expression until day 5 of 
culture.  Lee et al compared CD40L on CD4s activated in Th1 (IL-12) and Th2 (IL-4) 
cultures and similarly found that both conditions induced high initial CD40L expression 
but it was only in the presence of Il-12 that expression was sustained for extended 
periods (Lee, Haynes et al. 2002).   
Thus, expression of CD40L is dynamic during in vitro culture of CD4 cells and depends 
on the polarising cytokines added to cultures.  As a consequence the ability to provide 
help through CD40 activation in vivo could potentially differ between subsets.   
However when I examined cells recovered from mice two days after adoptive transfer, 
CD40L was downregulated on Th1s and Th0s in cells recovered from the DLN and 
spleen.  Together these results suggested that CD40L expression is not maintained 
after initial activation unless IL-12 is present and that expression of CD40L during in 
vitro culture is not necessarily retained in vivo after adoptive transfer.  It is unclear 
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from these results whether in vitro differentiated CD4 subsets can re-express CD40L 
after meeting antigen in vivo and what role that local concentrations of cytokines such 
as IL-12 in vivo might have on CD40L expression on adoptively transferred CD4 cells.  
Surprisingly, in vitro differentiated Th1s and Th2s do not make IL-2 at the end of the 
five day culture period, whereas the other subsets produced substantial quantities.  IL-
2 production was lost in Th1s and Th2s after day 2 of activation, around the time that 
IFNg and IL-4 started to be produced.  The ability of IL-12 and IL-4 to suppress IL-2 
production on in vitro activated T cells has been described (Dickensheets, Freeman et 
al. 2000; Villarino, Tato et al. 2007) and loss of IL-2 occurred by 48 hours (Villarino, 
Stumhofer et al. 2006).   Interactions between Tbet and the RelA NFkB transcription 
factor link the Th1 differentiation pathway and loss of IL-2 production (Hwang, Hong et 
al. 2005).  The fact that Th0 cells, which were treated identically but did not receive IL-
12 or IL-4, sustained IL-2 production suggests that loss of IL-2 is a consequence of 
Th1/Th2 differentiation rather than simply a result of direct negative feedback from IL-
2 itself.  This is in contrast to the findings of Villarino et al who showed that IL-2 did 
negatively regulate IL-2 production (Villarino, Tato et al. 2007), although this could in 
part have been an indirect, IL-4 mediated effect as IL-2 itself can promote Th2 
differentiation and hence IL-4 production (Zhu, Cote-Sierra et al. 2003).   
Th1 cells recovered ex vivo 2 days after adoptive transfer did not produce IL-2 
following restimulation.  However this capacity had been regained by day 7 in a 
proportion of Th1s recovered from the spleen and tumour.  Similarly, Villarino 
demonstrated that loss of IL-2 production on helper CD4s was not permanent as cells 
had regained the capacity to make IL-2 after 15 days in vivo (Villarino, Tato et al. 2007).  
However, in this model Th1 cells in the DLN still made little IL-2 7 days after transfer, 
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suggesting that their helper function may still have been impaired in the priming 
phase.   
The importance of IL-2 produced by CD4 T cells in promoting CD8 responses is well 
recognised.  CD4 T cell derived IL-2 was found to be essential for supporting the 
expansion and survival of cognate CD8s (Antony, Piccirillo et al. 2005; Wilson and 
Livingstone 2008).  CD8s which have been helped during priming by the provision of IL-
 ?ĂƌĞĂďůĞƚŽƉƌŽůŝĨĞƌĂƚĞŽŶƐĞĐŽŶĚĂƌǇĐŽŶƚĂĐƚǁŝƚŚĂŶƚŝŐĞŶǁŚĞƌĞĂƐ ?ŚĞůƉůĞƐƐ ? ?Ɛ
undergo activation induced cell death (Janssen, Droin et al. 2005; Williams, Tyznik et 
al. 2006).   However, a recent report suggests that autocrine IL-2 production by CD8 
cells themselves determines CD8 memory formation, rather than paracrine production 
of IL-2 by helper CD4 cells (Feau, Arens et al. 2011).  In tumour bearing mice CD4s were 
also found to provide help at the effector site, where secretion of IL-2 by CD4s induced 
increased proliferation of intratumoural CD8s, which demonstrated enhanced cytolytic 
capacity (Bos and Sherman 2010). 
Studies which have generated CD4 subsets in vitro for use against tumours have often 
not reported IL-2 expression on the differentiated cells (Nishimura, Iwakabe et al. 
1999; Martin-Orozco, Muranski et al. 2009).  My results suggest that the ability of in 
vitro differentiated CD4 cells to produce IL-2 is highly dependent on the culture 
conditions employed, including the polarising cytokines, duration of activation stimulus 
and the addition of exogenous IL-2.   In accordance with my findings, IL-2 production 
by cells stimulated with anti CD3 and anti CD28 was reduced when cells were polarised 
to Th1s (Dickensheets, Freeman et al. 2000).  Additionally, studies that used peptide 
pulsed APCs to activate T cells report variability in IL-2 production by in vitro 
differentiated Th1s:  Muranski found that peptide-activated tumour antigen specific 
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Th1s produced substantially less IL-2 than CD4s polarised to a Th17 phenotype 
(Muranski, Boni et al. 2008).  Hegazy et al found that 4 days of Th1 culture with 
peptide activation produced over 60% IFNg +ve cells but only around 10% IL-2 +ve cells 
(Hegazy and Klein 2008).  However, Huang et al found IL-2 levels in the supernatant of 
peptide activated Th1s were only slightly lower than the levels of IFNg (Huang, Hao et 
al. 2007).  Rogers et al found that IL-2 was produced by CD4 T cells stimulated with low 
concentrations of peptide but was reduced when cells were stimulated with high 
concentrations of peptide, which may explain how both the nature and the duration of 
the activating stimuli could influence the ability of in vitro differentiated CD4s to 
produce IL-2 (Rogers and Croft 1999).    
The lack of production of IL-2 on in vitro differentiated Th1s could have explained their 
inability to provide help to CD8s in mice bearing established tumours.  I therefore 
looked to see whether I could alter the culture conditions in order to retain IL-2 
production by the in vitro differentiated Th1s.   It was possible to generate Th1 cells 
that produced both IFNg and IL-2 if activation stimuli were removed after 24 hours and 
cells were cultured in IL-12 and IL-7 for the remainder of the 5 days.  This phenotype 
was retained when cells were recovered after 2 days in vivo.  Interestingly, culturing 
cells in IL-2 after 24 hours activation produced an IL-2 negative phenotype, similar to 
cells which had been activated for the full three days.   This demonstrated that either 
ongoing TCR stimulation or expansion with IL-2 promotes loss of IL-2 production by in 
ǀŝƚƌŽĚŝĨĨĞƌĞŶƚŝĂƚĞĚ ? ?ĚĂǇĂĐƚŝǀĂƚĞĚdŚ ?Ɛ ? ?ĚĂǇĂĐƚŝǀĂƚĞĚdŚ ?ƐǁŚŝĐŚǁĞƌĞ ?ƌĞƐƚĞĚ ?ŝŶ
media containing IL-12 without any other cytokines also retained the ability to produce 
IL-2, suggesting that it is the removal of TCR stimulation and IL-2 which is important, 
rather than the addition of IL-7 per se.  However cells cultured in IL-7 expanded 2-3 
fold more than rested cells, so the role of IL-7 in these cultures may have been to 
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promote expansion/survival of cells without switching off IL-2.  Villarino et al found 
that IL-7, but not IL-15, partially inhibited IL-2 expression on CD4 cells but that addition 
of neutralising anti-IL-2 antibody to cultures abrogated this effect, suggesting IL-7 can 
inhibit IL-2 production but only in the presence of IL-2 itself (Villarino, Tato et al. 2007).  
Thus, using a neutralising antibody to remove any IL-2 still being produced by the 
activated CD4 cells could be another way to promote IL-2 production by helper T cells 
expanded in IL-7. 
dŚĞƐĞ ?ĞĂƌůǇ ?ĂĐƚŝǀĂƚĞĚ ?/>-7 expanded Th1s also expressed very high levels of CD62L, 
suggesting that they may have the potential to traffic to lymph nodes and provide IL-2 
during CD8 priming.   This was indeed shown to be the case, as 2 days after adoptive 
transfer they were found in the DLN at a frequency 6 fold greater than 3 day activated 
 ?ůĂƚĞ ?dŚ ?Ɛ ?dŚƵƐ ?ĞǆƉĂŶĚŝŶŐ ?ĞĂƌůǇ ?dŚ ?ƐŝŶ/>-7 restores a CD62Lhi, lymph node 
homing phenotǇƉĞ ?ǁŚĞƌĞĂƐ ?ůĂƚĞ ?dŚ ?ƐĂĐĐƵŵƵůĂƚĞƐůŽǁůǇŝŶƚŚĞ>E ?dŚĞŝŵƉŽƌƚĂŶĐĞ
of CD4 help in the early stages of CD8 priming was demonstrated by Lai et al, who 
showed that IL-2 provided by CD4 cells in the first two hours during in vitro stimulation 
of CD8 T cells promoted accumulation of viable CD8s, but this declined if IL-2 delivery 
was delayed by more than 3 hours (Lai, Lin et al. 2009).  Therefore, following adoptive 
transfer, discordant initial trafficking to the DLN of the naive HA-specific CD8s and the 
ŚĞůƉĞƌ ?ĐĞůůƐĐŽƵůĚŚĂǀĞĞǆƉůĂŝŶĞĚƚŚĞŝŶĂďŝůŝƚǇŽĨ ?ůĂƚĞ ?dŚ ?ƐƚŽƉƌŽǀŝĚĞŚĞůƉĚƵƌŝŶŐ
CD8 priming.   
/ŶĐŽŶƚƌĂƐƚ ? ?ůĂƚĞ ?dŚ ?Ɛ may have a greater propensity to infiltrate tumours than  ?ĞĂƌůǇ ?
Th1s, although this did not reach significance.  I hypothesised therefore that  ?ĞĂƌůǇ ?
Th1s may have a greater potential to provide help at the site of priming anĚ ?ůĂƚĞ ?dŚ ?Ɛ
may have the greater potential for activity at the effector site.  Villarino et al proposed 
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a model whereby naive CD4 cells are first activated in the DLN, where they mainly 
produce IL-2, and then as they fully differentiate into Th1s they migrate to effector 
sites, by which time they become mainly IFNg secreting (Villarino, Stumhofer et al. 
2006).  In keeping with this, I also observed differential levels of IL-2 and IFNg secretion 
on endogenous CD4 cells recovered from the DLN and tumour.  Additionally, the 
differing kinetics of IL-2 and IFNg production observed during in vitro differentiation of 
Th1s would also be consistent with theory that Th1 polarised CD4 cells may have 
different functions at different stages of differentiation.  This raised the possibility that 
a complete Th1 CD4 helper response could require cells in multiple stages of 
ĚŝĨĨĞƌĞŶƚŝĂƚŝŽŶ ?ǁŝƚŚďŽƚŚ ?ĞĂƌůǇ ?/>- ?ƐĞĐƌĞƚŝŶŐĐĞůůƐŝŶƚŚĞ>EĂŶĚ ?ůĂƚĞ ?/&EŐƐĞĐƌĞƚŝŶŐ
cells at the effector site.   
Overall the results described so far in this chapter again emphasise that the phenotype 
and in vivo behaviour of in vitro differentiated CD4 cells are highly dependent on the 
culture conditions used to produce them.   Although 3 day activated, IL-2 expanded 
Th1s and 1 day activated, IL-7 expanded Th1s appeared similar in terms of IFNg 
production, their ability to produce IL-2 and to traffic to the DLN differed markedly.   
Having adjusted the culture conditions such that I could generate Th1 cells which were 
able to secrete IL-2 as well as IFNg and were able to traffic to the DLN, I examined the 
anti-tumour activity of these cells and their ability to help HA specific CD8s in tumour 
bearing mice treated with gemcitabine.  I also looked to see whether combining both 
 ?ĞĂƌůǇ ?ĂŶĚ ?ůĂƚĞ ?dŚ ?ƐǁŽƵůĚŝŵƉƌŽǀĞŽƵƚĐŽŵĞƐ ?However, the addition of either of the 
types of Th1 did not have any positive effects on tumour rejection or on expansion of 
HA specific CD8s. 
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The reasons for this lack of efficacy could be explained by the unexpected failure of 
either the adoptively transferred HNT CD4 cells or the CL4 CD8 cells to expand to any 
great degree between day 2 and day 7.  Indeed, there was a substantial decline in 
numbers of Th1s during this period.  This was despite the cells being injected during 
the period of lymphodepletion induced by gemcitabine and a presumed increased 
availability of tumour antigens due to gemcitabine induced tumour cell death.  
Furthermore, this is the opposite to that observed in chapter 4, where Th1 cells 
administered to untreated tumour bearing mice expanded in all compartments 
between days 2 and 7.   
The second hypothesis stated at the start of this thesis was that the post-gemcitabine 
environment would provide favourable conditions for adoptive transfer.  The results in 
this chapter disprove this hypothesis.  In actual fact the post gemcitabine environment 
appears to adversely affect the survival of adoptively transferred cells when compared 
to mice that did not receive gemcitabine.   This is not due to direct cytoxicity of 
gemcitabine on the transferred cells, but rather due to a failure of these cells to 
survive/expand between day 2 and 7 following transfer.    
Experiments described in chapter 3 show that gemcitabine causes lymphodepletion 
followed by restoration of cell numbers by day 4.  In addition I showed in chapter 3 
that gemcitabine induces an endogenous immune response which may mediate 
tumour regression 7-10 days later.  It therefore is likely that the adoptively transferred 
cells are in competition with proliferating endogenous immune cells following 
gemcitabine.   Limited availability of growth factors such as IL-7 or IL-2 in this 
environment could explain the lack of proliferation of the adoptively transferred cells 
in the post gemcitabine setting compared to the untreated setting.  Notably, 
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expression of the IL- ?ƌĞĐĞƉƚŽƌǁĂƐůŽǁĞƌŽŶ ?ĞĂƌůǇ ?dŚ ?ƐƚŚĂŶ ?ůĂƚĞ ?dŚ ?ƐĂŶĚ
expression of the IL-7 receptor by both types of Th1 was substantially lower than that 
seen on naive cells, potentially putting the adoptively transferred cells at a 
disadvantage in such a scenario. 
 
In summary the results described in this chapter demonstrate: 
 Expression of helper functions, CD40L and IL-2, is dynamic during in vitro 
differentiation and varies between different CD4 subsets.  IL-2 production by 
Th1s is highly dependent on the culture conditions, including duration of TCR 
activation and the addition of IL-2. 
 DǇŝŶŝƚŝĂůŝŶǀŝƚƌŽĚŝĨĨĞƌĞŶƚŝĂƚŝŽŶƉƌŽƚŽĐŽůƐŐĞŶĞƌĂƚĞ ?dŚ ? ?ĐĞůůƐǁŚŝĐŚĂƌĞĂďůĞƚŽ
infiltrate the tumour and produce IFNg but are less able to track to the DLN, 
where they are unable to make IL-2. 
 ǆƉĂŶĚŝŶŐ ?ĞĂƌůǇ ?dŚ ?ƐŝŶ/>-7 restores their ability to track to the DLN and 
produce IL-2, but this did not improve anti-tumour activity in the post 
gemcitabine setting 
 The post gemcitabine environment is not favourable for adoptive transfer of in 
vitro differentiated CD4 subsets.  This is not due to direct cytotoxicity but due 
to failure of cells to expand between day 2 and 7 after transfer. 
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7 Removal of endogenous 
suppressive CD4 cells prior to 
treatment with gemcitabine 
and adoptive cell transfer 
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7.1 Introduction 
 
Results in chapter 5 showed that adoptive transfer of HA specificTregs reduced tumour 
infiltration of HA specific CD8s, whereas transfer of effector CD4 subsets had no impact 
on CD8 recovery.  This suggested that the tumour environment was permitting the 
activity of suppressive CD4 cells but may be suppressing the activity of effector cells.   
Thus it was possible that overriding suppression from endogenous regulatory cells 
could have explained the lack of activity of adoptively transferred effector CD4 cells 
against established tumours, and hence the lack of help provided to cognate CD8s.  In 
chapter 3 I showed that gemcitabine causes lymphodepletion and a reduction in 
tumour infiltrating Tregs 7 days after treatment, however depletion of Tregs was not 
complete and was not seen in the DLN, the site of CD8 priming.  In addition, Tregs 
expand rapidly during the early phases of immune constitution following lymphopenia 
(Zhang, Chua et al. 2005; Rezvani, Mielke et al. 2006) meaning a more complete 
depletion of Tregs may be required to abrogate their suppressive effects.  Additionally 
results in chapter 6 suggested that in the post gemcitabine environment adoptively 
transferred cells did not expand between day 2 and day 7, unlike that seen in 
untreated mice.  One explanation for this could have been that the adoptively 
transferred cells were in competition with endogenous lymphocytes proliferating in 
response to gemcitabine induced lymphodepletion.    
For these reasons, I hypothesised that removing endogenous CD4 cells prior to 
gemcitabine treatment and adoptive transfer would improve the ability of the 
transferred cells to reject tumours.  Most adoptive transfer protocols in humans and 
mice have included a lymphodepleting preconditioning regimen, consisting of total 
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body irradiation, or highly myelosuppressive chemotherapy (Dudley, Wunderlich et al. 
2002; Muranski, Boni et al. 2008).   The intensity of the conditioning radiation 
correlated with efficacy of adoptive cell therapy (Wrzesinski, Paulos et al. 2011).   
However, these regimens deplete other immune cells as well as CD4 cells and are likely 
to have additional direct effects on the tumour, making it more difficult to determine 
the precise role CD4 cells play in outcomes.   I therefore developed a technique by 
which endogenous CD4 cells could be depleted in vivo using a CD4 depleting antibody 
without adversely affecting the cells adoptively transferred one day later.  This allowed 
me to examine whether the presence of endogenous, suppressive CD4 cells were 
limiting the effectiveness of adoptively transferred helper CD4s. 
Since Th1s were the only subtype to have demonstrated any anti-tumour activity in 
any setting, all experiments in this chapter were performed using in vitro 
differentiated Th1s.  As in previous experiments, these were co-transferred with HA 
specific naive CD8 T cells harvested from a naive CL4 mouse. 
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7.2 Results 
7.2.1 Titrating the dose of depleting anti-CD4 antibody 
 
In order to see whether suppressive endogenous CD4s were limiting the effectiveness 
of the adoptively transferred HA specific T cells against established, gemcitabine 
treated tumours, CD4 cells needed to be removed from mice prior to treatment.   In 
vivo depletions of CD4 cells can be performed by injection of anti-CD4 antibody 
(GK1.5), with doses reported between 100ug to 500ug (Nowak, Robinson et al. 2003; 
Teng, Swann et al. 2010).  One study showed that after high doses of GK1.5 CD4 cells 
remain depleted for over a week (Ghobrial, Boublik et al. 1989).  I initially tried 
removing CD4 cells with 200ug of GK1.5 but I found that, although this produced 100% 
CD4 depletion, it also depleted thy1.1+ve CD4 cells adoptively transferred 3 days later 
(data not shown), indicating excess antibody was still active in vivo.  Even when the 
dose of antibody was reduced to 25ug, thy1.1+ve CD4 cells transferred on day 3 after 
GK1.5 could not be recovered from spleens on day 6 after GK 1.5, even though the 
endogenous CD4 cells had started to regenerate by this time (data not shown).  This 
suggested that once a saturating dose of anti-CD4 antibody had been administered, 
the window for adoptive transfer, in which anti-CD4 was no longer active in vivo but 
before the endogenous CD4 cells had returned, was very narrow.  I therefore titrated 
down the dose of antibody further, aiming for a sub-saturating dose, such that the 
majority of endogenous CD4 cells would be depleted, but that there would be no 
excess antibody left to deplete any cells adoptively transferred 1 day later (Figure 
7-1A). 
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When the dose of GK1.5 was reduced to 4ug, over 90% of CD4 cells were depleted 
from the peripheral blood 24 hours later (Figure 7-1B).  At this dose, when harvests 
were performed four days after GK1.5, numbers of CD4 cells in the spleen were still 
depleted to around a third of baseline levels, whereas they were still 100% depleted 
with doses over 20ug (Figure 7-1C).  Although I did not perform counts on lymph nodes 
at this time point, at day +4 the CD4:CD8 ratio was similar in the LN and spleen, 
demonstrating that CD4s were being depleted to an equivalent extent in the spleen 
and lymph nodes (Figure 7-1D).  Importantly, recovery of thy1.1+ve CD4 cells 
adoptively transferred 1 day after GK1.5 was unaffected by doses up to 5ug, but these 
cells were completely depleted by doses over 10mg.  This indicated that the saturation 
point lay between 5 and 10ug, above which excess antibody was still present to 
deplete CD4 cells transferred 24 hours later (Figure 7-1E).  I therefore opted to use a 
dose of 4ug for experiments described in this chapter, where depletion of endogenous 
CD4 cells prior to adoptive transfer was required. 
 
 
Figure 7-1 Titrating the dose of anti-CD4 depleting antibody. 
A   Thy1.1- balb/c mice were injected intravenously with GK1.5 on day 0 and tail bleeds 
were performed 24 hours later to determine the depth of CD4 depletion.  Mice then 
received adoptive transfer of 1.5x10
6
 unmanipulated lymphocytes from a naive 
thy1.1+ve HNT mouse.  3 days after adoptive transfer spleens and lymph nodes were 
harvested and enumeration of recovered thy1.1+ve and thy1.1- CD4 cells was 
performed by flow cytometry.  B  shows the degree of CD4 depletion in peripheral 
blood 1 day after GK1.5.   C  shows numbers of splenic CD4 cells present at the time of 
harvest on day +4.  D  shows the CD4:CD8 ratio in endogenous (thy1.1-) cells in the 
DLN and spleen on day +4.  E  shows the number of adoptively transferred thy1.1+ve 
CD4 cells recovered from spleen at day +4 and the thy1.1+ CD4:CD8 ratio. 
 203 
 
 
 
 
0
1u
g
3u
g
4u
g
5u
g
7u
g
9u
g
10
ug
20
ug
50
ug
75
ug
10
0u
g
0
5.0×105
1.0×106
1.5×106
2.0×106
2.5×106
3.0×106
CD
4s
 
pe
r 
m
l
0u
g
3u
g
4u
g
5u
g
7u
g
9u
g
20
ug
50
ug
75
ug
10
0u
g
0
2.5×106
5.0×106
7.5×106
1.0×107
Blood 1 day post aCD4 Spleen 4 days post aCD4
Endogenous CD4:CD8 ratio day +4 spleen
Co
ntr
ol 1u
g
5u
g
10
ug
20
ug
50
ug
75
ug
10
0u
g
0.0
0.5
1.0
1.5
Dose anti-CD4
Endogenous CD4:CD8 ratio day +4 DLN
1u
g
5u
g
10
ug
20
ug
0.0
0.5
1.0
1.5
Dose anti-CD4
A
Day 0 +1
Bleed
+4
Harvest
aCD4 Cells
Gated on CD3+
B C
D
E thy1.1 CD4s
co
ntr
ol 3u
g
4u
g
5u
g
7u
g
9u
g
10
ug
20
ug
0
5.0×10 3
1.0×10 4
1.5×10 4
2.0×10 4
2.5×10 4
Dose anti CD4
Ce
lls
 
pe
r 
s
pl
e
e
n
co
ntr
ol 3u
g
4u
g
5u
g
7u
g
9u
g
10
ug
20
ug
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
Dose anti CD4
Th
y1
.
1 
CD
4/
CD
8
Recovered Thy1.1+ve CD4s day +4 spleen Thy1.1+ve CD4:CD8 ratio day +4 spleen
C
D
4
s 
p
e
r 
S
p
le
e
n
 204 
 
7.2.2 Depletion of endogenous CD4 cells prior to adoptive transfer of HA 
specific Th1s and CD8s improves survival in the post gemcitabine 
treatment  setting 
  
To test whether removal of endogenous CD4 cells prior to adoptive transfer would 
improve the ability of HA specific Th1s and CD8s to eradicate AB1HA tumours, mice 
were depleted of CD4 cells with 4ug of GK1.5 given intravenously, followed 24 hours 
later by adoptive transfer of CL4 CD8 T cells with or without in vitro differentiated HNT 
Th1s.  This experiment was initially performed in the prophylactic setting and survival 
was compared to mice that did not receive CD4 depletion (Figure 7-2A).  This showed 
that in the prophylactic treatment setting, removing endogenous CD4 cells did not 
improve the ability of mice to reject tumours.  In mice receiving Th1s and CL4s, fewer 
mice rejected tumours when endogenous CD4s were removed, although this was not 
significant (p= 0.24). 
This experiment was then performed in a therapeutic treatment setting, where mice 
with established AB1-HA tumours were treated with gemcitabine on day 9 (Figure 
7-2B).  Some groups of mice received adoptive transfer of HA specific T cells 24 hours 
after gemcitabine.  In addition, some mice were depleted of endogenous CD4 cells 
prior to treatment where indicated.   
Compared to mice that were treated with gemcitabine alone, removal of CD4s prior to 
gemcitabine treatment resulted in a non-significant trend towards increased survival 
(p=0.063), with around 20% of mice surviving long term. Survival was also improved by 
treatment with gemcitabine followed by adoptive transfer of HA specific CD8s (p=0.04, 
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compared to gemcitabine only group) and with gemcitabine followed by Th1s + CD8s 
(p=0.13, compared to gemcitabine only). 
However, when CD4 depletion was combined with adoptive transfer, a highly 
significant improvement in survival was observed.  Compared to mice that received 
gemcitabine and adoptive transfer alone, depletion of CD4 cells prior to treatment 
improved survival in mice receiving HA specific CD8s (10 of 18 survivors; p=0.0065) and 
in mice receiving Th1s and CD8s (11 of 18 survivors; p=0.0004).    
Amongst mice treated with CD4 depletion, gemcitabine and adoptive transfer, there 
was no difference in survival between mice receiving HA specific CD8s and mice 
receiving Th1s and CD8s (p=0.61), indicating that in established tumours, it is the 
removal of endogenous CD4s combined with the addition of HA specific CD8s which 
accounts for the majority of the effect seen.  In contrast to the prophylactic treatment 
setting, the Th1s do not appear to be contributing to the ability of mice to reject 
tumours in the gemcitabine treatment setting. 
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Figure 7-2 The effects of CD4 depletion prior to treatment in prophylactic and 
gemcitabine treatment setting 
A    Mice received adoptive transfer of 5x10
5
 CL4 CD8 T cells with 1x10
6
 in vitro 
differentiated HNT Th1s where indicated and were challenged with 5x10
5
 AB1-HA cells 
subcutaneously.  CD4 cells were depleted from groups as indicated the day prior to 
adoptive transfer through intravenous injection of 4ug of GK1.5 antibody.  Mice were 
culled when tumours reached 100mm
2
.  N=6, experiment performed once.  B  Mice 
with 9 day old AB1-HA tumours were treated with 240ug/g gemcitabine i.p.  and 24 
hours later received adoptive transfer of 5x10
5
 CL4 CD8 T cells with 1x10
6
 HNT Th1 
cells where indicated.  Some groups of mice were also depleted of CD4 cells 1 day prior 
to gemcitabine by intravenous injection of 4ug of GK1.5 antibody.  * denotes 
significance by logrank test (* p<0.05, ** p<0.01, *** p<0.001).  Combined results of 
three independent experiments shown with total between 6-18 mice per group. 
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7.2.3 Depletion of endogenous CD4 cells prior to treatment, does not 
improve survival of Th1s adoptively transferred following 
gemcitabine 
 
In order to examine whether the improved survival described above was reflected in 
an improved ability of HA specific CD4 cells to provide cognate help to HA specific CD8 
T cells, concurrent to the above experiment, groups of mice were treated with CL4 
CD8s or CL4 CD8s plus HNT Th1s, with or without the prior depletion of endogenous 
CD4 cells.  The effects of HA specific Th1 help on recovery of thy1.1+ CL4 CD8s 7 days 
after adoptive transfer was determined in both the post gemcitabine setting and in 
mice that did not receive gemcitabine.  In order to have tumours of a sufficient size to 
yield adequate numbers of cells for analysis, gemcitabine treated mice were treated at 
day 14, when tumours were larger than that seen in the growth experiments.   To 
enable adoptively transferred cells to be injected on the same day and harvests to be 
performed on the same day, tumour inoculations were staggered between 
gemcitabine treated mice and non-gemcitabine treated mice (Figure 7-3A). 
Recovered thy1.1+ve CD4 cells were identified by flow cytometry and numbers of cells 
in DLN, spleen and tumour analysed (Figure 7-3B).  Depletion of endogenous CD4 cells 
prior to adoptive transfer did not significantly alter recovery of thy1.1+ CD4 cells in 
untreated mice from the DLN, spleen or tumour.  As noted in chapter 6, survival of 
adoptively transferred CD4 cells in all compartments was impaired in mice treated with 
gemcitabine, compared with untreated mice, but this was only significant in the spleen 
(p=0.04).  Depletion of endogenous CD4s prior to gemcitabine treatment did not 
significantly improve recovery of thy1.1+ CD4s from the DLN, spleen or tumour.   
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Overall these results indicated that recovery of thy1.1+ CD4s was reduced in the post 
gemcitabine setting, and that depletion of endogenous CD4s prior to treatment did not 
significantly improve the survival of adoptively transferred Th1s. 
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Figure 7-3 Recovery of adoptively transferred HA specific thy1.1+ CD4 T cells 7 
days after adoptive transfer 
A   Groups of mice were either treated with gemcitabine on day 14 or were not 
treated.  All mice received adoptive transfer of 5x10
5
 CL4 CD8 T cells with or without 
1x10
6
 HNT Th1s.  Adoptive transfer was performed on day 10 after AB1HA inoculation 
for untreated mice and day 15 for gemcitabine treated mice.  Some groups were 
depleted of CD4 cells by intravenous injection of 4ug of GK1.5 antibody 24 hours prior 
to treatment as indicated.  Harvests were performed 7 days after adoptive transfer 
and recovered thy1.1+ve cells identified by flow cytometry .   B  Numbers of recovered 
thy1.1+ve CD4 cells in DLN, spleen and tumour in mice treated with CD4 depletion and 
gemcitabine.  Tumour values expressed as percentage of total tumour cells. N=3 per 
group. 
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7.2.4 HA specific Th1s do not help CD8s infiltrate tumours following 
gemcitabine treatment 
 
The effects of endogenous CD4 depletion and addition of HA specific Th1s on recovery 
of HA specific CD8 T cells 7 days after adoptive transfer was determined in mice 
treated as described in Figure 7-3.   Thy1.1+ CD8 T cells were identified in cells 
recovered from the DLN, spleen and tumour by flow cytometry.  In mice that were not 
treated with gemcitabine, neither CD4 depletion, Th1 transfer nor a combination of 
the two made any difference to the numbers of thy1.1+ CD8 T cells found in the DLN or 
spleen (Figure 7-4).  Tumour infiltration of thy1.1+ CD8s was not altered by either 
depletion of endogenous CD4s or transfer of HA specific Th1s alone.  However, if 
endogenous CD4 depletion and transfer of HA specific Th1s were both performed, 
then thy1.1+ve CD8 tumour infiltration was significantly increased, suggesting that the 
Th1s were able to help CD8s infiltrate tumours but only if endogenous CD4s were 
removed first. 
In the post gemcitabine setting this effect was not observed.  Although total numbers 
of thy1.1+ve CD8s were generally higher in the DLN in gemcitabine treated mice than 
in non-gemcitabine treated mice, no improvement in thy1.1+ CD8 recovery was seen 
with CD4 depletion or Th1 transfer in either the DLN, spleen or tumour (Figure 7-4). 
 
  
 211 
 
 
Figure 7-4 Recovery of adoptively transferred HA specific thy1.1+ CD8 T cells 7 
days after adoptive transfer 
Groups of mice were treated according to the schedule in A, as described in Figure 7-3, 
Tumour inoculations were staggered between mice treated with gemcitabine or not to 
ensure tumour sizes were equal at the time of harvest.   B  Numbers of recovered 
thy1.1+ve CD8s were determined by flow cytometry.  Tumour values expressed as a 
percentage of total cells.  3 mice per group.  * p<0.05 by students t test. 
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The observation that HA specific CD8 tumour infiltration in mice not treated with 
gemcitabine was increased by co-transfer of Th1s, suggested that Th1s had the 
potential to help CD8s infiltrate tumours.  The lack of help given by Th1s to CD8s in the 
post gemcitabine setting could have been explained by the reduced survival of Th1s 
transferred following gemcitabine, as described in section 6.2.7.   Therefore, when this 
experiment was repeated, an increased number of Th1s were transferred in an 
attempt to compensate for this loss and see if the effects seen in the untreated setting 
could be replicated in the post gemcitabine setting.   
Mice were again treated according to the schedule described in Figure 7-3A, but 
received a threefold increased number of Th1s.  When thy1.1+ CD4 cells were 
recovered from mice 7 days after adoptive transfer, the number of thy1.1+ CD4 cells 
present in the DLN, spleen and tumour (Figure 7-5A) had increased from that seen in 
the original experiment (Figure 7-3B), consistent with the increased numbers of cells 
injected.  However, despite the increased numbers of Th1 CD4 cells present, no effects 
of Th1s on CD8 recovery from DLN, spleen or tumour were observed in mice treated 
with or without gemcitabine, or in mice depleted of CD4s prior to transfer (Figure 
7-5B).  The previously observed positive effects on CD8 tumour infiltration of 
combined CD4 depletion and Th1 transfer in the non gemcitabine treated setting was 
not repeatable. 
Thus, there was no consistent evidence that in vitro differentiated HA specific Th1 cells 
were able to provide any help to HA specific CD8 cells in either the untreated or 
gemcitabine treated setting, with or without prior CD4 depletion. 
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Figure 7-5 Repeat of experiment described in Figure 7-3 and Figure 7-4, with 
transfer of increased numbers of Th1s 
Mice were treated as described in Figure 7-3A, but received 3x10
6
 Th1s alongside 
5x10
5
 CL4 CD8s.  Recovery of Thy1.1+CD4+ cells and Thy1.1+CD8+ cells 7 days after 
transfer is shown in A and B respectively.  3 mice per group. 
No gemcitabine Gemcitabine treatedB
DLN Thy1.1+ CD8s
Nil Th
1
aC
D4
aC
d4
 
+ 
Th
1
0
1.0×10 4
2.0×10 4
3.0×10 4
4.0×10 4
N
um
be
r 
Th
y1
.
1 
CD
8s
DLN Thy1.1+ CD8s
Ge
m
Ge
m 
+ T
h1
aC
D4
/Ge
m
aC
D4
/Ge
m/
Th
1
0
1.0×10 4
2.0×10 4
3.0×10 4
4.0×10 4
Th
y1
.
1 
CD
8s
 
pe
r 
D
LN
Spleen Thy1.1+ CD8s
Nil Th
1
aC
D4
aC
d4
 
+ 
Th
1
0
1.0×10 4
2.0×10 4
3.0×10 4
Th
y1
.
1 
CD
8s
 
pe
r 
sp
le
en
Spleen Thy1.1+ CD8s
Ge
m
Ge
m
 
+ 
Th
1
aC
D4
/Ge
m
aC
D4
/Ge
m
/Th
1
0
1.0×10 4
2.0×10 4
3.0×10 4
Th
y1
.
1 
CD
8s
 
pe
r 
sp
le
en
Tumour Thy1.1+ CD8s
Ge
m
Ge
m
 
+ 
Th
1
aC
D4
/Ge
m
aC
D4
/Ge
m
/Th
1
0.00
0.05
0.10
0.15
0.20
%
 
to
ta
l c
el
ls
Tumour Thy1.1 CD8s
Nil Th
1
aC
D4
aC
d4
 
+ 
Th
1
0.00
0.05
0.10
0.15
0.20
%
 
o
f t
o
ta
l c
e
lls
Spleen Thy1.1 CD4s
Nil aCD4 Gem aCD4/Gem
0
2.5×10 5
5.0×10 5
7.5×10 5
Th
y1
.
1+
CD
4s
 
/ S
pl
e
e
n
DLN Thy1.1 CD4s
Nil aCD4 Gem aCD4/Gem
0
10000
20000
30000
40000
Th
y1
.
1+
CD
4s
 
/ D
LN
Tumour Thy1.1 CD4s
Nil aCD4 Gem aCD4/Gem
0.00
0.25
0.50
0.75
1.00
1.25
1.50
1.75
%
 
o
f t
o
ta
l c
el
ls
A
 214 
 
7.2.5 Transfer of in vitro differentiated T regs abrogates the beneficial 
effects of CD4 depletion followed by adoptive transfer of HA specific T 
cells 
 
Although CD4 depletion did not improve the capacity of HA specific Th1s to help HA 
specific CD8s expand or infiltrate tumours, it was evident that CD4 depletion in 
combination with adoptive transfer of HA specific CD8s did significantly improve 
survival in the context of gemcitabine treatment (Figure 7-2B).   I hypothesised that 
removal of established regulatory CD4 cells was the mechanism by which CD4 
depletion improved anti-tumour responses.  To confirm that it was removal of the Treg 
subset which was critical to this response, I looked to see if I could abrogate this effect 
by adoptively transferring in vitro differentiated T regs alongside the Th1s and CD8s.  
Mice bearing established AB1HA tumours received CD4 depletion on day 8 and were 
treated with gemcitabine on day 9.  Adoptive transfer of CL4 CD8s and HNT Th1s was 
performed on day 10 with one group of mice also receiving an equal number of in vitro 
differentiated HNT Tregs. 
In those groups receiving adoptive transfer of CD8s and those receiving Th1s and CD8s, 
a high proportion of mice rejected tumour (Figure 7-6).   However the adoptive 
transfer of HA specific Tregs alongside HA specific CD8s and Th1s completely 
abrogated the beneficial effect of CD4 depletion and adoptive transfer (p= 0.02).  The 
survival curve of this group was no different to that of mice treated with gemcitabine 
alone, demonstrating that the anti-tumour activity of HA specific CD8s is suppressed 
by Tregs and that that the beneficial effect of CD4 depletion is mediated through 
removal of endogenous Tregs. 
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Figure 7-6 Adoptive transfer of in vitro differentiated Tregs abrogates the effects 
of CD4 depletion and adoptive transfer of HA specific effector T cells 
Groups of AB1-HA tumour bearing mice were treated on day 9 with 240ug/g 
gemcitabine.  Some groups were depleted of CD4 cells on day 8 where indicated.  
Adoptive transfer was performed on day 10.  Mice received 5x10
5
 CL4 CD8 cells 
alongside 1x10
6
 HNT Th1s where indicated.   One group also received adoptive transfer 
of 1x10
6
 in vitro differentiated HA specific Tregs.  Survival curves analysed by log rank 
test and * denotes p<0.05.  Experiment performed once, N=6 per group. 
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7.3 Discussion 
 
The experiments described in this chapter were performed because results from 
chapter 5 suggested that suppression by regulatory CD4 T cells could be limiting the 
anti-tumour activity of adoptively transferred tumour specific T cells.  Additionally, in 
chapter 6 I demonstrated that in vitro differentiated Th1 cells do not expand in vivo 
when transferred in the post gemcitabine setting, and I hypothesised that this could be 
due to competition from proliferating endogenous T cells.   For both of these reasons, I 
hypothesised that increasing the depth of the CD4 depletion prior to treatment would 
improve the ability of the adoptively transferred cells to eradicate tumours. 
Through the use of a very low dose of CD4 depleting antibody, it was possible to 
remove nearly all circulating CD4 cells without adversely affecting the CD4 cells 
adoptively transferred 24 hours later.  This technique was dependent on titrating the 
amount of antibody to just below the saturating dose, so that there was no free 
antibody available to deplete the CD4 cells adoptively transferred 24 hours later.  It is 
striking that the dose required to achieve this effect is several fold lower than that 
commonly used elsewhere (Nowak, Robinson et al. 2003; Teng, Swann et al. 2010).  
Although I did not examine whether this dose depleted CD4 cells within the tumour, 
depletion of CD4 cells in the lymph nodes and spleen was seen, indicating that removal 
of CD4 mediated suppression of CD8 priming was potentially possible.  Others have 
shown that dose response curves for GK1.5 are equivalent for spleen, lymph node and 
blood but higher doses are required to deplete CD4 cells from the thymus (Ghobrial, 
Boublik et al. 1989). 
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I found that removal of endogenous CD4 cells prior to treatment did not improve the 
ability of HA specific T cells to reject AB1HA tumours in the prophylactic setting.   In 
naive mice, immune cells suppressive to anti-tumour responses have not had a chance 
to develop, so this finding is not unexpected.  However it does contrast with my 
findings in chapter 3 and with the findings of others (Teng, Swann et al. 2010), where 
prophylactic CD4 depletion did mediate tumour rejection.  However these experiments 
did not involve adoptive transfer of effector T cells prior to inoculation.  Darasse-Jeze 
showed that if effector T cells were present at the time of tumour inoculation then 
Tregs were ineffective at suppressing immune responses, implying Treg depletion may 
not have added benefit in such a setting (Darrasse-Jeze, Bergot et al. 2009).  This is of 
relevance to the prophylactic model described here, where mice received HA specific 
Th1s and CD8s prior to tumour inoculation, and could explain why Tregs are not 
limiting in such as situation. 
Another mechanism by which lymphodepletion may enhance the activity of adoptively 
transferred cells is through augmenting homeostatic proliferation (Muranski and 
Restifo 2009).  However these findings suggest that, at least in the prophylactic 
situation, the activity of adoptively transferred Th1s is not enhanced by the provision 
ŽĨŵŽƌĞ ?ƐƉĂĐĞ ?ĨŽƌĞǆƉĂŶƐŝŽŶƚŽŽĐĐƵƌ ? 
In contrast to the prophylactic setting, I found that removal of endogenous CD4 cells 
prior to gemcitabine and adoptive transfer significantly increased survival in mice 
receiving HA specific T cells.  This suggested that, in established tumours, inhibitory 
CD4s were suppressing effector T cells responses and that the lymphodepletion 
induced by gemcitabine was insufficient to remove this suppression.   In the absence of 
adoptive transfer of HA specific T cells, there was a trend towards improved survival 
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when CD4s were depleted prior to gemcitabine but only a small proportion of mice 
were cured.  Thus removal of suppressive CD4s prior to gemcitabine was not in itself 
sufficient to mediate tumour rejection, which still required the addition of effector T 
cells. 
However, there was no added benefit of co-transfer of Th1s and CD8s over CD8 
transfer alone in mice treated with CD4 depletion and gemcitabine.  This contrasts 
with the prophylactic experiments where cures were only seen in mice receiving both 
Th1s and CD8s.  This demonstrates that removal of suppressive CD4 cells is critical to 
achieving CD8 mediated tumour eradication of gemcitabine treated established 
tumours, but that the addition of Th1 polarised helper CD4 cells is not of added benefit 
in such a setting.   
The inability of Th1s to help CD8s eradicate established, gemcitabine treated tumours 
is reflected in the lack of effects of Th1 co-transfer on expansion or infiltration of HA 
specific CD8s in the DLN, spleen or tumour.  In chapter 6, it was observed that in vitro 
differentiated Th1 cells transferred after gemcitabine did not expand between days 2 
and 7 after transfer, which contrasted with what was seen in untreated mice.  In the 
experiments described in this chapter, numbers of recovered thy1.1+ CD4 cells were 
also reduced at day 7 compared with mice that did not receive gemcitabine.  Depletion 
of endogenous CD4 cells did not significantly improve the recovery of transferred Th1 
cells in the DLN, spleen or tumour.  Therefore the limited help provided by the 
adoptively transferred Th1s to CD8s in these experiments could be explained in part by 
the detrimental effects of the post gemcitabine environment on their survival.   
However, increasing the number of transferred Th1s did not improve their capacity to 
help CD8s.  Furthermore, in mice not treated with gemcitabine I was similarly unable 
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to consistently demonstrate that CD8 expansion or tumour infiltration had been 
affected by the provision of Th1 help.  This suggests that the reduced survival of Th1s 
in the post gemcitabine setting does not fully explain why Th1s did not provide 
effective help to CD8s in this situation.   
The mechanism by which CD4 depletion improves survival in mice treated with 
gemcitabine and CD8 adoptive transfer was examined.  When in vitro differentiated 
HA specific Tregs were adoptively transferred alongside Th1s and CD8s, the beneficial 
effects of CD4 depletion and adoptive transfer were completely abrogated.  This 
confirmed that it was the depletion of the established CD4 Treg subset which 
explained the improved survival seen following CD4 depletion. 
Although the growth experiments suggested that CD4 depletion was necessary to 
achieve cures with adoptive transfer of HA specific CD8s, when cells were harvested 7 
days after transfer, I was unable to show that removing established CD4s improved 
expansion or tumour infiltration of HA specific CD8s.  Although Treg depletion can 
promote non-CD8 mediated mechanisms of tumour rejection, CD8s were found to be 
essential mediators of tumour rejection following Treg depletion (Teng, Swann et al. 
2010), so it would be surprising if CD8s were not involved in this response.  It is 
possible that endogenous CD4 depletion promotes activity of endogenous CD8s, 
resulting in an additive rather than synergistic effect with the adoptively transferred 
HA specific CD8s.  It is also important to note that in order to harvest sufficient cells 
from tumours for analysis, it is necessary to use tumours which are larger at the time 
of treatment than used in the growth experiments.  This approach relies on the 
presumption that adoptively transferred T cells will behave in the same way in small 
and large tumours, which may not be the case.  In addition, I only performed harvests 
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7 days after adoptive transfer, it is possible that using an earlier time point may have 
shown different results.   
In summary the results in this chapter show that: 
 Established, endogenous regulatory T cells limit the activity of adoptively 
transferred HA specific CD8s and removal of Tregs is critical to achieving a high 
proportion of cures with chemotherapy followed by adoptive CD8 
immunotherapy. 
 Lymphodepletion induced by gemcitabine chemotherapy is insufficient on its 
own to remove Treg mediated immunosuppression. 
 HA specific, in vitro differentiated Th1 helper CD4s do not help HA specific CD8s 
to expand or infiltrate established tumours and do not have anti-tumour 
activity against gemcitabine treated tumours. 
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8 Final Discussion 
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At the start of this project I hypothesised that: 
y The balance between different effector and suppressive CD4 subsets 
determines tumour rejection or tolerance 
y Adoptive transfer of in vitro differentiated tumour specific CD4 subsets could 
promote tumour rejection 
y The post chemotherapy environment presents a favourable window for 
adoptive cell transfer  
To investigate these hypotheses I had to establish a model with which to investigate 
tumour antigen specific T cell immune responses, specifically looking at the different 
roles that CD4 subtypes play in anti-tumour responses.  The aims of this project were: 
y To establish protocols for in vitro differentiation of tumour specific Th1s, Th2s, 
Th17s, Tregs  
y To investigate the in vivo activity of in vitro differentiated tumour antigen 
specific CD4 cells against tumours treated with cytotoxic chemotherapy 
y To investigate the effects of cognate help provided by HA specific CD4 subsets 
on HA specific CD8 T cells  
 
In this chapter I will review all the results obtained with reference to these hypotheses 
and aims.  In instances where the results do not allow conclusions to be drawn but 
instead have generated further hypotheses, I shall suggest additional experiments 
which could be considered to investigate the questions raised by this project. 
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The balance between CD4 subsets determines tumour rejection/tolerance? 
The initial premise behind this project was that CD4 T cells play an important role in 
determining the immunological outcome to a tumour.   This premise is supported by a 
growing body of literature which has shown that effector CD4 cells promote CD8 and 
other anti-tumour immune responses and, conversely, that removing regulatory CD4 T 
cells can lead to tumour rejection (discussed in section 1).    When I depleted CD4 cells 
from mice during treatment with repeated doses of gemcitabine followed by anti-
CD40 antibody, I found that, although the time to tumour outgrowth was increased by 
the removal of CD4 T cells, there was no difference in the number of mice cured of 
tumour.  This suggests that CD4 cells may be having some anti-tumour effects but did 
not imply that they were of crucial importance to final outcome in this setting.   It is 
possible that the effects of CD4 cells during this treatment regimen are blunted 
through the repeated dosing schedule or because anti-CD40 replaces one of the main 
mechanisms of CD4 help. 
When CD4 cells were depleted from mice prior to a single dose of gemcitabine, 
followed by adoptive transfer of tumour antigen specific CD8s there was a significant 
improvement in the ability of mice to reject established tumours.  This was due to 
removal of suppression by established regulatory T cells.  In chapter 3 depletion of CD4 
cells during treatment with gemcitabine and anti-CD40 increased CD8 activation and in 
chapter 5 it was seen that adoptively transferred Tregs trafficked to the tDLN and 
reduced HA specific CD8 tumour infiltration, suggesting that regulatory CD4s inhibit 
CD8 responses, and that this was likely to occur at the level of CD8 priming in the DLN. 
In addition, CD4 T cells appeared to have a different influence on anti-tumour 
responses during different periods of tumour emergence and growth.  In mice 
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subsequently treated with gemcitabine and anti-CD40, depletion of CD4s prior to 
tumour inoculation delayed tumour growth and improved survival times, which is 
consistent with other similar studies (Teng, Swann et al. 2010) and may reflect the 
observation that the regulatory CD4 T cell response is most rapidly established on first 
exposure to tumour antigen (Darrasse-Jeze, Bergot et al. 2009)resulting in an overall 
negative impact from CD4s on anti-tumour responses at this early stage.  Rejection of 
tumour in the prophylactic setting only occurred when tumour specific Th1s were 
adoptively transferred alongside CD8s.  This was not affected by prior depletion of CD4 
cells.  These results suggest that on first exposure to tumour antigen it is the presence 
or absence of effector, Th1 polarised antigen specific CD4s which determines whether 
tumour rejection occurs.   
 In contrast, in established gemcitabine treated tumours, rejection only occured when 
regulatory CD4s were depleted prior to adoptive transfer of tumour specific CD8s.  This 
was not affected by the additional provision of Th1 help, suggesting that once a 
tumour has established then it is the presence or absence of regulatory CD4 cells, 
rather than effector CD4 cells, which determines whether CD8s can eradicate tumours.  
 
Adoptive transfer of in vitro differentiated tumour specific CD4 subsets will mediate 
tumour rejection 
Tumour rejection mediated through adoptive transfer of tumour antigen specific Th1s, 
in conjunction with CD8s, was observed in the prophylactic situation, demonstrating 
the potential for Th1 polarised CD4 cells to help eradicate AB1-HA tumour cells.  
However this result was not replicated in a more clinically relevant scenario, when 
mice with established tumours were treated with gemcitabine followed by adoptive 
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cell transfer.  Thus once a tumour was established I was unable to demonstrate any 
positive anti-tumour effects from adoptive transfer of in vitro polarised CD4 cells. 
The reasons why CD4 cells did not have any effects on tumours beyond the 
prophylactic setting are discussed later in this chapter. 
 
The post chemotherapy environment provides a favourable window for adoptive 
transfer 
Cytotoxic chemotherapy can synergise with immunotherapy through a number of 
mechanisms, including increased tumour antigen release, inducing immunogenic 
tumour cell death, depletion of immunosuppressive cells and promoting homeostatic 
proliferation (discussed in section 1.4).  For these reasons I hypothesised that the post 
chemotherapy environment would provide a favourable environment for adoptive 
transfer of tumour specific CD4 T cells, and thus provide a window of opportunity to 
redirect the immune response away from tolerance and towards rejection. 
The results described herein do not support this hypothesis.  Not only did adoptive 
transfer of CD4 cells in the post chemotherapy environment have no effect on the 
ability of mice to reject tumours, but surprisingly the survival of in vitro differentiated 
Th1 cells was adversely affected by the post gemcitabine environment compared to 
cells injected into untreated tumour bearing mice.   
The reduced persistence of Th1s in the post gemcitabine environment was not due to 
direct cytotoxicity on the transferred cells but instead the population of cells failed to 
expand between day 2 and 7 after transfer.  The reasons for this are not clear.  If we 
consider the immune-modulating effects of chemotherapy outlined above, it is 
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possible that increased release of tumour antigen and increased antigen presentation 
could provoke apoptosis in cells which are vulnerable to activation induced cell death.  
Additionally, since the cells were injected during a period of lymphopenia then IL-7 
driven homeostatic proliferation is likely to have been the main driver of restoration of 
total T cell numbers.  In vitro differentiated Th1 cells express low levels of the IL-7 
receptor, potentially putting them at a disadvantage in such a setting.   
However, increasing the depth of the CD4 depletion using a CD4 depleting antibody 
did not improve the persistence of the adoptively transferred cells in the post 
gemcitabine environment, suggesting that competition from proliferating endogenous 
lymphocytes for cytokines may not be the only reason why gemcitabine was 
detrimental to survival of adoptively transferred CD4 cells.  Others have shown that 
CD8 T cells expanded in vitro in IL-2 underwent apoptosis without continuous IL-2 
supplementation and survived poorly in vivo in the absence of exogenous IL-2 
provision (Yee, Thompson et al. 2002; Mueller, Schweier et al. 2008).  Therefore Th1 
cells expanded in vitro in IL-2, which do not themselves produce IL-2, may also be 
dependent on IL-2 produced by other T cells for survival.  Thus lymphodepletion by 
gemcitabine could reduce the amount of IL-2 available for the transferred Th1s.  It is 
noteworthy that most adoptive cell therapy protocols involve the administration of 
large quantities of exogenous IL-2 following cell transfer (Dudley 2011). 
 
8.1 ǯ ?
CD8s in this model? 
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Although Th1s were observed to have anti-tumour activity in the prophylactic 
treatment model, this was not observed in treatment of established tumours.  This 
may have been partly due to the negative effects of gemcitabine on their persistence 
in vivo.  However,  when I performed harvests and tracked the behaviour of the 
transferred cells in vivo, it was clear that co-transfer of HA specific Th1s had no 
consistent impact on HA specific CD8 expansion or tumour infiltration in either 
gemcitabine treated mice or in untreated mice.   One of the aims of this model was to 
examine the effects of cognate help from CD4s on CD8s and hence provide some 
mechanistic data behind any treatment effects observed.  Previous work with this 
model has shown that transfer of naive HA specific CD4s alongside HA specific CD8s at 
the time of tumour inoculation increased survival of the CD8s and their ability to 
infiltrate the tumour site and eradicate tumours (Marzo, Kinnear et al. 2000).  It is 
important to consider why no such effects were seen in the experiments described. 
Problems with the model? 
In the absence of a clear positive control demonstrating that HNT CD4 cells have the 
capacity to help CL4 CD8s in vivo, it is important to consider first whether there may be 
a problem with the HA-transgenic system utilised.  The AB1-HA transgenic model relies 
on a number of factors:  1) HA is expressed by tumour cells; 2) HA protein can be 
assimilated and processed by antigen presenting cells and epitopes presented on MHC 
class I and class II; 3) The T cell receptor on HNT CD4 cells can bind to HA epitopes 
presented on MHC class II; 4)  The T cell receptor on CL4 CD8 T cells can bind to HA 
epitopes presented on MHC class I;  5)  Upon ligation of their TCR, HNT and CL4 
lymphocytes display normal effector functions. 
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The expression of HA by AB1-HA cell lines was confirmed by RT-PCR within the lab on 
several occasions.  It would be important to repeat this on tumours harvested ex vivo, 
especially those which have not responded to HA targeted treatments, to ensure HA 
expression is not being lost in vivo.  However, the observation that HA specific Th1s 
and HA specific CD8s, are activated and expand in vivo in the presence of AB1-HA 
tumour, and are recoverable from AB1-HA tumours and the tumour DLN at a high 
frequency suggests that HA expression is being maintained, that HA protein is being 
presented by antigen presenting cells and that HNT and CL4 lymphocytes can 
recognise HA epitopes presented on MHC.  Repeating this experiment with a control 
group using the AB1 parent line would confirm that this was an HA specific response. 
In addition, I confirmed that in vitro differentiated HNT CD4 cells were able to respond 
in vitro to splenocytes loaded with HNT peptide and it has been confirmed that CL4 
CD8 cells are able to respond to CL4 peptide (Amanda Cleaver  W unpublished data).  
Repeating this experiment with APCs loaded with HA protein and/or AB1-HA tumour 
lysate would demonstrate that APCs were able to process and present HA protein 
effectively in vitro. 
Finally the model requires that HNT and CL4 lymphocytes function normally, that is in 
the same way as the parent balb/c lymphocytes.   Although these cells did respond in 
vitro to peptide stimulation, to test whether HNT CD4s are able to help CL4 CD8s in 
vivo, an adoptive transfer experiment into RAG knockout mice lacking T cells could be 
performed in conjunction with an HA stimulus, such as AB1-HA tumour challenge, 
influenza inoculation or an HA directed vaccine.  The magnitude of the CL4 CD8 
response in the presence or absence of HNT CD4s or wildtype CD4s could then 
determined. 
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Assuming all the above criteria have been satisfied, it is still necessary to look for the 
effects of CD4 help on HA specific CD8s at a time and location where differences are 
detectable.  Since mice cured of tumour do not have tumours available for harvest, it 
was necessary to use larger tumours for the harvest experiments than those used in 
the treatment experiments.  The lack of effects of the adoptively transferred CD4s in 
the harvest experiments, could therefore have been confounded by different tumour 
sizes.  In addition, I chose to perform harvests 7 days after adoptive transfer, as this 
was around the time when tumours were seen to regress in the treatment 
experiments.  However, it is not certain that this is the optimal time to observe the 
peak CD8 response, especially as tumour sizes were not equivalent between the 
treatment and harvest experiments. 
 
What kind of CD4 cell is generated through in vitro differentiation? 
It is apparent from the results presented in chapter 4 that the viability and phenotype 
of in vitro differentiated CD4 cells are highly affected by the precise culture conditions 
employed, including the duration of the activation stimulus, the polarising cytokines, 
the type of media and the addition of exogenous IL-2.  The conditions needed to 
produce polarised cells at a high viability differed between subsets, with continual TCR 
stimulus necessary to maintain Th17 differentiation but being detrimental to Th1, Th2 
and Treg viability.  Furthermore, by shortening the duration of the activation stimulus 
and adding IL-7 instead of IL- ?ƚŽĐƵůƚƵƌĞƐ ?ŝƚǁĂƐƉŽƐƐŝďůĞƚŽƉƌŽĚƵĐĞ ?dŚ ? ?Đells, which 
had markedly different levels of IL-2 and CD62L expression from those produced using 
the original protocol, despite the expression of similar levels of IFNg.  The in vivo 
behaviour of these cells following adoptive transfer differed accordingly.   Thus 
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comparisons between different models which have used different methods to polarise 
CD4 cells need to be made cautiously. 
I found that Th1s were the only CD4 subset with anti-tumour activity in this model.  
Although Th1 responses have long been known to be important in tumour 
immunology, recent work has suggested that in vitro differentiated Th17s elicit more 
effective anti-tumour responses than Th1s following adoptive transfer into 
C57BL/6mice (Muranski, Boni et al. 2008; Martin-Orozco, Muranski et al. 2009).   
However, I was unable to find evidence that Th17s survived in vivo after adoptive 
transfer in the model used here.   It is unclear why this is the case but it could be due 
to differences in the model used in these studies, including the mouse strains, the use 
of a lymphoablating preconditioning regimen and different differentiation protocols.   
 
Wrong place, wrong time? 
Not only does the function of in vitro differentiated CD4 cells depend on their 
differentiation phenotype but will also depend on the locations that these cells track to 
after adoptive transfer.  Following injection, in vitro differentiated CD4 subsets display 
differing capacity to track to lymphoid organs and to the tumour.  In naive mice Th1s 
and Tregs possessed the greatest capacity to home to lymph nodes, and this is 
reflected in their high expression of CD62L.  In the presence of tumour however, Tregs 
accumulated in the draining node substantially faster than Th1s.  However, Tregs 
disappeared by day 7 and were not found in the tumour site.  This suggests that the 
suppressive effects of in vitro differentiated Tregs are likely to be mediated at the level 
of the lymph node in the first few days after transfer.    
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This is of relevance to the model we chose to use in this project.  We co-transferred 
naive HA specific CD8s alongside the CD4 cells, in order to ensure adequate numbers 
of CD8 effectors were available for the CD4 helper cells to help.  Naive CD8s express 
high levels of CD62L and accumulate readily in the DLN immediately after transfer.  For 
the HA specific CD8 response to be initiated, these cells need to be activated in the 
DLN, meaning that priming of naive HA specific CD8s in the DLN is the first rate limiting 
step in this process.   Thus, this model is likely to be sensitive to interventions at the 
level of CD8 priming and hence the effectiveness of CD4 help is likely to be dependent 
on whether CD4 helper cells are present in the DLN at this early stage during CD8 
priming.  Thus, discordant initial tracking to the DLN of the CD4 effector subsets and 
the naive, HA specific CD8s could explain why we did not see any effect of CD4 help by 
Th1s on the CD8s, whereas we were able to observe a negative impact from transfer of 
Tregs.   
 
Does in vitro differentiation produce Th1 effectors, not helpers? 
These observations raise the question of what type of CD4 cell in vitro differentiation 
actually generates and how closely do they represent their in vivo counterparts.   CD4 
ƐƵďƐĞƚƐĂƌĞĐŽŵŵŽŶůǇŝĚĞŶƚŝĨŝĞĚďǇƚŚĞƐĞĐƌĞƚŝŽŶŽĨƚŚĞŝƌ ?ƐŝŐŶĂƚƵƌĞ ?ĐǇƚŽŬŝŶĞ- IFNg 
for Th1s, IL-4 for Th2s, IL-17 for Th17s  W or by expression of the transcription factor 
foxp3 for Tregs.  However CD4 cells perform multiple functions in addition to secretion 
of these cytokines.   Hence the true functional capability of CD4 cells may not be 
reflected by measurement of just one phenotypic marker.   When in vitro 
differentiated CD4 cells were analysed for expression of other markers associated with 
CD4 helper functions, CD40L and IL-2, it was clear that some subsets lost expression of 
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these markers during in vitro culture.   Th1s were the only subset to maintain 
expression of CD40L during in vitro culture, however this was not detectable on Th1s 
ex vivo, two days after adoptive transfer.   Secretion of IL-2 was lost by Th1s and Th2s 
after the first two days of in vitro culture, at the point that they began to express IFNg 
and IL-4 respectively.   
I hypothesised that, in the case of Th1s, 5 days of in vitro culture produced Th1 cells 
with an effector phenotype, rather than a helper phenotype.  It also appeared that 
during differentiation Th1 cells may be moving through a helper phase, characterised 
by high expression of IL-2 and CD40L, into an effector phase, characterised by high 
expression of IFNg.  Whether these in vitro observations reflect events during in vivo 
differentiation of CD4 cells is not clear. Villarino et al proposed a similar model and 
also suggested that the dynamics of IL-2 and IFNg expression may correlate with 
migration of cells from lymph nodes into effector site tissue (Villarino, Stumhofer et al. 
2006).  Interestingly, I observed that the endogenous CD4 cells isolated from the DLN 
of tumour bearing mice produce large amounts of IL2 and little IFNg, whereas CD4 cells 
isolated from tumours produce large amounts of IFNg and little IL-2.  Thus the 
secretion profile of IFNg and IL-2 by Th1 cells at the end of in vitro differentiation 
resembled endogenous CD4 cells found in the effector site and not at the site of 
priming. 
Since Th1s were found to be effective in the prophylactic treatment setting, it is clear 
that they do possess some anti-tumour activity.  In the absence of any demonstrable 
effects on HA specific CD8s it is possible that these cells are acting through non-CD8 
related mechanisms.  CD4 cells can exhibit direct effector function against tumour cells 
or can recruit other immune cells such as macrophages, granulocytes or NK cells 
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(discussed in section 1.2.3).  Thus the adoptively transferred Th1s and the CD8s may be 
acting independently of one another and the survival advantage seen with transfer of 
Th1s and CD8s together in the prophylactic situation could be an additive rather than a 
synergistic effect.  Repeating the prophylactic treatment experiment with transfer of 
Th1s alone would demonstrate whether their effect is independent of HA specific 
CD8s.  Depletion of the endogenous CD8s could then be performed using a CD8 
depleting antibody to determine whether Th1s acted entirely through non-CD8 
mechanisms.   
 
Endogenous immune cells may be confounding the effects of HA specific adoptively 
transferred cells 
It is important to consider the influence the endogenous immune system has on the 
activity of the transferred HA specific cells and the influence this may be having on 
assays which look at the transferred HA specific cells only.  Depletion of endogenous 
CD4 cells prior to adoptive transfer clearly indicated that endogenous regulatory CD4s 
were suppressing the ability of HA specific CD8 cells to eradicate established tumours.  
When HA specific Tregs were transferred back in these effects were abrogated.  
Repeating this experiment with Tregs generated from wild type balb/c mice would 
enable us to determine whether the suppressive effects of these Tregs were 
dependent on HA antigen recognition. 
I assumed that HA specific CD4s would be able to provide cognate help for HA specific 
CD8s.  However, presuming this to be true, this still does not preclude the possibility 
that HA specific CD8s may also be able to receive help from endogenous CD4 cells, 
whether they are cognate for HA or for other tumour antigens co-expressed by AB1-
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HA.   One explanation for the lack of benefit from transfer of HA specific Th1s in 
established tumours is that adequate CD4 help for the HA specific CD8s is already 
available from endogenous helper CD4 cells, albeit this is only unmasked when 
overriding suppression from regulatory CD4s is removed.  This would contrast to the 
prophylactic situation where the recipient mouse is naive to tumour antigens and 
hence the transfer of tumour antigen specific CD4 helper cells does provide help which 
is not otherwise available. 
Thus it is possible that interactions between endogenous immune cells, both 
suppressive and effector, and the transferred HA specific T cells could be interfering 
with the ability to detect interactions between the HA specific CD4s and the CD8s.   
 
8.2 Conclusions 
 
In summary I developed a model with which to study the effects of different subtypes 
of tumour specific CD4 cell on tumour eradication by CD8 T cells in conjunction with 
cytotoxic chemotherapy.  Four main conclusions can be drawn from these results. 
1) The phenotype of in vitro differentiated CD4 subsets and their behaviour in 
vivo following adoptive transfer is highly dependent on the in vitro culture conditions.   
2) Th1s were the only subtype with anti tumour activity on this model, but only 
when injected prior to tumour inoculation.  The protocols utilised in this project 
produced Th1 cells which displayed an effector rather than a helper phenotype and 
they did not  provide cognate help to CD8s. 
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3)  Gemcitabine does not provide a favourable window for adoptive transfer of in 
vitro differentiated CD4 cells.  Persistence of these cells in vivo is reduced in the post 
gemcitabine environment through mechanisms other than direct cytotoxicty on the 
transferred cells. 
4) The ability of tumour specific CD8s to eradicate established tumours following 
gemcitabine is suppressed by endogenous regulatory T cells.  Removal of Tregs is 
critical to achieving cures with chemotherapy and adoptive CD8 transfer. 
 
These results provide a rationale for trying to combine different immunotherapies 
alongside conventional cytotoxic chemotherapy.  Combining chemotherapy with both 
the provision of a CD8 targeted stimulus and removal of CD4 mediated suppression 
should be further explored as a strategy to improve outcomes for patients with cancer. 
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